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Abstract 
Many human cancers are more prevalent in men than women. This disparity is not fully 
explained by differences in key risk factor exposures, which suggests a possible genetic cause. 
Recent research has reported a link between loss of the Y chromosome (LoY) and increased 
incidence of non-haematological cancers. 
Using data from The Cancer Genome Atlas, I conducted an integrated, multi-‘omic analysis 
of Y chromosome methylation and copy number aberrations in three different cancers – 
colon, head and neck and kidney. 
My results indicate that aberrant methylation of the Y chromosome is common in all three 
cancer types. Hyper-methylation occurs in short, discrete regions, interspersed among wider 
regions of more general hypo-methylation. I also show that LoY is the most common 
aneuploidy in all three cancers, affecting between one third and one half of patients. 
Furthermore, both aberrant methylation and LoY are associated with reduced expression of 
potentially important genes.  
Most interestingly, for HPV negative head and neck cancer patients, I show a statistically 
significant association between LoY and worse survival, and that LoY may be linked to 
smoking. Subject to further validation, this suggests that LoY could be important in the 
pathogenesis of head and neck cancer for HPV negative patients. 
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1. Introduction 
Many human cancers are more prevalent in men than in women
1
. This discrepancy is not fully 
explained by men having greater exposure to key risk factors
2
, which raises the possibility 
that there may be underlying genetic differences between the sexes which result in men being 
more susceptible to cancer. 
The most fundamental genetic difference between men and women is that the former have 
one maternally inherited X chromosome and one paternally inherited Y chromosome, whereas 
the latter have two X chromosomes. So it is reasonable to speculate that aberrations in either 
or both of these chromosomes could be, at least partially, responsible for the difference in 
cancer prevalence. 
1.1 Project outline 
My project is focussed on the Y chromosome. Recent research
3
 has suggested that loss of the 
Y chromosome in peripheral blood may be linked to increased risk of cancer in men and also 
shorter survival times. Additional research by the same group
4
 has linked Y chromosome loss 
to smoking. Furthermore, there is recent evidence that the Y chromosome contains a small 
number of genes whose functions are fundamentally important to male survival
5
, including 
two potential tumour suppressor genes
6
. 
The initial focus of my project was on methylation of the Y chromosome and how this is 
altered in male tumours. I chose methylation as this is a biological process which is known to 
be altered in tumours
7
, and because there is very little research into aberrant methylation of 
the Y chromosome.  
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I have studied three different cancer types using data provided on-line by The Cancer Genome 
Atlas (“TCGA”)8. All of these cancer types are more prevalent in men than in women1. 
My initial analyses were based on TCGA’s kidney renal clear-cell carcinoma (KIRC) dataset9. 
I chose this dataset because, at the time, it was relatively under-studied compared with other 
datasets, it has a large amount of methylation data, and, in particular, it has a large number of 
normal tissue samples against which the tumour samples can be compared. 
I then performed similar analyses on TCGA’s colon adenocarcinoma dataset (COAD)10. I 
chose this dataset because aberrant methylation is a well-known feature in a subset of colon 
cancers
11
. 
Finally, I also studied TCGA’s head and neck squamous cell carcinoma dataset (HNSC)12, 
which has a very large number of samples processed on TCGA’s chosen methylation analysis 
platform. A further advantage of this dataset is that useable data on smoking history is also 
available (which is not the case for the KIRC and COAD datasets). In addition, one of the risk 
factors for head and neck cancer is infection with the human papillomavirus (HPV)
13
, so by 
analysing this dataset I was able to compare tumours with and without viral infection. 
An advantage of the way in which TCGA’s methylation data are produced is that they can 
also be used to estimate copy number variations
14
. So the next part of my project used the 
methylation data for this purpose. TCGA also provide separate copy number data, so I used 
these additional data to corroborate my results based on the methylation data.  
For each of the three cancer types, I then used TCGA’s gene expression data to look for 
Ychromosome genes whose expression appeared to be affected by either aberrant methylation 
or copy number variation (in particular loss). 
3 
 
I was then interested to discover whether the Y chromosome changes I had found were 
associated with any differences in survival. TCGA also provide clinical information for the 
samples they have processed, and this contains data on overall survival. 
Finally, for the HNSC dataset only, I performed more detailed analyses of the associations 
between Y chromosome aberrations and the key risk factors of smoking and HPV infection. 
For this purpose I also made use of TCGA’s somatic mutation data. 
To my knowledge this is the first time that a multi-‘omic study of changes in the Y 
chromosome in human cancer has been undertaken. Figure 1 below summarises the order in 
which my results are presented: 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 - overview of results chapters 
Chapter 3 – analysis of differential methylation of Y chromosome 
Chapter 4 – analysis of copy number changes in Y chromosome 
Chapter 5 – analysis of expression of Y chromosome genes 
Chapter 6 – analysis of Y chromosome aberrations and survival 
Chapter 7 – further analyses of head and neck tumours 
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1.2 The Y chromosome 
The Y chromosome is the third shortest of all the human chromosomes at around 60 million 
base pairs (Mbp). In contrast to its sex-chromosomal partner, the X chromosome, it contains 
the genetic material which uniquely defines the male gender, and this is its primary, and most 
researched, function.  
The Y chromosome is fundamentally different to the 22 human autosomes in that it only 
recombines (with the X chromosome) over a very small part of its overall length. 
Furthermore, its transmission from generation to generation is wholly via the male gender. 
These two factors have had important implications for Y chromosome evolution. Over recent 
years, research has provided insights into this evolutionary process, along with details of the 
Y chromosome’s genetic make-up and functionality beyond sex-determination15,16. 
1.2.1 Evolution of the Y chromosome 
Separate sex-defining chromosomes have evolved independently in many different species. 
The human X and Y chromosomes are believed to have originated over 200 million years ago 
from an ancestral pair of autosomes in eutherian mammals
15
.  
Whilst the precise mechanism of how the process of sex-differentiation started is unclear, it is 
thought that an important first step was the acquisition of a key sex-determining gene on the 
prototype Y chromosome (the SRY gene in humans). The process was then accelerated by 
suppression of recombination between the two erstwhile autosomes, possibly by means of 
chromosomal inversions
15
. Comparison of the DNA sequences of homologous genes on the X 
and Y chromosomes has revealed heterogeneous levels of sequence divergence, suggesting 
that suppression of recombination was a multi-step process, leading to distinct evolutionary 
strata on the Y chromosome
17
. The afore-mentioned SRY gene is located within the oldest 
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identified strata, consistent with the idea that it was a very early acquisition to the Y 
chromosome. 
Suppression of recombination means that natural selection acts over the whole length of the 
chromosome (except for the two pseudoautosomal regions – see below). This leads to greater 
accumulation of deleterious mutations than would otherwise occur in a normally recombining 
pair of chromosomes, which in turn results in substantial levels of gene decay. Research 
suggests that gene decay on the Y chromosome occurred at a rapid rate initially, but slowed 
down over time, until a steady cohort of genes was established
15
. This and the fact that 
transmission of the Y chromosome occurs wholly through males, implies that those genes 
which survive are likely to be important for male viability. 
1.2.2 Genetic content of the Y chromosome 
The Y chromosome is acrocentric with its centromere located at around 12.5Mbp. It can be 
broken down into a number of different regions, with different properties, as shown in figure 
2 (reproduced from Bachtrog
15
): 
 
 
 
Figure 2 - overview of the human Y chromosome 
Schematic diagram of the Y chromosome (taken from Bachtrog
15
) showing gene locations and the different regions (colour-
coded as per legend). The diagram runs from the end of the short arm (left) to the end of the long arm (right).  
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At either end of the chromosome are the two pseudoautosomal regions (“PARs”). These short 
regions still undergo recombination during meiosis with homologous regions at the ends of 
the X chromosome, a process which is essential for correct segregation of the chromosomes
18
. 
PAR1 is located at the tip of the short arm and is around 2.7Mbp long. PAR2 is located at the 
opposite end of the chromosome, and is much shorter at around 0.3Mbp
19
. The two PARs 
contain 24 and five genes respectively, all of which are also found on the X chromosome
20
. 
The possible existence of a third PAR on the short arm of the Y chromosome has also been 
suggested
21
, although this is not generally accepted yet. 
In between the two PARs is the so-called “male-specific region”, which does not recombine 
during meiosis, and which can be sub-divided into four sub-regions. A significant part 
(around 70%) is hetereochromatic and contains no known functioning genes. The remaining, 
euchromatic part contains around 60 known genes, and can be sub-divided into three distinct 
regions
15,16
. 
1. X-degenerate – contains 16 functional genes which have survived chromosomal decay 
from the original ancestral autosome, and which all have homologs on the X 
chromosome. These genes are expressed in many areas of the body, and have a broad 
range of house-keeping functionality. 
2. X-transposed – a short 3.4Mbp region which was transposed from the X chromosome 
around 3-5 million years ago and which contains only two genes. 
3. Ampliconic – contains highly repetitive DNA sequences which are home to nine 
distinct gene families. These genes have male-specific functions, and are mainly 
expressed only in the testes. 
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My project focuses on the male-specific region, and in particular, though not exclusively, on 
12 genes in this region which have recently been proposed as potentially essential to male 
viability
5
. The genes concerned, all of which have homologs on the X chromosome which 
escape X inactivation, are: RPS4Y1, ZFY, TBL1Y, PRKY, USP9Y, DDX3Y, UTY, 
TMSB4Y, NLGN4Y, CYorf15A, KDM5D and EIF1AY. All of these genes are located within 
the X-degenerate sub-region. 
1.2.3 Y chromosome and cancer 
The Y chromosome is often overlooked in cancer research. Indeed, TCGA’s own studies into 
the datasets I have used do not feature it
9,10,12
. This is likely to be because much research is 
performed on a unisex basis, and hence any results involving the Y chromosome are diluted 
by a proportion of the samples being female. However, there is evidence of Y chromosome 
aberrations in numerous cancer types. 
Aberrant methylation of the Y chromosome in cancer has had very little attention. However, 
some research has indicated that hyper-methylation of certain Y-linked genes, including the 
key sex-determining gene SRY, is observed in prostate cancer
22,23
. 
There is substantially more evidence that loss of the Y chromosome (“LoY”) is a common 
feature in numerous cancer types
24
, including the three types that I have investigated
25,26,27
. 
LoY in peripheral blood cells has also been linked to increased risk of solid tumours
3
. 
There has been some debate as to whether LoY is simply a by-product of general 
chromosomal instability, possibly linked to ageing, or whether it is an important causal event 
in tumour formation. However, there is evidence for the latter. For example, research into the 
effect of smoking on LoY in peripheral blood cells has indicated that different types of 
haematopoietic cell suffer differing degrees of loss, suggesting that it is not a totally random 
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process across all cell-types
4
. Secondly, research into head and neck cancer has indicated that 
LoY is not age-related and may impact on survival
27,28
. Finally, a pan-cancer study which 
looked at the mutational profiles of over 8,200 human tumour samples has suggested that two 
genes on the Y chromosome (UTY and ZFY) may be tumour suppressor genes
6
.  
There is also some evidence that aberrant expression of the TSPY gene may have a role in the 
formation of germ cell tumours
29
. 
1.3 The Cancer Genome Atlas 
Following on from the initial complete sequencing of the human genome in 2003 by the 
Human Genome Project, attention was given to how this knowledge could be applied to the 
cure and prevention of human diseases, including cancer. The research community already 
appreciated that the molecular causes of cancer were many and varied, and, therefore, that a 
coordinated approach to cancer research was vital. 
The need for greater collaboration between research teams was heightened by the explosive 
growth of biological "omic" data which was becoming available as a result of technological 
advances such as microarrays and next generation sequencing. These technologies enabled 
researchers to investigate the molecular characteristics of cancer on a genome-wide scale 
using actual clinical samples, with a view to extracting biomarker data which could be useful 
for diagnosis and prognosis
30
. However, they generate vast amounts of data, giving rise to 
significant issues of data handling and analysis, which are difficult for small research teams to 
deal with. Furthermore, piece-meal research by small teams has led to many novel findings 
which have been difficult to validate independently because they are based on small data sets 
and hence lack statistical credibility
31
. Hence a more coordinated approach is required so that 
analyses can be made more credible by being based on larger data sets. 
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In recognition of the need to foster greater collaboration between research teams, The Cancer 
Genome Atlas (TCGA: http://cancergenome.nih.gov/) was formed in the USA in 2006 with 
funding from the National Cancer Institute (NCI: http://www.cancer.gov/) and National 
Human Genome Research Institute (NHGRI: http://www.genome.gov/)
8
.  The key purpose of 
TCGA is to provide, on a standardised basis, a central database of molecular and clinical data 
relating to cancer, which can be accessed freely by the international research community. The 
intention is that this will foster greater sharing of knowledge and ideas amongst researchers 
generally. 
A vast amount of biological and clinical data is freely available on-line via TCGA's data-
portal (https://tcga-data.nci.nih.gov/tcga/). The database contains information on over twenty 
of the most commonly occurring human cancers, and, to date, has records in respect of over 
10,000 actual human samples. These include both cancerous and matched normal tissues, 
enabling case / control comparisons to be made.  
A number of different types of biological data can be downloaded: 
 Gene expression 
 DNA sequencing  
 SNPs 
 MiRNA expression 
 Protein expression 
 Copy number  
 DNA methylation 
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Within each type of data, samples have been processed in the same way using the same 
technologies, thereby facilitating comparison between samples (NB for some data types, for 
example DNA methylation, more than one different technology has been used with samples 
grouped by each technology). The data are presented with various (typically 3) levels of pre-
processing having already been performed. Level 1 data are the "raw" data taken straight from 
the relevant microarray / sequencing technology etc with no pre-processing, with subsequent 
levels having increasing levels of processing. For example, the level 2 DNA methylation data 
have had some background correction (see later) applied to the level 1 intensity values, and 
the level 3 data are the calculated methylation levels (called beta values) for probes which 
have passed certain filtering criteria. 
TCGA has developed a systematic pipeline in order to standardise and streamline the 
production of data. There are four key components of this pipeline: 
1. The Biospecimen Core Resource (BCR), located at The Research Institute at 
Nationwide Children’s Hospital, Columbus, Ohio - this institution is responsible for 
reviewing and handling all tissue samples so that data-handling is performed in a 
consistent manner for all samples and to the standards required by TCGA. 
2. Genome Characterization Centers (GCCs) - using the relevant technologies (e.g. 
microarray), these centres process the tissue samples which have been passed on by 
the BCR. Different centres specialize in different types of analysis (for example, 
University of Southern California and John Hopkins University specialize in DNA 
methylation analysis). 
3. Genome Sequencing Centers (GSCs) - these centres perform genome-wide DNA 
sequencing on data passed on by the BCR. 
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4. The Data Coordinating Center (DCC) at  SRA International, Arlington, Virginia - this 
centre manages the collection, storage and distribution to the wider research 
community of the data produced by the GCCs and GSCs. 
Figure 3, taken from the TCGA website, is a schematic of how the various parts of TCGA fit 
together. 
 
Figure 3 - overview of TCGA process 
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In addition to the facilities mentioned above, TCGA has also established Genome Data 
Analysis Centers (GDACs) whose role is to develop new bioinformatic tools for processing 
and analysing TCGA data. 
1.4 DNA methylation 
DNA methylation is a form of epigenetic modification of genomic DNA, which means that it 
does not actually change the sequence of DNA bases themselves, but that it can still be passed 
on to future generations of cells via mitosis (and also potentially future generations of the host 
organism).   
The extent of methylation and mechanism by which it occurs vary significantly between 
different organisms
32
. In mammals, methylation most commonly, though not exclusively, 
affects cytosine/guanine di-nucleotides (referred to as "CpG sites"), whereby the cytosine half 
of the pair is "tagged" with a methyl group which replaces one of the hydrogen atoms.  
The distribution of CpG sites across the human genome is not uniform. The genome is 
generally depleted of CpG sites, there being approximately 28 million CpG sites out of a total 
of around 3 billion bases. This depletion is believed to be caused by the fact that methylated 
cytosines can be converted naturally to thymines by deamination. There are, however, 
concentrated areas (typically around 1,000 bases in length) of relatively high CpG density 
which are known as CpG islands, and these are present in over half of human genes
33
. 
Across all cell types in the human body, the overall profile of methylation throughout the 
whole genome is bimodal, with well over half of CpG sites being highly methylated whereas 
CpG islands have typically low levels of methylation
34
. It should be pointed out, however, 
that any such measurement of methylation level is an average across cells, since for each 
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individual CpG site on each individual piece of DNA, methylation is essentially a binary state 
- either the CpG site is unmethylated or it is methylated. 
Methylation of genomic DNA is typically carried out by a family of enzymes known as 
methyltransferases. Two of these, known as DNMT3A and DNMT3B, are de novo 
methyltransferases which can tag previously unmethylated DNA, whilst DNMT1 is a 
maintenance methyltransferase which facilitates the copying of methylation status during cell 
division by recreating the methyl group on the replicated strand.  
Unlike genomic DNA, which is mostly the same in all cells within the human body, the 
methylation profile of a cell can vary considerably, both across different cell types and also 
over time. This means that the influence of methylation also varies between cell types and 
over time. In particular, variation in methylation profiles between different cell types reflects, 
in part, different gene expression profiles between cell types (see below). 
Recent research
34
 suggests that in early embryonic development there is wide-scale 
demethylation across the entire human genome, with the exception of certain DNA sequences 
such as those involved with genomic imprinting. There then follows, at around the time of 
implantation, a reestablishment of global methylation patterns, and these are then maintained 
throughout future cell division. Again there are some exceptions, such as CpG islands, which 
are believed to be protected from this genome-wide methylation. Furthermore, methylation 
states after implantation are not entirely static, and can be influenced by environmental factors 
(such as diet and alcohol consumption) and / or sporadic genetic mutations
35
. Increasing 
methylation levels are also believed to occur as a result of the aging process. 
Methylation is thought to have a number of functions
33
. For example, it is important for 
chromosomal stability when it occurs in repeat DNA regions such as centromeres
36
, and aids 
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genomic stability by repressing other repeat regions such as transposable elements. Its main 
function, however, concerns the pattern of tissue-specific gene expression patterns. 
There has been much research in recent years investigating the impact of methylation on gene 
expression patterns. It is currently believed that the influence which methylation exerts on 
transcription of any particular gene depends on both its location relative to the gene and also 
on whether it occurs within a CpG island or not
33
. 
As mentioned above, CpG islands have typically low levels of methylation. Hence when a 
gene which contains a CpG island near its transcriptional start site (TSS) is repressed, this is 
generally by means of some cause other than methylation - for example by interaction of the 
gene's promoter with the so-called Polycomb complex of proteins. This form of repression 
allows some flexibility so that genes can be expressed in a tissue-specific manner as and when 
necessary
33
. 
There are, however, some CpG islands associated with TSSs which are highly methylated. 
These areas tend to occur in genes which are subject to long-term, stable repression, such as 
imprinted genes and inactivated X-chromosome genes in females. In this scenario, research 
has linked the methylation of CpG islands to the inability of transcription to be initiated
37
. 
However, the current line of thinking is that for these genes, methylation does not directly 
cause repression of transcription, but rather that it is a mechanism for stabilising repression 
which has already been brought about through another mechanism
33
. In this way, the 
flexibility for the affected genes to be expressed at certain times / places is lost and instead 
permanent silencing of the genes is achieved. 
The situation is different for TSSs which do not contain CpG islands. In this scenario, the 
level of CpG methylation is much more variable and tissue-specific, and there appears to be 
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an inverse correlation between methylation and gene expression levels
38
. Again it is believed 
that methylation is not the initial cause of transcription repression, although there is no 
definitive evidence for this yet. 
The considerations for methylation in gene bodies are different again. Most gene bodies have 
low CpG density and are highly methylated. Seemingly paradoxical to the inverse correlation 
noted above for TSSs, methylation levels in gene bodies have been found to be positively 
correlated to gene expression
39
. One theory for this is that methylation in TSSs blocks the 
initiation of transcription, but when it occurs in gene bodies it does not prevent the 
propagation of transcription that has already started upstream of the gene body. 
A further potential complication to the above analysis is that most genes have more than one 
TSS, which means that at least one downstream TSS will effectively be in the body of the 
transcriptional region of another upstream TSS. Hence, if the measurement of gene expression 
level is not calculated specifically to each TSS (as is often the case), then direct linkage of the 
methylation level of the downstream TSS to the gene expression level could lead to incorrect 
conclusions about the association between methylation and expression being drawn
33
. 
Finally, genome-wide methylation profiling research has observed that exons tend to have 
higher levels of methylation than introns. Furthermore, the switch from high to low 
methylation appears to occur around exon / intron boundaries. One potential implication of 
this is that methylation may influence the locations where gene splicing takes place
40
. 
1.5 DNA methylation and cancer 
In recent years there has been a significant amount of scientific research into links between 
DNA methylation and cancer, and this has shown that abnormal levels of methylation, both 
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low and high, play an important part in cancer progression
7
. This involvement is not 
surprising given methylation's role in the control of transcription repression, as outlined in the 
previous section. However, research has also suggested that abnormal methylation does not 
necessarily act alone in tumorigenesis, but rather that it is coordinated with both genetic 
alterations and also potentially with other epigenetic changes such as histone modifications 
and nucleosome remodelling
7
.  
Two key types of aberrant patterns of DNA methylation have been consistently reported in 
various types of cancer
34
. Firstly, increased (hyper) methylation of large numbers of CpG 
islands positioned in gene promoters has been identified in cancerous tissue relative to normal 
tissue. Secondly, associations have also been made to genome-wide reduced (hypo) 
methylation in non-CpG islands relative to non-cancerous tissue. Each of these phenomena is 
considered in turn below. 
1.5.1 Cancer-related hyper-methylation 
The first of these effects has been the most extensively researched to date, given that 
methylation of CpG island promoters has been shown to repress gene transcription 
permanently
41
.  
Normally, permanent repression of this nature only occurs in imprinted genes, inactivated X-
chromosome genes and germ-cell specific genes
41
. So when abnormal hyper-methylation of 
other genes occurs, this could potentially lead to the permanent repression of genes whose 
controlled regulation via other mechanisms is essential for the normal functioning of cells. 
Tumour-suppressor genes are an obvious potential example of this. 
Hyper-methylation has been observed to occur in hundreds (typically between 5% and 10%) 
of CpG island promoters within the same tumour
41
, and this has given rise to the term CpG 
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island methylator phenotype (CIMP), to define a subset of CpG island promoters which are 
all simultaneously hyper-methylated in cancer
11
. Whilst this is merely a hypothesis at the 
present time, there is some evidence suggesting that it may be a real effect
42,43
. 
How and when such hyper-methylation is involved in cancer progression is not entirely clear 
yet
34
. With regards to timing, there is evidence that hyper-methylation may be an early event 
in cancer progression. For example, in studies of colon cancer, hyper-methylation has been 
observed to already occur in polyps
44
.  
One model for how hyper-methylation may play an early part in tumorigenesis
45
 hypothesises 
that increased methylation (for example caused by aging), may affect critical "epigenetic 
gatekeeper" genes which, under normal conditions, are responsible for the regulation and 
differentiation of stem cells. Permanent silencing of such genes causes abnormal growth of 
these cells and stops their differentiation. This in turn provides time for genetic mutations to 
occur in genes which are involved in critical developmental pathways (such as the Wnt 
pathway in colon cancer), leading to increased tumour progression. 
A justification for this hypothesis is based on the idea of cancer stem cells being key initiators 
of cancer formation
7
. In normal stem cells, long-term repression of genes is controlled by the 
Polycomb complex of proteins. Many genes involved in the CIMP have also been found to be 
regulated by this complex
46
. There is evidence that genes regulated by Polycomb proteins are 
targeted by DNA methylation
47
. So increased methylation (e.g. as a result of aging) may be 
targeted to these stem cell genes, transforming the cells into cancer stem cells which then 
drive tumour formation. 
On the other hand, hyper-methylation may also be a downstream consequence of other 
genetic mutations. For example, the TET group of proteins are known to remove methylation 
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marks
48
. Hence a mutation which causes loss of function in one of these enzymes could lead 
to aberrantly high methylation, though this is yet to be proved. 
Another way in which hyper-methylation could promote tumour progression is by repressing 
microRNAs
41
. Such repression could cause increased transcription of the miRNA's target 
gene. If this gene were an oncogene (e.g. BCL-6)
49
 then this could promote tumour growth. 
1.5.2 Cancer-related hypo-methylation 
As mentioned above, at the same time as the hyper-methylation of CpG island promoters is 
occurring in cancer, the opposite effect of hypo-methylation has also been observed to occur 
in non-CpG islands. Whilst research has generally concentrated on the former, characteristics 
of these hypo-methylated regions are now also being elucidated
41
. 
Although this cancer-related hypo-methylation occurs on a genome-wide basis, recent 
research suggests that, rather than being randomly distributed, it tends to be concentrated in 
large, megabase stretches of DNA which in normal conditions are highly methylated
41
. These 
cancer-related regions of hypo-methylation are broken up by much smaller regions of hyper-
methylation, typically affecting CpG islands
50
. A key feature of these parts of the genome is 
that they appear to be associated with the nuclear envelope lamina
51
, and this has two 
potential implications. 
Firstly, DNA associated with the nuclear envelope lamina is subject to late replication. This 
potentially provides an explanation for the regions of hypo-methylation, in that the DNA 
maintenance methyltransferase DNMT1 may be overwhelmed by the extra methylation that 
has occurred in the hyper-methylated CpG islands. Hence there may not be sufficient DNMT1 
to fully maintain the methylation of the other, normally highly methylated areas, which 
19 
 
therefore experience passive demethylation via cell division and thereby become hypo-
methylated in cancer
34
. 
Secondly, in stem cells the nuclear envelope lamina region contains the majority of genes 
which are potentially subject to hyper-methylation in cancer
41
. Hence this gives further weight 
to the cancer stem cell theory mentioned above. 
It is not clear yet whether this wide-scale hypo-methylation has any causal effect on cancer, or 
whether it is simply a passive side-effect. However, there is some evidence that demethylation 
may be an important cause in some cancers (for example in some leukemias)
52
. 
1.6 Difficulties with genome-wide methylation analyses 
There are a number of technical difficulties in connection with the profiling of genome-wide 
methylation levels
53
. Firstly, DNA samples usually contain a mixture of cell types, each of 
which may have their own different methylation profiles. Hence, any measurement of 
methylation levels will be an average over all the different cells present in the sample.  
Of course the cell-type mixture is a problem for many other analytical techniques (eg gene 
expression analysis using microarrays). However, there are a couple of other issues which are 
specific to methylation profiling. Firstly, methylated cytosines are frequently mutated to 
thymine naturally, but this depletion does not occur at a uniform rate across the whole 
genome. Hence, there is a non-uniform distribution of methylated cytosines, which can have 
implications for the way in which experimental assays for detecting methylation are designed, 
especially if a genome-wide analysis is sought. 
Secondly, methylated and unmethylated cytosines cannot be distinguished by methods which 
rely on DNA hybridisation (such as microarrays). Furthermore, methylation tags are erased 
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when DNA is amplified by PCR. Hence experimental techniques are required to pre-process 
the DNA so that there is no subsequent erasure of information and / or so that hybridisation 
methods will work. Three key techniques, endonuclease digestion, methylated DNA 
immunoprecipitation, and bisulphite conversion have been devised for this purpose
53,54
. 
TCGA’s methylation data used in this project are based on bisulphite conversion. This 
method makes use of the fact that when denatured DNA is treated with sodium bisulphite, 
unmethylated cytosines are converted to uracil much more rapidly than methylated 
cytosines
55
. Hence, a difference in methylation status can effectively be converted to a genetic 
difference, which is then amenable to detection by techniques such as microarray 
hybridisation or next generation sequencing. Figure 4 is a schematic of the bisulphite 
conversion process taken from Illumina’s “Epigenetics” data-sheet. 
 
Figure 4 - schematic of bisulphite conversion process 
Schematic diagram of the bisulphite conversion process (taken from Illumina’s “Epigenetics” data-sheet). Unmethylated 
cytosines are converted to uracils, whereas methylated cytosines are not converted. 
However, the reduced complexity of the genome after conversion (effectively from four bases 
to three, except for methylated cytosines) means that careful consideration has to be given to 
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the design of hybridisation probes or methods for sequence alignment to allow for the reduced 
specificity
53
. 
The most widely used microarray technology for methylation profiling after bisulphite 
conversion is Illumina's HumanMethylation Beadchip
54
. This provides genome-wide 
methylation profiling at individual CpG site resolution. However, as with all microarray 
technologies, it suffers from the fact that the genome coverage is restricted to the actual CpG 
sites queried by the array - the more modern 450k version queries around 485,000 sites, 
whereas there are estimated to be around 28 million CpG sites in total throughout the human 
genome. 
1.7 TCGA methylation data 
TCGA use two different, but related, technology platforms to analyse the methylation levels 
of their samples. Both are produced by Illumina Inc. The older technology, which was in use 
until 2012, is the HumanMethylation27 BeadChip ("27k platform")
56
. This was superseded  
by the HumanMethylation450 BeadChip ("450k platform")
57
, which is the technology now 
being used. Both use microarray technology applied to DNA which has been bisulphite 
converted, as described in the previous section. After bisulphite conversion, the DNA is 
amplified using PCR, fragmented and then hybridised to specially designed oligonucleotides 
on the platform
53
. 
1.7.1 27k platform 
The 27k platform is the older technology which was introduced by Illumina in 2009
56
. It is 
capable of measuring genome-wide methylation levels of 27,578 different CpG sites for up to 
12 samples simultaneously. The CpG sites which are interrogated were chosen, primarily, 
because they fall within the proximal promoter regions of genes. 14,475 genes are covered 
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(by an average of 2 sites per gene), including over 200 cancer-related or imprinted genes. 254 
sites within the promoters of 110 miRNAs are also included. Where possible, CpG sites 
which fall within so-called CpG islands
58
 were selected. 
The 27k platform uses Illumina's proprietary Infinium I technology to measure the 
methylation states of individual CpG sites. The array is designed such that for each targeted 
CpG site there are two sets of "beads" which are used to hybridise with the sample DNA. One 
set is designed to hybridise with unmethylated cytosines, whereas the other is designed for 
methylated cytosines. Both types of hybridisation are recorded by the incorporation of a 
fluorescently labelled nucleotide of the same colour (which can be red or green depending on 
the based immediately before the interrogated cytosine). The methylation level for any 
particular CpG site is calculated as the ratio of the total number of hybridisations with 
methylated beads to the total number of hybridisations with both types of bead. 
1.7.2 450k platform 
The 450k platform
57
 is an updated version of the 27k platform, and therefore has many 
features in common with its predecessor. Again, up to 12 samples can be processed on one 
array. However, the 450k platform has much greater coverage of the genome, as it is capable 
of simultaneously measuring the methylation levels of 485,577 different CpG sites. There is a 
much more varied distribution of CpG sites across promoters / non-promoters and CpG 
islands / non-CpG islands. 99% of RefSeq genes are covered, at an average of 17 sites per 
gene, as are 96% of known CpG islands. Regions adjacent to CpG islands are also extensively 
covered. 
The other key difference relative to the 27k platform is that the 450k platform uses a 
combination of the Infinium I technology and Illumina's more recently developed Infinium II 
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technology. Whereas the former uses two beads for each CpG site, the latter uses only one 
bead. It works by single-base extension, whereby the colour of the incorporated, fluorescently 
labelled nucleotide is dependent on the methylation state of the interrogated CpG site. For an 
unmethylated site, a red-labelled adenine base, complementary to the bisulphite-converted 
uracil, will be incorporated, whereas for a methylated site a green-labelled guanine will be 
incorporated. The ratio of green fluorescence to total fluorescence detected then determines 
the methylation level. 
72% of the CpG sites on the 450k platform are interrogated using the Infinium II technology, 
with the other 28% being interrogated using the Infinium I technology. A diagram of how the 
Infinium techniques work, taken from the second Bibikova paper
57
, is included in figure 5. 
 
Figure 5 - diagram of (A) Infinium I and (B) Infinium II technology 
Schematic diagrams of (A) Infinium I and (B) Infinium II technologies (taken from Bibikova
57
). In (A) there are two separate 
probes, one for unmethylated cytosines and the other for methylated cytosines. Bisulphite-converted DNA will hybridise to 
only one of these depending on the methylation status of the target CpG site. Both types of hybridisation are recorded by 
the incorporation of a fluorescently labelled nucleotide of the same colour (which can be red or green depending on the 
base immediately before the interrogated cytosine). In (B) there is only one probe for each target CpG site. The colour of 
the incorporated, fluorescently labelled nucleotide is dependent on the methylation state of the interrogated CpG site. For 
an unmethylated site, a red-labelled adenine base, complementary to the bisulphite-converted uracil, will be incorporated, 
whereas for a methylated site a green-labelled guanine will be incorporated. 
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Out of the 27,578 CpG sites interrogated by the 27k platform, 25,978 are also interrogated by 
the 450k platform. Of these 25,978, 23,663 are measured using the Infinium II technology. 
Illumina claim that the correlation between platforms for the 25,978 common sites is greater 
than 95%
57
. 
1.7.3 Annotation of probes 
Illumina provide, for both platforms, annotation details of the interrogated CpG sites, which 
can be used for subsequent analysis of the methylation measurements. These details include 
items such as chromosome, starting position on chromosome and UCSC reference gene to 
which a site is associated.  
Also included are two separate labels, one of which indicates each site's position relative to 
the nearest gene ("gene location"), and the other its position relative to the nearest CpG 
island
36
 ("CpG island region").  
The classifications used to annotate the gene locations are as follows: 
 "Body" - the region between 3'UTR and the 1st exon 
 1st exon - the first transcribed exon 
 3'UTR - the untranslated region at the 3' end 
 5'UTR - the untranslated region at the 5' end 
 TSS1500 - the region between 200 and 1,500 bases upstream of the transcriptional 
start site 
 TSS200 - the region between the transcriptional start site and 200 bases upstream of 
this 
 other sites which do not fall into any of the above categories are unlabelled. 
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The classifications used to annotate the CpG island regions are as follows: 
 Island58 - a region of at least 500bp with more than 50% GC composition and 
observed / expected ratio of CpG dinucleotides of at least 60% 
 North shore59 - 2kb region immediately upstream of an island 
 South shore - 2kb region immediately downstream of an island 
 North shelf - 2kb region immediately upstream of a north shore 
 South shelf - 2kb region immediately downstream of a south shore 
 other sites which do not fall into any of the above categories are unlabelled. 
A schematic representation of both of these sets of labels, taken from the second Bibikova 
paper
57
, is shown in figure 6: 
 
Figure 6 - schematic of (A) gene locations and (B) CpG island regions 
Schematic diagrams of (A) gene location and (B) CpG island region annotation details provided by Illumina for each targeted 
CpG site (taken from Bibikova
57
). (A) shows the different types of gene location dependent on where the target CpG site is 
located relative to the nearest gene. (B) shows the different island regions dependent on where the target CpG site is 
located relative to the nearest CpG island. 
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1.7.4 TCGA level 1 data 
The primary outputs from the Illumina platforms are the fluorescent signals emitted by the 
incorporated nucleotides and detected by the imaging hardware. The initial processing of the 
images to produce raw intensity values is usually performed using the BeadScan software 
provided by Illumina themselves. The resultant intensity values are stored in special .idat 
files. These can then be input into Illumina's own GenomeStudio software for further 
processing, or other packages can be used for this purposes – Minfi60 and Methylumi61, both 
available in R
62
, being two common examples. The .idat files produced from TCGA's 
application of the Illumina platforms to their samples are freely available for download in 
their level 1 DNA methylation data. 
1.7.5 TCGA level 2 data 
The raw intensity values stored in the .idat files potentially need some degree of pre-
processing before they can be used to calculate methylation (“beta”) values63. In particular, 
intensity values may be inflated, to varying degrees, by "background" levels of fluorescence 
which are in no way related to differences in the biological samples being analysed. Also, due 
to imperfections in the imaging hardware, the way and extent to which intensity values have 
been detected may vary between samples for reasons other than genuine biological 
differences. Hence there may be a need to "normalise" measurements between samples.  
Neither of these “correction” processes is straightforward, and several approaches have been 
proposed for each 
64-68
. The key issue is to try and remove as much unwanted variation 
between samples as possible, whilst at the same time retaining as much genuine biological 
variation as possible. In their level 2 methylation data, TCGA provide separate intensity 
27 
 
values for methylated and unmethylated probes which have been adjusted for both 
background correction and normalisation using TCGA’s preferred methods. 
For background correction, TCGA use a method called normal exponential convolution
65
, 
which makes use of negative control probes on the Illumina platform. These probes are not 
intended to hybridise to the DNA samples, and so their purpose is to capture any background 
signal "noise" which is independent of the samples used. The method assumes that the signal 
for each probe can be considered to be the sum of the actual signal and the background noise, 
where the actual signal is assumed to follow an exponential distribution and the background 
signal is assumed to be normally distributed. The parameters for these distributions are then 
determined empirically from the data. 
TCGA also undertake a basic level of normalisation whereby samples in different “batches” 
have their intensities in each of the two channels (green or red) multiplicatively scaled to 
match a reference sample (the sample with red / green ratio closest to 1.0.) 
1.7.6 TCGA level 3 data 
TCGA’s level 3 methylation data contain, for each sample and probe, the estimated beta value 
calculated as the ratio of the level 2 methylated intensity to the sum of the level 2 methylated 
and unmethylated intensities. However, one further adjustment is made, because there may be 
some probes which have failed to work properly or which may need to be filtered out because 
they are prone to cross-hybridisation. Again the extent to which this adjustment is made is a 
matter of judgement, rather than there being any hard and fast rule. 
Probes which have failed to work properly, for whatever reason, can be identified through the 
so-called "detection p-values" which are produced by the Illumina software for each probe for 
every sample. These values are calculated using the negative control probes on the Illumina 
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platforms, and represent the probability for each given sample that the probe in question has 
registered a genuine signal rather than simply recording some background noise. The lower 
the detection p-value, the less likely it is that the probe has simply made a background reading 
(i.e. it is more likely that the probe has worked properly).  
The probabilities are calculated based on the distribution of actual measurements recorded by 
the negative control probes. For any given probability threshold, the user can decide to 
exclude any probes which have detection p-values greater than the threshold for a specified 
proportion of samples.  
The TCGA level 2 data include the detection p-values as a separate item for each probe on 
each sample, and the level 3 beta value data are replaced by "NA" where the p-value has 
exceeded 5%. The end user can then decide what proportion of samples with "NA" needs to 
be reached before any individual probe is filtered out across all samples for this reason. 
Incorrect hybridisation is a problem for certain subsets of probes. Probes which have common 
genetic variants in their sequences or which overlap with repetitive stretches of DNA are 
particularly prone to this
63
. So users need to be aware of this and potentially filter out affected 
probes. In their level 3 beta value data, TCGA have replaced the calculated beta values with 
"NA" for any probes whose sequences either: 
1. contain a Single Nucleotide Polymorphism within 10 base pairs of the interrogated 
CpG site (the dbSNP database is used for this purpose); or 
2. overlap with a repetitive DNA element within 15 base pairs of the interrogated site 
(based on UCSC hg19 human reference genome). 
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1.7.7 Data used for project 
The Y chromosome is the least represented chromosome on both Illumina platforms. The 27k 
platform contains only seven probes which interrogate CpG sites on the Y chromosome. 
However, the 450k platform contains 416 probes covering the vast majority of known Y 
chromosome genes in the male-specific region. Given the much greater coverage, my project 
has, therefore, been based on data obtained using the more modern platform. 
As indicated above, TCGA’s level 3 data already excludes beta values for certain subsets of 
probes. I preferred to work with the full probe-set, and make my own decisions on which 
probes to exclude. I, therefore, decided to use the background-corrected and normalised 
intensity values in TCGA’s level 2 data, from which I could derive beta values. One further 
advantage of this approach is that the total (methylated plus unmethylated) intensity values 
can also be used to estimate copy number variations
14
. 
1.7.8 Other processing issues 
For the 450k platform there is a further complication not allowed for by TCGA, namely that 
two different technologies (Infinium I and Infinium II) are used for different subsets of probes 
as described previously. Research has shown that the distribution of methylation values for 
the two subsets are different, in particular that the Infinium II probes have a smaller range of 
values than the Infinium I probes even when differences in the characteristics of the targeted 
probes are taken into account
69
.  Hence this difference could lead to further distortions in any 
subsequent analyses, as Infinium I probes may appear to be have higher levels of differential 
methylation relative to Infinium II probes simply because of their greater dynamic range. 
A number of techniques have been proposed to adjust for this imbalance between the two 
Infinium technologies
69-74
. However, it is not clear which , if any, is the most suitable, nor 
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indeed whether further normalisation (on top of the background and normalisation correction 
already undertaken by TCGA) is required at all. A large-scale benchmarking study would be 
required to answer this, and would need an objective, independent method (for example 
pyrosequencing) to compare results and determine the most appropriate technique. In the 
absence of such a study, the final answer is a judgement, which can be assisted, for example, 
by investigating any major inconsistencies in results for probes produced using the different 
technologies
63
.  
Even after corrections for background effects and normalisation have been made, and 
unreliable probes have been filtered out, there is yet one more potential source of inaccuracy 
in the data. These are generally known as "batch" effects, and relate to the fact that different 
groups (or batches) of samples which have been processed at different times and / or by 
different researchers may have been subject to slightly different experimental conditions
63
. It 
is possible that such batch effects may introduce systematic bias in any downstream analysis 
if they are not corrected for.  
The existence of batch effects can often be identified by using unsupervised clustering of 
samples (for example using Principal Components Analysis) to discover whether samples 
group together according to their methylation profiles. If such clustering is observed, then 
some form of correction may be necessary. Batch effects have been shown to be a potential 
problem for methylation data generated on the Illumina platforms
75
. Furthermore, batch 
effects are potentially an even greater problem for total intensity values. 
There are two ways, in particular, in which TCGA samples have been grouped which could 
cause batch effects. Firstly, different groups of samples have been collected by different 
institutions (known as "tissue source sites"). Secondly, TCGA groups samples into "batches" 
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when handling them. Both of these groupings could potentially produce unwanted batch 
effects due to any unintentional differences in the way different groups of samples are 
handled (even though the overall handling procedures are in theory the same). However, both 
of these pieces of information are available to download for all TCGA samples, so the 
existence of any batch effects can be investigated and corrected if necessary. 
1.8 Other data types used 
My project has been based primarily on TCGA’s methylation data, both for methylation 
analyses and also copy number estimation. However, I have also used three other biological 
datasets from TCGA to supplement my analyses: 
1.8.1 Copy number data 
I used TCGA’s level 3 copy number data to act as a check on my estimates based on the 
methylation data and for some subsequent analyses. The copy number data had been produced 
using the Affymetrix Genome-Wide Human SNP Array 6.0
76
. The raw values had then been 
tangent-normalized
77
 and segmented using Circular Binary Segmentation
78
. 
1.8.2 Gene expression data 
To analyse the transcriptomic effects of aberrant methylation and copy number variations, I 
then used TCGA’s level 3 RNA sequencing data, which provides a measure of gene 
expression. Raw read data had been produced using the Illumina HiSeq 2000 RNA 
Sequencing platform
79
 and aligned to the reference human genome using MapSplice
80
. The 
RSEM algorithm
81
 had then been used to estimate expression levels from the raw read data, 
and these estimates had been normalised between samples at the gene-level by setting the 
upper quartile value to 1,000. 
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1.8.3 Somatic mutation data 
Finally, for the HNSC dataset only, I also made use of TCGA’s level 2 somatic mutation data. 
In particular I used these data to identify those tumour samples which harboured a mutation of 
the TP53 gene. Raw sequencing data had been produced using the Illumina HiSeq200 
platform and aligned to the reference genome using the Burrows-Wheeler alignment 
algorithm
82
. Mutations had then been identified using the MuTect algorithm
83
. 
1.9 Cancer types investigated 
As mentioned previously, my analyses have been based on three different cancer types. Brief 
overviews of key characteristics of each of these are set out below: 
1.9.1 Colon adenocarcinoma 
Colon cancer is the third most common cancer worldwide, with over one million new cases 
reported every year. It is more prevalent in men than in women, and incidence is strongly age-
related. Around 5% of cases are believed to be inherited, but the vast majority are sporadic
84
.  
As well as a family history of cancer, there are several other risk factors, including 
inflammatory bowel disease, smoking, alcohol consumption, eating red meat, obesity and 
diabetes. Treatment is usually via a mixture of surgery, radiotherapy and chemotherapy. 
Survival rates have increased gradually over time, with five year survival now averaging 
around 65%
84
.  
Colon cancer is known for its molecular heterogeneity. Three main molecular features have 
been observed, involving micro-satellite instability (MIN), chromosomal instability (CIN) and 
CpG island methylator phenotype (CIMP) 
85
. These features are not mutually exclusive. 
Around 70% of cases involve an early mutation in the APC tumour suppressor gene. Other 
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frequently mutated genes include the KRAS and BRAF oncogenes and the TP53 tumour 
suppressor gene. 
Aberrant methylation has been extensively studied in colon cancer, which was the first cancer 
type in which the CIMP was observed
11
. CIMP tumours typically also include BRAF 
mutations and high micro-satellite instability
86
. Promoter methylation of the MLH1 tumour 
suppressor gene is also a common characteristic. 
Very little research has been reported on the effects of Y chromosome aberration in colon 
cancer. However, there is evidence that LoY is a common feature in male colon cancers
26
. 
1.9.2 Head and neck squamous cell carcinoma  
Head and neck cancer, of which squamous cell carcinoma is by far the most common subtype, 
is the sixth most common cancer worldwide
1
 with around 600,000 new cases each year
87
. It is 
more prevalent in men than in women. It is sub-categorised by location into five sub-regions: 
oral cavity, larynx, hypopharynx, oropharynx and nasopharynx
88
. It is treated with a mixture 
of surgery, radiotherapy and chemotherapy, but its high level of molecular heterogeneity 
makes prediction of outcome very difficult, with five year survival rates of around only 
50%
13
. 
Mutational inactivation of the TP53 tumour suppressor gene is a common feature of head and 
neck cancer, and this often results in general chromosomal instability
13
. The two most 
common risk factors are smoking and alcohol consumption, and research has indicated that 
these may act synergistically in the carcinogenic process
89
. A further, important risk factor is 
infection with the human papillomavirus (HPV), which is believed to inactivate both TP53 
and Rb tumour suppressor genes. HPV induced cancers represent around 25% of new cases, 
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and are particularly prevalent in the orophayrnx
13
. It is believed that their aetiology is 
different to other head and neck cancers
90
, and that they may have a better prognosis
91
. 
Again there has been very little research into the effects of Y chromosome aberrations. 
However, LoY has been observed in high proportions of male head and neck cancers, and has 
been reported as possibly being linked to impaired survival
27,28
. 
1.9.3 Kidney renal clear cell carcinoma 
There are around 300,000 new cases of kidney cancer diagnosed worldwide each year, and 
around 75% of these are clear-cell carcinomas
92
. The prevalence in males is roughly 1.5-2 
times higher than in females, and key risk factors are smoking, hypertension and obesity
93
. 
Surgery is the main form of treatment, as kidney tumours are notoriously resistant to 
chemotherapy and radiotherapy. However, some do respond to angiogenesis inhibitors
94
.  
A small proportion of cases are hereditary and associated with von Hippel Lindau disease, 
involving mutation of the VHL gene on the short arm of chromosome 3. VHL is also 
inactivated in around 90% of sporadic tumours, either by mutation or hyper-methylation
92
.  
There is considerable mutational heterogeneity within tumours
95
. Loss of chromosome 3p is 
also commonly observed. Other genes on 3p are also inactivated, either by mutation or hyper-
methylation, including PBRM1 and RASSFIA
95,96
. 
Once again there has been very little research into Y chromosome aberrations and kidney 
cancer, but LoY has been observed to occur in around 55% of male cases
25
. 
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2. Materials and methods 
My project considers the following changes in the male-specific region of the Y chromosome, 
and their impacts in male cancers: 
1. Aberrant DNA methylation 
2. Loss of chromosome 
3. Correlation of 1 and 2 with changes in gene expression 
4. Impact of 1 and 2 on survival 
5. Association of 2 with key risk factors for head and neck tumours 
This chapter sets out details of the data, software and methods used for the analyses described 
in subsequent chapters. 
2.1 Data used 
My project is based entirely on TCGA data which can be freely downloaded via their data 
portal (https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp). I downloaded all data using the 
“Data matrix” option within TCGA’s data portal.  
2.2 Datasets used 
As the initial focus of my project was on DNA methylation, I reviewed the available data to 
find some large methylation datasets which could be used for my analyses. I concentrated on 
data produced using Illumina’s 450k platform, as the 27k platform contains only 7 probes for 
the Y chromosome. The 450k platform contains 416 Y-linked probes. 
As previously mentioned I initially chose TCGA’s kidney renal clear cell carcinoma (KIRC) 
dataset. I downloaded the KIRC methylation and clinical data on 30 January 2013. 
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I subsequently selected a second dataset so that I could compare results with those obtained 
from my analyses of the KIRC dataset. For this purpose, I chose the colon adenocarcinoma 
(COAD) dataset. I initially downloaded the COAD methylation and clinical data on 23 July 
2013.  
In order to create a consolidated set of analyses for both case studies based on the most up to 
date information available at the time, I downloaded the methylation and clinical data for both 
datasets again on 2 December 2013. 
Finally, on 4 February 2015 I selected and downloaded methylation and clinical data for a 
third dataset. This time I used TCGA’s head & neck squamous cell carcinoma (HNSC) 
dataset. 
I used the methylation data for each of the three cancer types to:  
1. analyse changes in DNA methylation in respect of probes targeted at the Y 
chromosome; and 
2. perform initial analyses of copy number changes for the Y chromosome (in particular 
chromosomal loss). 
Subsequent to the above analyses, I downloaded the following additional data for each cancer 
type to perform further analyses: 
1. Level 3 copy number data to verify the results of 2 above and for further downstream 
analyses; and 
2. Level 3 RNA-sequencing data to investigate the effects of aberrant methylation and 
loss of Y chromosome on expression of Y-linked genes 
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I also downloaded level 2 somatic mutation data for the HNSC dataset only, to investigate 
correlations between loss of Y chromosome and frequently occurring mutations (in particular 
in TP53). 
I set out further details of the data which I downloaded in the following sections. 
2.3 Methylation data 
I downloaded all available level 2 and level 3 methylation data generated on the Illumina 
450k platform for each of the three datasets.  
Table 1 provides a summary of the numbers of samples for which I downloaded methylation 
data: 
 COAD HNSC KIRC 
Tumour samples 291 528 301 
Normal samples 38 52 160 
Total 329 580 461 
 
Table 1 - summary of downloaded methylation data 
 
All data are stored in individual text files for each sample, and were downloaded in 
compressed format. For each cancer type I merged the individual files into one large data file 
using R
62
 for subsequent analyses. 
On inspection of the data, I noticed that a small number of samples contained duplicate 
records. I therefore removed the extra copies – this resulted in 5 KIRC duplicates and 17 
COAD duplicates being removed. 
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My analyses are based on the level 2 data which contain, for each sample, measurements of 
methylated intensity, unmethylated intensity and detection probability values for each probe. I 
derived beta values for each sample / probe as the ratio of methylated intensity to total 
intensity, the latter being the sum of methylated and unmethylated intensities. 
I also downloaded annotation data for the 450k platform directly from Illumina’s website. 
2.4 Clinical data 
TCGA also make freely available anonymised clinical information for patients. I downloaded 
all available clinical data in the “Biotab” format for each dataset at the same time as the 
corresponding methylation data were downloaded.  
The clinical data are provided across several text files, and can be sub-divided into three 
broad categories: 
1. General information – e.g. gender, age, year of diagnosis 
2. General cancer-related information – e.g. stage, grade, histological type, treatment 
details 
3. Cancer-type-specific information – e.g. anatomic subdivision (COAD), HPV status 
(HNSC), laterality (KIRC) 
Unfortunately, no clinical data were available for 3 COAD, 17 HNSC and 11 KIRC samples, 
and so I have excluded these samples from all my analyses. 
Table 2 sets out the final numbers of methylation data samples which I have used in my 
analyses, after removal of samples which were either duplicated or had no corresponding 
clinical information: 
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 COAD HNSC KIRC 
 Male Female Male Female Male Female 
Tumour samples 148 122 375 138 189 96 
Normal samples 21 18 38 12 106 54 
Total 169 140 413 150 295 150 
 
Table 2 - summary of final methylation data numbers 
2.5 Copy number data 
In order to check the Y chromosome copy number estimates derived from the methylation 
data, and also for further use in downstream analyses, I downloaded TCGA’s copy number 
data for each dataset. For this purpose I used the level 3 data produced using the Affymetrix 
Genome-Wide Human SNP Array 6.0. 
I downloaded the level 3 copy number data for COAD, HNSC and KIRC on 21 January 2015, 
5 February 2015 and 3 December 2014 respectively. These data contain segmented copy 
number data for each chromosome (including Y). 
For each dataset there were four separate text files for each sample which had been processed 
on the Affymetrix platform.  Two of the four files contain results which had been produced 
using version hg18 of the human reference genome, with the other two containing results 
based on version hg19. The latter is consistent with the reference genome used by Illumina’s 
450k platform, and I, therefore, used these data for my analyses. 
Within the hg19 data there were two separate files for each sample – one of these was labelled 
“nocnv” and contains only somatic copy number variations. The other file potentially also 
contains germline as well as somatic copy number variations. Ideally I would have used the 
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“nocnv” data, but unfortunately I discovered, by inspection, that these files do not contain any 
results for the Y chromosome. I, therefore, decided to use the other data files. I performed 
comparisons of the results from the two types of file for other chromosomes, and found that 
they were highly consistent (data not shown). I was, therefore, confident that I could use my 
chosen files for my analyses. 
In order to organise the data into a more helpful format, for each cancer type I merged all the 
results for all chromosomes and samples into one large array using R. I restricted myself to 
those samples for which 450k methylation data were also available, and also removed 
duplicate samples. My final merged data files contained 308 COAD samples (out of 309 on 
the 450k platform), 555 HNSC samples (out of 563) and 433 KIRC samples (out of 445). 
2.6 Gene expression data 
To analyse the association between aberrant methylation / copy number loss of the Y 
chromosome with gene expression, I downloaded TCGA’s RNA-sequencing data for each 
dataset. For this purpose I used the level 3 data produced using the Illumina HiSeq 2000 RNA 
Sequencing platform and TCGA’s version 2 pipeline. 
I downloaded the level 3 RNA-sequencing data for COAD, HNSC and KIRC on 21 January 
2015, 14 February 2015 and 28 November 2014, respectively. 
For each dataset there were six separate files for each sample which had been processed on 
the Illumina HiSeq platform. For my analyses, I used the files labelled 
“rsem.genes.normalized_results”, which contain normalised expression levels at gene-level 
for over 20,000 genes, including those on the Y chromosome. 
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Once again, I merged all the results for all genes and samples into one large file using R, and 
restricted myself to those samples for which 450k data were also available. My final merged 
data files contained 271 COAD samples (out of 309 on the 450k platform), 542 HNSC 
samples (out of 563) and 308 KIRC samples (out of 445). 
2.7 Somatic mutation data 
The final data I downloaded from TCGA contained somatic mutations, for the HNSC dataset only. For 
this purpose I used TCGA’s level 2 data produced using the IlluminaGA DNASeq platform. I 
downloaded these data on 29 March 2015. The output consisted of a database containing a list of all 
somatic mutations identified for each sample. The data included gene name and type of mutation. 
2.8 Software used for analyses 
All analyses were performed using a combination of Microsoft Excel and (mainly) programs 
written in R. During my analyses, I used a number of special R packages which can be freely 
downloaded. Details of these packages are set out in table 3 below: 
Package Use 
BSgenome.Hsapiens.UCSC.hg19 Calculating CpG densities in chapter 3 
DNAcopy Segmentation of copy number data derived from 
methylation data in chapter 4 
Scatterplot3d Producing 3D scatterplots in chapter 5 
Survival Survival analyses in chapter 6 
 
Table 3 - R packages used in analyses 
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2.9 Statistical analyses 
I used a number of standard statistical methods in my analyses. In particular: 
 Kruskal-Wallis test for comparing extent of loss of chromosomal arms between 
different sub-groups of male patients 
 Kaplan-Meier (with log-rank test) and Cox Proportional Hazards methods for survival 
analyses 
I used a significance level of 5% in all statistical tests. 
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3. Differential methylation of the Y chromosome 
In this chapter I set out details of my analyses of differential methylation, between normal and 
tumour samples, of CpG sites on the Y chromosome.  
An overview of the process I have followed is provided in figure 7: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 - overview of experimental process for differential methylation analyses 
 
I set out details of each of the above stages in the following sections. 
Filter out suspicious samples / probes 
Consider and correct potential batch effects 
Overview of 450k platform probes for Y chromosome 
Analyse Y chromosome methylation of normal samples 
Analyse general Y chromosome methylation differences in tumour samples 
Analyse CpG-site-specific Y chromosome methylation changes in tumour samples 
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3.1 Filtering of samples and probes 
My first consideration was to check whether there are any Y chromosome probes on the 450k 
platform which may be prone to cross-hybridisation with other parts of the genome and 
which, therefore, could provide misleading measurements. My plan was to identify any such 
probes and remove them from my analyses. 
In order to perform this check, I decided to investigate the total (methylated plus 
unmethylated) probe intensities for the female samples – my reasoning being that since 
females do not possess a Y chromosome, their total intensities should be at a very low 
background level, and much lower than the corresponding values for male samples. Any 
probes for which female samples have high total intensities, comparable with male values, are 
likely to have cross-hybridised with other parts of the genome. 
3.1.1 Filtering of samples 
Whilst carrying out my analysis, I also observed that there were a number of samples, both 
male and female, whose total intensity measurements were consistent with someone of the 
opposite gender – i.e. it is likely that their gender had been misrecorded.  
In total I identified nine female samples (six COAD, one HNSC and two KIRC – the latter 
being one patient for whom there was both a normal and tumour sample, the others all being 
tumour samples) whose Y chromosome probe intensities suggested that they were more likely 
to be male.  
Although these samples were not important for the main parts of my analyses, I decided to 
remove them at this stage before checking the total intensities of individual probes. 
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I also observed six COAD, one HNSC and two KIRC male samples whose Y chromosome 
intensities were consistent with those of female samples (i.e. very low). It is possible that 
these males had suffered a complete loss of Y chromosome. However, their intensity 
measurements were so significantly lower than those of any other males, including patients 
who appeared to have suffered significant Y chromosome loss (see chapter 4), that I 
considered this possibility unlikely.  
It is also possible that the gender labels for the nine females and nine males had in some way 
been interchanged, but I considered this unlikely (I double-checked my merging of the data to 
ensure that I had not inadvertently caused an error). Hence, as I could not be certain of the 
reason for the apparent discrepancies, I decided to also remove the nine male samples from 
my analyses.  
I set out in table 4 the final data numbers allowing for the removal of the 18 samples 
described above: 
 COAD HNSC KIRC 
 Male Female Male Female Male Female 
Tumour samples 142 116 374 137 188 95 
Normal samples 21 18 38 12 105 53 
Total 163 134 412 149 293 148 
Table 4 - summary of final numbers of methylation samples used 
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3.1.2 Filtering of probes 
I then looked at the total female intensities (tfi) for all 416 Y chromosome probes. Figure 8 
shows a plot of the tfis for each probe summed across all female KIRC samples, in increasing 
order from left to right:  
 
Figure 8 - plot of KIRC total female intensities 
The total intensity measurements across all female samples were calculated for each of the 416 Y chromosome probes. The 
416 total intensity values are shown in increasing order from left to right. 
The plot shows that there is a small proportion of probes which have very high tfis – there 
were 43 probes with a tfi of at least 50,000. These probes are potentially cross-hybridising 
with other parts of the genome. I chose a threshold of 50,000 because there was a significant 
increase in the differences between consecutive, ordered tfis at this point – from 46,817 to 
53,607, which was more than four times higher than the previous highest difference. 
I observed similar tfi patterns for both the COAD and HNSC datasets. For COAD there were 
42 probes with a tfi of at least 50,000, and for HNSC there were 40 probes with a tfi of at 
least 100,000.  
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Figure 9 compares, for each probe, the KIRC tfis against COAD (left) and HNSC (right): 
  
Figure 9 - comparison of KIRC total female intensities vs COAD & HNSC 
The chart on the left shows KIRC total female intensities plotted against COAD total female intensities for each of the 416 
probes. The blue lines represent the thresholds of 50,000 in both cases. The chart on the right shows KIRC versus HNSC 
total female intensities, with the blue lines representing the thresholds of 50,000 and 100,000 respectively. 
Figure 9 shows that there is excellent consistency between the different datasets (Pearson 
correlation of 0.99, p-value less than 0.0001 in both cases). 
There were 39 probes for which the tfi exceeded 50,000 for both COAD and KIRC and 
100,000 for HNSC, and these were my prime candidates for cross-hybridising probes. I then 
used NCBI’s nucleotide BLAST facility to check whether there is any evidence that these 
probes actually map to other parts of the genome. I discovered that 32 of the 39 probes have 
high (89% or more) sequence homology with regions on the X-chromosome. I, therefore, 
decided to exclude these 32 probes from my subsequent analyses. A list of the 32 probes is 
included in Appendix 1. I retained the other 384 of the original 416 probes for further 
analyses. 
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3.1.3 Summary 
18 samples were removed across the three datasets on account of their gender information 
looking suspicious. 32 Y chromosome probes were removed because of potential cross-
hybridisation issues, leaving 384 probes for further analysis. 
 
3.2 Consideration of potential batch effects 
I then considered whether any batch effects were present in the male methylation data. I 
investigated two data items of potential interest – “batch” and “tissue source site” – and 
performed separate analyses of beta values and total intensities. In all cases I performed 
principal components analysis (PCA) to determine whether there were any batch effects. 
3.2.1 Impact of low total intensity measurements 
Figure 10 shows a plot of the first two principal components of my PCA for the KIRC male, 
Y chromosome beta values. 
 
Figure 10 - PCA of KIRC beta values 
Principal components analysis was performed using the KIRC male Y chromosome beta values. The first two principal 
components for each sample are shown on the x- and y- axes respectively. Tumour samples are shown in red and normal 
samples in blue. 
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The normal samples (in blue) are grouped together at the top left of the chart, whereas there 
appear to be two distinct groups of tumour samples (in red). I, therefore, next considered 
whether the grouping of tumour samples may have been caused by batch issues. Figure 11 
shows the same plot as in figure 10 but with samples now colour-coded according to “batch” 
(in the left hand plot) and “tissue source site" (in the right hand plot): 
  
Figure 11 - PCA of KIRC beta values using "batch" and "tissue source site" 
Principal components analysis was performed using the KIRC male Y chromosome beta values. The first two principal 
components for each sample are shown on the x- and y- axes respectively. Samples are colour-coded according to “batch” 
in the left hand chart and “tissue source site” in the right hand chart. 
These plots show that the observed grouping of tumour samples was not caused by the 
“batch” or “tissue source site” data items. Similar results were obtained for the COAD and 
HNSC datasets (data not shown). 
Whilst I was reviewing the data, I had noticed that there were some male samples (all 
tumours) in each dataset which had low total intensity values for most of the Y chromosome 
probes. I believe these samples to be cases which have suffered some loss of chromosomal 
DNA (see next chapter). I wondered whether copy number loss of Y chromosome may impact 
on beta value measurements and may be the cause of the observed grouping.  
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As a preliminary step, I therefore plotted, for each of the 384 probes, total intensity 
measurement against beta value for all male samples. By reviewing these plots, I noticed a 
couple of anomalies which were common to all three datasets: 
 For CpG sites which were generally methylated at low levels, those tumour samples 
which had low total intensity measurements tended to have higher beta values than the 
other samples; and 
 Conversely, the same samples tended to have lower beta values than other samples for 
CpG sites which were generally highly methylated. 
Figure 12 shows a couple of plots using the KIRC dataset to illustrate these issues: 
  
Figure 12 - examples of beta value anomalies caused by low intensity measurements 
The charts show plots of beta value (x-axis) versus total intensity (y-axis) for all male KIRC samples. The left hand chart is for 
probe cg00272582, and the right hand chart is for probe cg08528516. Tumour samples are shown in red and normal 
samples in blue. 
In both plots, the beta values for tumour samples with low total intensity measurements tend 
towards the centre of the plot (i.e. beta value of 0.5). Including these samples in my 
differential methylation analyses could distort the results. 
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In order to assess the scale of the problem, I plotted the total intensities for all samples 
(normal and tumour) in ascending order, as shown for the KIRC dataset in figure 13: 
 
Figure 13 - plot of total intensities for KIRC samples in ascending order 
For each KIRC sample, the average total intensity measurement was calculated across all 384 probes, and plotted in 
ascending order from left to right. Tumour samples are shown in red and normal samples in blue. 
Figure 13 shows that there is a sizeable subset of tumour samples whose total intensities are 
lower than the corresponding measurements for all normal samples, and that the latter are 
grouped together in a relatively narrow band. I observed the same pattern for both the COAD 
and HNSC datasets. 
I decided that, for the purposes of my differential methylation analyses, I would remove all 
tumour samples for which the total intensity measurements (across all 384 probes) were lower 
than the lowest corresponding measurement across all the normal samples within the same 
dataset. As a result, I removed 70 (out of 142) COAD tumour samples, 153 (out of 374) 
HNSC samples, and 80 (out of 188) KIRC samples. 
Figure 14 shows the same plots as shown in figure 12 after the low intensity tumour samples 
had been removed: 
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Figure 14 - examples of removal of beta value anomalies 
The charts show plots of beta value (x-axis) versus total intensity (y-axis) for male KIRC samples after the low intensity cases 
had been removed. The left hand chart is for probe cg00272582, and the right hand chart is for probe cg08528516. Tumour 
samples are shown in red and normal samples in blue. 
Figure 15 is a repeat of figure 10 with the low intensity tumour samples now coloured green: 
 
Figure 15 - PCA of KIRC beta values showing low intensity cases separately 
Principal components analysis was performed using the KIRC male Y chromosome beta values. The first two principal 
components for each sample are shown on the x- and y- axes respectively. Low intensity tumour samples are shown in 
green, other tumour samples are shown in red and normal samples in blue. 
The plot clearly shows that the low intensity cases form a distinct group from the other 
tumour samples. Similar results were obtained for the COAD and HNSC datasets (data not 
shown). 
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I then repeated my initial PCA after the low intensity tumour samples had been removed. A 
plot of the first two principal components is shown in figure 16: 
 
Figure 16 - PCA of KIRC beta values excluding low intensity cases 
Principal components analysis was performed using the KIRC male Y chromosome beta values, with the low intensity cases 
removed. The first two principal components for each sample are shown on the x- and y- axes respectively. Tumour 
samples are shown in red and normal samples in blue. 
After the low intensity samples had been removed, normal and tumour samples clearly 
formed two separate clusters based on the first principal component (shown on the x-axis), 
and there were no longer two distinct groups of tumour samples. Again, similar results were 
obtained for the COAD and HNSC datasets (data not shown). 
3.2.2 Checking of batch effects – beta values 
Although the low intensity issue had been the main confounding factor in the beta value data, 
I also wanted to check that there were no serious batch effects for the samples which I had 
retained for my methylation analyses. Figure 17 shows the results of my PCA for the KIRC 
dataset, with samples colour-coded according to “batch” and “tissue source site”: 
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Figure 17 - PCA of KIRC beta values using "batch" and “tissue source site” 
Principal components analysis was performed using the KIRC male Y chromosome beta values, after the low intensity cases 
had been removed. The first two principal components for each sample are shown on the x- and y- axes respectively. 
Samples are colour-coded according to “batch” in the left hand chart and “tissue source site” in the right hand chart. 
There are no obvious batch effects present in the above plots as there is no obvious grouping 
of samples by either variable. Given this and the fact that sample type (tumour or normal) was 
clearly the most significant discriminator between samples (confirmed by multiple linear 
regression analysis – p-value < 0.0001 for association between the first principal component 
and sample type), I decided that no further remedial action was required in respect of the beta 
value measurements. Similar results were obtained for the COAD and HNSC datasets. 
3.2.3 Checking of batch effects – total intensity values 
In the next chapter I look at Y-chromosome copy number variations, using, in the first 
instance, the total methylation intensity data to estimate copy number. I, therefore, also 
wanted to check whether there were any serious batch effects which may have distorted the 
total intensity measurements. 
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Figure 18 shows the results of my initial PCA of the total intensity measurements using all the 
male samples: 
 
 
Figure 18 - PCA of KIRC total intensity measurements 
Principal components analysis was performed using the KIRC male Y chromosome total intensity values. The first two 
principal components for each sample are shown on the x- and y- axes respectively. Low intensity tumour samples, as 
previously defined, are shown in green, other tumour samples are shown in red and normal samples in blue. 
The previously identified low intensity cases (in green) form a distinct subgroup of samples, 
as I had expected. The remaining tumour and normal samples form another group. There is, 
however, some variability within both groups, suggesting that there might be some batch 
effects. Similar results were also obtained for the COAD and HNSC datasets (data not 
shown). 
I then performed the same analysis again, but this time colour-coding the samples according 
to either “batch” or “tissue source site”. Figure 19 shows the first two principal components of 
my PCA for the KIRC total intensity measurements using “batch” and “tissue source site” as 
the items of interest: 
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Figure 19 - PCA of KIRC total intensities using "batch" & "tissue source site" 
Principal components analysis was performed using the KIRC male Y chromosome total intensity values. The first two 
principal components for each sample are shown on the x- and y- axes respectively. Samples are colour-coded according to 
“batch” in the left hand chart and “tissue source site” in the right hand chart. 
The plots confirm that there is a potential batch effect present, especially in relation to the 
“batch” variable. A similar issue was observed for both the COAD and HNSC datasets. To 
illustrate this point further, figure 20 shows a plot of all male total intensity values (averaged 
across all 384 probes) for the KIRC dataset, broken down by “batch”: 
 
Figure 20 - plot of KIRC average male total intensities split by "batch" 
For each KIRC sample, the average total intensity measurement was calculated across all 384 probes, and plotted against 
the y-axis. Normal samples are shown in blue, corresponding matched tumour samples in light blue, and other unmatched 
tumour samples in red. Samples are subdivided into “batch” along the x-axis. 
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The above plot illustrates that there are some discrepancies between batches. In particular, 
looking at the values for normal samples (in dark blue), batch 63 values are higher than for 
other batches. Once again, a similar issue was observed for the COAD and HNSC datasets. 
I, therefore, decided to make some adjustment to the total intensity values, so that the 
distributions of values across different batches were more consistent. I decided to base my 
adjustment on the measurements for normal samples, as there is much lower variability 
between normal samples compared with tumour samples. I calculated the median average 
intensity across all normal samples within each batch, and then adjusted the total intensity 
values for all samples within a batch by the ratio: 
median normal intensity across all batches /  batch-specific median normal intensity 
This method better aligned total intensity values between batches, as shown in figure 21 for 
the KIRC dataset: 
  
Figure 21 - KIRC average male total intensities split by "batch" before and after adjustment 
For each KIRC sample, the average total intensity measurement was calculated across all 384 probes, and plotted against 
the y-axis. Normal samples are shown in blue, corresponding matched tumour samples in light blue, and other unmatched 
tumour samples in red. Samples are subdivided into “batch” along the x-axis. The left hand plot shows values before 
“batch” correction, and the right hand plot show values after correction. 
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I employed the same process for both the COAD and HNSC datasets. Note that beta values 
were left unadjusted – only total intensity values were adjusted. 
One issue with this method is that it did not make any adjustment for batches which contained 
no normal samples – this was a particular issue for the COAD and HNSC datasets. However, 
I took the view that there was too much variability in measurements for tumour samples for 
me to be able to make a sensible adjustment for such batches and, consequently, I accepted 
that there might be a small amount of error in total intensity measurements for samples in 
these batches. I also tried another method for making these adjustments, known as trimmed 
mean quantile normalisation
67
 (applied to all 450k platform probes, not just those targeting 
the Y chromosome), and obtained very similar results (data not shown). 
3.2.4 Summary 
Beta values appeared to be distorted by low overall intensity measurements. Samples with 
consistently low intensity measurements were removed from subsequent analyses which used 
the methylation data. No residual batch effects were detected for beta values. However, batch 
effects were detected for total intensity values, and were partially corrected. 
 
3.3 Overview of Y chromosome probes on 450k platform 
Following the filtering out of potentially cross-hybridising probes, 384 Y chromosome probes 
on the 450k platform remained for further analysis. These probes span the male-specific 
region on the Y chromosome between 2.65 million and 28.55 million bases, which represents 
less than one half of the length of the entire chromosome (approx 59 million bases). However, 
they cover 55 genes (out of an estimated total of around 60). 
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I set out in the following sections details of key characteristics of the 384 probes, and how 
they compare to the whole set of probes on the 450k platform. 
3.3.1 CpG density of Y chromosome probes 
As described in chapter 1, some regions of the human genome are sparsely populated with 
CpG sites, whereas others are densely populated. It is possible that CpG density may 
influence changes in methylation patterns in cancer
34
. I, therefore, investigated the CpG 
density of those regions to which the 384 Y chromosome probes are targeted. 
For each CpG site, I counted the number of CpG dinucleotides located in the 500bp window 
centred on the site. For this purpose I used the “BSgenome.Hsapiens.UCSC.hg19” package in 
R.  
Figure 22 shows the distribution of CpG densities for the 384 probes, and the corresponding 
distribution for all the probes on the 450k platform: 
  
Figure 22 - distribution of CpG densities of Y probes and all 450k probes 
The number of CpG dinucleotides in the 500bp window centred on each targeted CpG site was calculated. The left hand 
histogram shows the distribution of counts for the 384 Y chromosome probes. The right hand histogram shows the 
distribution for all probes on the 450k platform.  
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Figure 22 shows that there appears to be a bi-modal distribution of CpG density, with a peak 
at very low values, and a second slightly lower peak at a count of around 30 CpG sites. This 
pattern is similar to the pattern for all 450k probes, although for the latter there is a smoother 
distribution (as there are a lot more probes), and the second peak occurs earlier at a count of 
around 20 CpG sites. 
3.3.2 Breakdown of Y chromosome probes by island regions 
As described in Chapter 1, Illumina provide for the 450k platform an annotation item which 
describes the relationship between each interrogated CpG site and the nearest CpG island. I 
will use the term “island region” for this item. 
I set out in figure 23 a pie-chart showing the distribution of island regions for the 384 Y 
probes, along with a corresponding pie-chart for all 450k probes: 
 
  
Figure 23 - distribution of island regions of Y probes and all 450k probes 
Pie-charts showing the distribution of island regions in which probes on the 450k platform are located. The left hand chart 
shows the distribution for the 384 Y chromosome probes. The right hand chart shows the distribution for all probes on the 
450k platform. 
61 
 
Figure 23 shows some differences between the distribution of island regions for the 384 Y 
probes and the distribution for the whole 450k platform. In particular, the Y probes contain a 
greater proportion of sites located in “north shores” (23% vs 13%), and a lower proportion 
(23% vs 36%) in areas more than 4,000 base pairs away from the nearest island (which I have 
called “oceans”). 
In figure 24 I compare the distribution of CpG densities across the different island regions: 
  
Figure 24 - distribution of CpG counts across island regions for Y probes and all 450k probes 
Boxplots showing the distribution of CpG counts for probes on the 450k platform split by island region. The left hand chart 
shows the distribution for the 384 Y chromosome probes. The right hand chart shows the distribution for all probes on the 
450k platform. 
The above plots show, as expected, that islands typically have higher CpG densities than the 
other regions, and that CpG density generally declines as the distance from the nearest island 
increases. 
3.3.3 Genes covered by Y chromosome probes 
265 out of the 384 probes are linked to genes on the Y chromosome. 55 separate genes are 
covered by these 265 probes – a list of the genes included is set out in table 5: 
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AMELY BCORL2 CD24 CYorf15A DAZ1 
DAZ2 DDX3Y EIF1AY FAM197Y2 FAM41AY2 
HSFY1 KDM5D LOC100101115 LOC100101121 LOC401629 
LOC401630 NCRNA00185 NLGN4Y PCDH11Y PRKY 
RPS4Y1 RPS4Y2 SRY TBL1Y TMSB4Y 
USP9Y UTY ZFY   
RBMY1A3P / 1D / 1F / 1J/ 2EP / 3AP 
TSPY1 / 2 / 3/ 4 
TTTY1 / 4 / 4B / 5 / 8 / 8B / 10 / 11 / 12 / 13 / 14 / 15 / 16 / 18 / 19 / 20 / 22 
Table 5 - Y chromosome genes covered by probes on the 450k platform 
Genes shown in red are of particular interest as they have previously been proposed as 
potential tumour suppressor genes
6
. Furthermore, there are another 10 genes, shown in 
orange, which have been proposed as being essential for male viability
5
. 125 probes are 
targeted at these 12 genes, though the coverage is very uneven – ranging from just one probe 
for USP9Y to 19 for NLGN4Y. 
3.3.4 Breakdown of Y chromosome probes by gene locations 
Illumina also provide for the 450k platform an annotation item which describes the 
relationship between each interrogated CpG site and the nearest gene. I will use the term 
“gene location” for this item. 
I set out in figure 25 a pie-chart showing the distribution of gene locations for the 384 probes, 
along with a corresponding pie-chart for all 450k probes: 
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Figure 25 - distribution of gene locations of Y probes and all 450k probes 
Pie-charts showing the distribution of gene locations in which probes on the 450k platform are located. The left hand chart 
shows the distribution for the 384 Y chromosome probes. The right hand chart shows the distribution for all probes on the 
450k platform. 
Figure 25 shows some differences between the distribution of gene locations for the 384 Y 
chromosome probes and the distribution for the whole 450k platform. The Y chromosome 
probes contain higher proportions of sites within 200 and 1,500 base pairs of a gene’s 
transcriptional start site (14% vs 11% and 22% vs 14% respectively), and also sites not linked 
to any gene (labelled “nil” – 31% vs 25%). Conversely, there are lower proportions of Y 
chromosome probes within gene bodies, 3’UTRs and 5’UTRs (22% vs 33%, 2% vs 4% and 
5% vs 9% respectively). 
In figure 26 I compare the distribution of CpG densities across the different types of gene 
location: 
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Figure 26 - distribution of CpG counts across gene locations for Y probes and all 450k probes 
Boxplots showing the distribution of CpG counts for probes on the 450k platform split by gene location. The left hand chart 
shows the distribution for the 384 Y chromosome probes. The right hand chart shows the distribution for all probes on the 
450k platform. 
The above plot shows that CpG density varies across different gene locations, with sites 
located in TSS200s and first exons typically being in regions of higher density (interquartile 
ranges above 20 counts), and sites in 3’UTRs in lower density regions (median counts = 6 and 
9 respectively). 
3.3.5 Summary 
The 384 probes retained cover just under one half of the total length of the male-specific 
region of the Y chromosome, but cover the vast majority of known genes in this region, 
including 12 which could be of particular interest to cancer development. The characteristics 
of the retained probes are broadly consistent with the 450k platform as a whole, but with 
some differences. 
 
3.4 Methylation of normal male samples 
In this section I outline key characteristics of the Y chromosome methylation profiles of 
normal samples. I will then use these characteristics as a base for investigating differential 
methylation of tumour samples in subsequent sections. 
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The KIRC dataset has many more normal male samples (105) than either the COAD (21) or 
HNSC (38) datasets. My analysis of normal samples is, therefore, based on the KIRC dataset, 
but includes comparison with the other datasets. 
3.4.1 Overall methylation profile of KIRC normal samples 
Figure 27 shows the distribution of all beta values across all normal samples and all 384 Y 
chromosome probes for the KIRC dataset: 
 
Figure 27 - distribution of beta values for all KIRC normal samples and probes 
Histogram of all beta values for all KIRC normal, male samples across all 384 Y chromosome probes 
The above plot shows that there are two clear peaks in the distribution of beta values, one at 
very low (i.e. unmethylated) values and the other at very high (i.e. fully methylated) values, 
with much smaller frequencies for intermediate values.  
Figure 28 shows how the methylation profile for the KIRC normal samples varies according 
to island region: 
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Figure 28 - distribution of KIRC normal beta values across island regions 
Boxplots showing the distribution of beta values across all 384 Y chromosome probes for all KIRC normal male samples split 
by island region. 
The plot shows that, whilst there is some variability within all regions, CpG sites located in 
islands tend to be less methylated than sites in other regions (median beta value = 0.29, 
compared with greater than 0.60 for all other regions). 
Figure 29 shows, for each of the 384 probes, a plot of mean beta value for the KIRC normal 
samples against CpG density: 
 
Figure 29 - plot of mean normal KIRC beta values vs CpG count 
For each of the 384 Y chromosome probes, the CpG count based on the 500bp window centred on the targeted site was 
plotted against the mean beta value across all KIRC normal male samples. 
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Again there is some variability. However, figure 29 shows that CpG sites in areas of low CpG 
density tend to be highly methylated, whereas sites in regions of high CpG density tend to be 
unmethylated (Pearson correlation = -0.46, p-value <0.0001). 
Finally, figure 30 shows how the methylation profile for the KIRC normal samples varies 
according to gene location: 
 
Figure 30 - distribution of KIRC normal beta values across gene locations 
Boxplots showing the distribution of beta values across all 384 Y chromosome probes for all KIRC normal male samples split 
by gene location. 
Once again there is a large amount of variability within each location type. However, CpG 
sites located in TSS200s and 1stExons tend to be lowly methylated (median values = 0.105 
and 0.051 respectively), whereas sites located in TSS1500s, gene bodies and 3’UTRs tend to 
be highly methylated (median values = 0.735, 0.763 and 0.768 respectively), as do sites not 
linked to any gene (median value = 0.792). Sites located within 5’UTRs tend to have 
intermediate methylation levels (median value = 0.299). 
3.4.2 Comparison of normal methylation profiles between datasets 
I also looked at distributions of overall Y chromosome methylation for both the COAD and 
HNSC datasets, as shown in figure 31: 
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Figure 31 - distribution of beta values for all COAD and HNSC normal samples and probes 
Histograms of all beta values for all COAD (left) and HNSC (right) normal, male samples across all 384 Y chromosome probes 
When compared with the KIRC methylation distribution shown in figure 27, both the COAD 
and HNSC datasets, but in particular COAD, have slightly lower peaks at low beta values and 
slightly higher peaks at high beta values. 
I also performed a probe-by-probe comparison between the datasets, using the mean beta 
values for each probe. Figure 32 shows the comparison of mean beta values between KIRC 
and COAD datasets on the left and between KIRC and HNSC datasets on the right: 
  
Figure 32 - comparison of mean Y chromosome beta values between datasets 
For each dataset, the mean beta value for each of the 384 Y chromosome probes was calculated across all normal, male 
samples. The left hand plot shows KIRC vs COAD values, and the right hand plot shows KIRC vs HNSC values. 
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The above plots show that there is generally very good correlation in mean beta values 
between datasets (Pearson correlation = 0.95 and 0.99 respectively, p-values < 0.0001). 
However, there are some inconsistencies, in particular with the COAD dataset.  
3.4.3 Investigation of probes with inconsistent methylation profiles 
I was then interested to investigate those CpG sites where there was a large discrepancy in 
mean beta values between datasets. These sites may be important in distinguishing between 
different tissue types, and may also be a source of aberrant methylation in cancer. Table 6 
shows those sites for which there was a difference in mean beta values of at least 0.3 between 
at least two of the datasets (this threshold yielded the top 5% of all 384 sites): 
CpG site 
ID 
Position 
(Mbp) 
Gene 
Gene 
location 
Island 
region 
CpG 
count 
Mean beta values 
COAD HNSC KIRC 
cg13654344 2.65 SRY 3'UTR N_Shelf 15 0.615 0.310 0.402 
cg11898347 2.66 SRY TSS200 N_Shore 9 0.433 0.131 0.111 
cg27636129 2.66 SRY TSS200 N_Shore 9 0.500 0.251 0.168 
cg09595415 2.66 SRY TSS200 N_Shore 8 0.673 0.403 0.252 
cg18058072 2.81 ZFY 5'UTR S_Shelf 6 0.864 0.806 0.541 
cg09728865 6.78 TBL1Y 5'UTR Island 23 0.693 0.495 0.217 
cg08921682 6.89 TBL1Y 5'UTR Ocean 4 0.305 0.592 0.636 
cg14671357 7.68 TTTY12 Body Ocean 3 0.583 0.933 0.919 
cg14210405 9.93 nil nil Island 34 0.668 0.459 0.241 
cg14720093 10.03 nil nil Island 35 0.816 0.643 0.515 
cg01463110 14.65 nil nil N_Shore 4 0.501 0.663 0.865 
cg17430262 14.65 nil nil Island 34 0.650 0.344 0.209 
cg18188392 14.65 nil nil Island 43 0.449 0.111 0.044 
cg05608794 14.65 nil nil Island 26 0.556 0.277 0.131 
cg02730008 15.81 TMSB4Y TSS1500 N_Shore 11 0.500 0.926 0.913 
cg26198148 15.81 TMSB4Y TSS1500 N_Shore 24 0.452 0.883 0.715 
cg10363397 15.86 nil nil Island 32 0.826 0.317 0.386 
cg09748856 16.64 NLGN4Y Body Island 39 0.462 0.074 0.062 
cg16894943 20.49 LOC401630 TSS200 Island 33 0.602 0.272 0.315 
Table 6 - CpG sites differentially methylated in normal samples 
The table shows CpG sites for which there was a difference of at least 0.3 in mean beta values between any pair of normal 
sample datasets. 
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Nine out of the 19 sites are located in CpG islands, with a further six found within 2,000 base 
pairs of an island in north shores. Seven genes are represented in the table, including four out 
of the 12 genes of interest previously mentioned in section 3.3.3 (NLGN4Y, TBL1Y, 
TMSB4Y and ZFY), and the SRY gene, which has four sites in the list. However, the 
differences between the datasets are not consistent across the different genes / CpG sites. 
For each of the four CpG sites targeted at the SRY gene, the COAD normal samples are more 
highly methylated than both the HNSC and KIRC normal samples. Figure 33 compares the 
beta values across all three datasets for one of these sites (cg09599415): 
 
Figure 33 - comparison of normal sample beta values for cg09595415 
Boxplots of all normal, male beta values for CpG site cg09595415 within the SRY gene, split by dataset. The plots for COAD, 
HNSC and KIRC samples are shown in red, blue and green respectively. 
The KIRC normal samples are the least methylated (median = 0.239), the COAD samples are 
the most highly methylated (median = 0.655), and the HNSC samples have intermediate 
methylation levels (median = 0.377). 
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One of the TBL1Y sites (cg09728865) has similar methylation patterns to the SRY sites. 
However, the other TBL1Y site (cg08921682) has the opposite pattern, with the COAD 
samples being the least methylated (median = 0.288 vs 0.581 and 0.649 respectively for 
HNSC and KIRC), as shown in figure 34: 
 
Figure 34 - comparison of normal sample beta values for cg08921682 
Boxplots of all normal, male beta values for CpG site cg08921682 within the TBL1Y gene, split by dataset. The plots for 
COAD, HNSC and KIRC samples are shown in red, blue and green respectively. 
CpG site cg18058072 targeted at the ZFY gene has a different pattern again, with both COAD 
and HNSC samples being highly methylated (median = 0.877 and 0.828 respectively), but 
KIRC samples having lower methylation levels (median = 0.541), as shown in figure 35: 
 
Figure 35 - comparison of normal sample beta values for cg18058072 
Boxplots of all normal, male beta values for CpG site cg18058072 within the ZFY gene, split by dataset. The plots for COAD, 
HNSC and KIRC samples are shown in red, blue and green respectively. 
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 The two CpG sites within the TMSB4Y gene have similar methylation patterns, which are 
again different from the other genes. The comparison across the datasets for site cg02730008 
is shown in figure 36. This time the HNSC and KIRC samples are highly methylated (median 
= 0.930 and 0.917 respectively), whereas the COAD samples have methylation levels around 
50% (median = 0.510).  
 
Figure 36 - comparison of normal sample beta values for cg02730008 
Boxplots of all normal, male beta values for CpG site cg02730008 within the TMSB4Y gene, split by dataset. The plots for 
COAD, HNSC and KIRC samples are shown in red, blue and green respectively. 
Finally, the pattern for site cg09748856 within the NLGN4Y gene is shown in figure 37: 
 
Figure 37 - comparison of normal sample beta values for cg09748856 
Boxplots of all normal, male beta values for CpG site cg09748856 within the NLGN4Y gene, split by dataset. The plots for 
COAD, HNSC and KIRC samples are shown in red, blue and green respectively. 
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This time the HNSC and KIRC samples have low methylation levels (median = 0.065 and 
0.058 respectively), whereas the COAD samples have higher levels (median = 0.453). 
In all five cases, the Kruskal-Wallis test comparing datasets gave a significant result (all p-
values less than 0.0001). 
There is also evidence of some clustering of methylation differences, with four of the 19 sites 
very close together on the Y chromosome at around 14.65 million base pairs, in addition to 
the four sites within the SRY gene and the two pairs of sites within the TBL1Y and TMSB4Y 
genes. 
3.4.4 Summary 
The normal samples within all three datasets had similar overall Y chromosome methylation 
profiles, with peaks at both low and high methylation values. However, COAD samples 
tended to be slightly more methylated on average than both HNSC and KIRC samples. 
Furthermore, for a small number of individual CpG sites, there were some significant 
differences in methylation profiles between the tissue types. 
 
3.5 Overview of differential methylation in tumours 
Next I considered how Y chromosome methylation differed between normal and tumour 
samples in my three chosen datasets. It is possible that aberrant methylation of the Y 
chromosome could be an important factor in tumour development. 
I initially decided to split my analysis into two parts. Firstly I considered, for each dataset, 
those tumour samples for which there were also matching normal samples. I then investigated 
all the other tumours for which there were no matching normal samples. 
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The key advantage of comparing matched normal / tumour pairs is that I could make a direct 
comparison of changes in methylation for each CpG site within each matched pair of samples. 
However, this comes at the cost of not utilising all the available data, which is a particular 
issue for the COAD and HNSC datasets for which there are only relatively small numbers of 
normal samples compared with the numbers of tumour samples.  
There is also the possibility that unmatched tumour samples may exhibit different methylation 
profiles from the matched samples. Therefore, by initially splitting my analyses, I could check 
whether there were any such differences. 
3.5.1 Overall methylation changes in matched tumour samples 
I first investigated general differences in methylation between normal and matched tumour 
samples. Initially, I compared mean normal and tumour beta values for each probe, as shown 
in figure 38 for the KIRC dataset: 
 
Figure 38 - comparison of mean beta values for matched samples (KIRC) 
Plot of mean beta values for all 384 Y chromosome probes for KIRC normal vs matched tumour samples. 
There is high correlation between the mean normal and matched tumour methylation values 
for the KIRC dataset (r=0.98, p-value < 0.0001), although that there are some differences.  In 
figure 39 I show the corresponding plots for the COAD and HNSC datasets: 
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Figure 39 - comparison of mean beta values for matched samples (COAD & HNSC) 
Plot of mean beta values for all 384 Y chromosome probes for COAD (left) and HNSC (right) normal (x-axis) vs matched 
tumour samples (y-axis). 
For both there is again high correlation (r=0.90 and 0.94 respectively, p-values < 0.0001), 
although the correlations are lower than for the KIRC dataset, in particular for COAD. 
I then compared the variation in methylation between normal and tumour samples. For this 
purpose I calculated the standard deviation of beta values for each probe. Figure 40 shows 
that methylation is clearly more variable within KIRC matched tumour samples compared 
with normal samples (Wilcoxon p-value < 0.0001): 
 
Figure 40 - comparison of beta value variability for matched samples (KIRC) 
Plot of standard deviation of beta values for all 384 Y chromosome probes for KIRC normal (x-axis) vs matched tumour 
samples (y-axis). 
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Figure 41 shows a similar picture for the COAD and HNSC datasets: 
  
Figure 41 - comparison of beta value variability for matched samples (COAD & HNSC) 
Plot of standard deviation of beta values for all 384 Y chromosome probes for COAD (left) and HNSC (right) normal (x-axis) 
vs matched tumour samples (y-axis). 
3.5.2 Overall methylation changes in unmatched tumour samples 
Next I separately considered tumour samples for which there were no matched normal 
samples.  For the COAD and HNSC datasets there were many more unmatched tumour 
samples than there were matched samples. 
As for the matched cases, I observed: 
 some differences in mean beta values between tumour and normal samples for all 
datasets;  
 greater variability in methylation amongst the tumour samples for all datasets;  
 larger differences within the COAD dataset. 
Figure 42 shows comparisons of the means and standard deviations of beta values between 
normal and unmatched tumour samples for the COAD dataset: 
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Figure 42 - comparison of unmatched tumour and normal samples (COAD) 
Left hand side - plot of mean beta values for all 384 Y chromosome probes for COAD normal (x-axis) vs unmatched tumour 
samples (y-axis). Right hand side – plot of standard deviation of beta values for all 384 probes for COAD normal (x-axis) vs 
unmatched tumour samples (y-axis). 
3.5.3 Comparison of methylation changes in matched and unmatched tumour samples 
I next wanted to check whether the methylation profiles of unmatched and matched tumour 
samples were similar. For this purpose I calculated, for both groups of tumour samples, the 
differences in mean beta values between tumour and normal samples for each of the 384 
probes. Figure 43 shows that there is very high correlation (r=0.95) for the KIRC dataset: 
 
Figure 43 - comparison of mean beta value differences for matched/unmatched tumour samples (KIRC) 
Plot of differences in mean beta values for all 384 Y chromosome probes for KIRC tumour samples. X-axis shows difference 
between mean values for matched tumours and normal samples, y-axis shows corresponding values for unmatched 
tumours. 
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There is also high correlation for the COAD and HNSC datasets (r=0.94 and 0.96 
respectively), as shown in figure 44, although the correlation is slightly lower for COAD: 
  
Figure 44 - comparison of mean beta value differences for matched/unmatched tumour samples (COAD & HNSC) 
Plot of differences in mean beta values for all 384 Y chromosome probes for COAD (left) and HNSC (right) tumour samples. 
X-axis shows difference between mean value for matched tumours and normal samples, y-axis shows corresponding values 
for unmatched tumours. 
These plots led me to believe that the methylation changes, relative to normal samples, were 
similar between unmatched and matched tumour samples.  
As a further check, I performed principal components analyses using all Y chromosome beta 
values and all male samples. Figure 45 shows that the matched and unmatched tumours are 
intermingled for the KIRC dataset: 
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Figure 45 - PCA of all male Y chromosome beta values (KIRC) 
Principal components analysis was performed using the KIRC male Y chromosome beta values. The first two principal 
components for each sample are shown on the x- and y- axes respectively. Matched tumour samples are shown in light 
blue, unmatched tumour samples are shown in red and normal samples in blue. 
Figure 46 shows the corresponding PCA plots for the COAD and HNSC datasets: 
 
Figure 46 - PCA of all male Y chromosome beta values (COAD & HNSC) 
Principal components analysis was performed using the COAD (left) and HNSC (right) male Y chromosome beta values. The 
first two principal components for each sample are shown on the x- and y- axes respectively. Matched tumour samples are 
shown in light blue, unmatched tumour samples are shown in red and normal samples in blue. 
In both cases, there is again no clear distinction between matched and unmatched tumour 
samples. 
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On the basis of my comparisons of mean changes in beta value and my principal components 
analyses, I concluded that the methylation profiles of matched and unmatched tumours were 
similar and that I could, therefore, merge the two groups together for my subsequent analyses. 
3.5.4 Summary 
There was clear evidence of differences in methylation in tumour samples compared with 
normal samples, both in terms of mean methylation level and variability. I observed similar 
patterns for both matched and unmatched tumour samples, and decided to group these 
samples together for my subsequent analyses. 
 
3.6 Site specific methylation changes in tumours 
Having considered general methylation changes between normal and tumour samples, I 
turned my attention to changes at an individual CpG site level. 
3.6.1 Locations of largest mean beta value changes 
First, for each of the 384 CpG sites, I plotted the difference in mean beta value between 
tumour and normal samples against location on the Y chromosome. The resultant plots, one 
for each of the three datasets, are shown in figure 47 overleaf. A hyper-methylated site is 
indicated by a red line above the x-axis, and a hypo-methylated site by a blue line below the 
x-axis. 
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Figure 47 - locations of mean beta value changes in tumours (all datasets) 
For each of the 384 Y chromosome probes, the difference in mean tumour beta value and mean normal beta value was 
calculated. These were then plotted (y-axis) against the position of each probe on the Y chromosome (x-axis). Results for 
the KIRC, COAD and HNSC datasets are shown separately in the top, middle and bottom plots respectively.  
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The plots show that hypo-methylation is more common than hyper-methylation in all three 
datasets, but that hyper-methylation when it occurs tends to be at a higher level. For example, 
in the KIRC dataset there were 242 probes for which the difference between tumour and 
normal mean beta values was negative and 142 for which it was positive. However, only two 
of the 242 negative values were lower than -0.2, whereas six of the positive values were 
greater than 0.2. COAD samples have the greatest amount of aberrant methylation on average 
(average hypo-methylation of -0.076 and average hyper-methylation of +0.084), with KIRC 
samples having the least amount (averages of -0.039 and + 0.047 respectively). 
The patterns of hyper-methylation are similar across all datasets. In particular, CpG sites at 
the following locations have high levels of hyper-methylation: 
  2.656Mbp, covering the SRY gene; 
 2.802Mbp, covering the ZFY gene; 
 6.779Mbp, covering the TBL1Y gene; 
 9.993Mbp, no genes in the vicinity; 
 14.650Mbp, no gene in the vicinity; 
 14.774Mbp, covering the TTTY15 gene; 
 21.239Mbp, covering the TTTY14 gene; and 
 21.665Mbp, covering the BCORL2 gene. 
There are a couple of other areas of high hyper-methylation specific to the COAD dataset, at 
2.710Mbp (RPS4Y1 gene) and 16.635Mbp (NLGN4Y gene). 
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There are also locations with a high density of hypo-methylation in all datasets at: 
 6.137Mbp, no genes in the vicinity; 
 6.743Mbp, covering the AMELY gene; 
 6.954Mbp, covering the TBL1Y gene; 
 Between 9.306 and 9.747Mbp, covering the TSPY1, TSPY3, TSPY4, RBMY3AP, 
TTTY1, TTTY8 and TTTY22 genes; 
 Between 13.914 and 14.104Mbp, no genes in the vicinity; 
 19.679Mbp, no genes in the vicinity; 
 20.736Mbp, covering the HSFY gene; 
 21.666Mbp, covering the BCORL2 gene; 
Additionally, there is evidence of hypo-methylation near the NLGN4Y gene in the COAD 
and HNSC datasets. 
3.6.2 Analysis of large individual beta value differences 
I next decided to refine my analysis by looking at the magnitude of methylation changes for 
each tumour sample and for each probe, and to compare them against a suitable threshold. For 
each CpG site I compared each tumour sample’s beta value against the mean of all normal 
sample values. 
For this purpose I needed to determine an appropriate threshold of change, above which I 
would determine a CpG site to be either hypo- or hyper- methylated in the tumour sample 
relative to normal samples. To help me decide on the threshold, I looked at the distribution of 
differences in beta values (tumour minus normal mean) across all probes and tumour samples 
for the three datasets. A plot of these distributions is set out in figure 48: 
84 
 
 
Figure 48 - distribution of methylation changes in all tumour samples and probes 
For each of the 384 Y chromosome probes, the difference between tumour beta value and mean normal beta value was 
calculated for each tumour sample. The plot shows the cumulative percentiles of all of these differences. Results for COAD 
(red), HNSC (blue) and KIRC (green) are shown separately. 
By inspection of the distributions, I calculated that just over 5% of all beta value changes 
(hypo- or hyper-methylated) across all probes / samples exceeded a threshold of 0.4. I, 
therefore, decided to use a change in beta value of 0.4 as my chosen threshold. I also used 0.2 
as a secondary threshold (this value is consistent with Bibikova’s analysis of the precision of 
the 450k platform
57
). 
Using these thresholds I produced heatmaps for each dataset indicating those tumour samples 
which were either hypo- or hyper-methylated. Figure 49 shows the heatmap for the KIRC 
tumour samples. Each column represents one of the 384 probes, which are ordered from left 
to right according to position on the Y chromosome. Each row represents a single tumour 
sample, and samples have been ordered from bottom to top in increasing order of the overall 
change in methylation levels across all 384 probes relative to normal samples (i.e. most 
hyper-methylated overall is at the top). Dark blue indicates hypo-methylation and red 
indicates hyper-methylation. 
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Figure 49 - heatmap of hypo- and hyper-methylated tumour samples (KIRC) 
Each column represents one of the 384 probes, which are ordered from left to right according to position on the Y 
chromosome. Each row represents a single KIRC tumour sample, and samples have been ordered from bottom to top in 
increasing order of the overall change in methylation levels across all 384 probes relative to normal samples (i.e. most 
hyper-methylated overall is at the top). Dark blue indicates that a sample was hypo-methylated at that probe and red 
indicates hyper-methylation. 
Figure 50 shows corresponding heatmaps for the COAD and HNSC datasets: 
  
Figure 50 - heatmaps of hypo- and hyper-methylated tumour samples (COAD & HNSC) 
Each column represents one of the 384 probes, which are ordered from left to right according to position on the Y 
chromosome. Each row represents a single COAD (left) or HNSC (right) tumour sample, and samples have been ordered 
from bottom to top in increasing order of the overall change in methylation levels across all 384 probes relative to normal 
samples (i.e. most hyper-methylated overall is at the top). Dark blue indicates that a sample was hypo-methylated at that 
probe and red indicates hyper-methylation. 
86 
 
The heatmaps show discrete bands of hyper-methylation common to large numbers of 
samples in all datasets, interspersed between more general areas of hypo-methylation. The 
hyper-methylated areas include sites targeted at the following genes: SRY, RPS4Y1 (not 
KIRC), ZFY, TBL1Y (in particular for COAD), TTTY15, NLGN4Y (in particular for 
COAD), TTTY14 (not KIRC), BCORL2, CYorf15A, and EIF1AY (in particular COAD). 
A list of the CpG sites with the highest proportions of hyper-methylated samples is included 
in Appendix 2. 15 of these 36 sites are located in CpG islands, with a further 15 in north 
shores. 13 are also located within 200bp of a gene’s transcriptional start site, with a further 10 
within 1,500bp. 11 are located in gene bodies. 
The regions of hypo-methylation are less uniform amongst samples compared with the hyper-
methylated areas. Genes included in the most heavily hypo-methylated areas are PCDH11Y, 
AMELY, TBL1Y, TTTY16, RBMY3AP, TTTY1, NLGN4Y (not KIRC) and BCORL2.  
A list of the CpG sites with the highest proportions of hypo-methylated samples is included in 
Appendix 3. This time less than half of the sites are near a transcriptional start site, and the 
most common island region is “ocean”. 
3.6.3 Summary 
Across all three datasets, hypo-methylation is more common than hyper-methylation. The latter 
tends to be concentrated in discrete regions of the Y chromosome, interspersed among more 
general regions of hypo-methylation. CpG sites targeted at several genes are located within 
these regions of hypo- and hyper-methylation. COAD samples have the highest level of 
aberrant methylation on average, and KIRC samples have the lowest amount. 
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3.7 Conclusions 
The key conclusions from my analyses of differential methylation between normal and 
tumour samples are as follows:  
 32 of the 416 Y chromosome probes were found to be subject to cross-hybridisation 
issues with other parts of the genome and have been removed, leaving 384 for further 
analyses; 
 The 384 remaining probes are targeted at CpG sites within 55 genes, including 12 
genes of particular interest; 
 18 samples appeared to have incorrectly labelled genders, and have therefore been 
removed; 
 Between 40% and 50% of all tumour samples across the three datasets appear to have 
suffered some loss of the Y chromosome; 
 Loss of  the Y chromosome appears to have had a distorting effect on methylation 
measurements, in particular for CpG sites which are either very highly or very lowly 
methylated in normal samples; 
 Batch effects were detected in the total intensity measurements, and have been 
(partially) corrected; 
 COAD normal samples tended to be more highly methylated than their HNSC and 
KIRC counterparts; 
 There are a small number of CpG sites which had significant methylation differences 
between different normal tissue samples; 
 The methylation levels of tumour samples are generally more variable than those of 
normal samples; 
88 
 
 In all three datasets there are discrete regions of the Y chromosome which are hyper-
methylated in sizeable subsets of tumours, and these regions are interspersed between 
larger regions of more general hypo-methylation; 
 Tumour hyper-methylation is particularly prevalent in sites targeted at several genes, 
namely SRY, RPS4Y1, ZFY, TBL1Y, TTTY15, NLGN4Y, TTTY14, BCORL2, 
CYorf15A, and EIF1AY; 
 Tumour hypo-methylation is also prevalent in sites targeted at a small number of 
genes, namely PCDH11Y, AMELY, TBL1Y, TTTY16, RBMY3AP, TTTY1, 
NLGN4Y and BCORL2. 
I follow up on these hypo- and hyper-methylated genes in chapter 5, when I investigate the 
effects of both aberrant methylation and loss of Y chromosome on gene expression. In the 
next chapter, I analyse in detail the level of Y chromosome loss which has been incurred 
across the three datasets. 
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4. Copy number changes in the Y chromosome 
In this chapter I investigate copy number changes to the Y chromosome (in particular loss).   
In the first instance, I used the methylation data to estimate copy number, as set out in Feber’s 
paper
14
. My analysis in chapter 3 hinted that there were sizeable proportions of samples in 
each dataset which appeared to have suffered some loss of the Y chromosome. I then used 
TCGA’s copy number data to corroborate my findings. 
An overview of the process I have followed is provided in figure 51: 
 
 
 
 
 
 
 
 
 
 
Figure 51 - overview of experimental process for copy number analysis 
I set out details of each of the above stages in the following sections. 
Analyse copy number changes using methylation intensity data for matched tumours 
Similar analysis for unmatched tumour samples 
Corroborate results using TCGA copy number data 
Compare Y chromosome copy number changes with other chromosomes 
Refine analysis to level of chromosome arms 
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4.1 Analysis of matched tumours using methylation data 
I initially investigated copy number changes in matched tumour samples, for which I could 
make direct comparisons with the corresponding normal samples. 
For each matched tumour / normal pair, I calculated, for each of the 384 probes, the ratio of 
the total intensity (methylated plus unmethylated) for the tumour sample over the normal 
sample. My logic was that the total intensity measurement provides a quantification of the 
amount of DNA present in a sample for the particular probe in question. Hence, the ratio of 
tumour / normal intensity gives an estimate of the copy number for the tumour sample relative 
to the normal sample. 
Figure 52 contains a heatmap of the resultant total intensity ratios for all of the KIRC matched 
tumour samples: 
 
Figure 52 - heatmap of Y chromosome intensity ratios for KIRC matched tumours 
For each KIRC matched tumour / normal pair, for each of the 384 Y chromosome probes, the ratio of the total intensity for 
the tumour sample over the normal sample was calculated. Each column of the heatmap represents one of the 384 probes, 
which are ordered from left to right according to their position on the Y chromosome (not to scale). Each row represents 
one of the tumour samples, which are ordered from bottom to top in increasing order of the total intensity ratio across all 
384 probes. Each ratio has been colour-coded according to four different thresholds (0.5, 0.8, 1.0 and 1.2) as shown in the 
legend. 
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Each column of the heatmap represents one of the 384 probes, which are ordered from left to 
right according to their position on the Y chromosome (not to scale). Each row represents one 
of the tumour samples, which are ordered from bottom to top in increasing order of the total 
intensity ratio across all 384 probes (i.e. those samples with the lowest overall ratios are 
located at the bottom). Each ratio has been colour-coded according to four different thresholds 
(0.5, 0.8, 1.0 and 1.2). 
The large band of dark blue at the bottom of the heatmap suggests that there is a sizeable 
proportion (39%) of KIRC matched tumour samples which appear to have lost at least 20% of 
their Y chromosome DNA across most of the entire length spanned by the 384 probes. There 
are a small number of probes for which there is little dark blue for any samples – these probes 
are discussed below. 
Figure 53 shows similar heatmaps for the COAD and HNSC matched tumours: 
  
Figure 53 - heatmaps of Y chromosome intensity ratios for COAD & HNSC matched tumours 
For each COAD (left) and HNSC (right) matched tumour / normal pair, for each of the 384 Y chromosome probes, the ratio 
of the total intensity for the tumour sample over the normal sample was calculated. Each column of the heatmap 
represents one of the 384 probes, which are ordered from left to right according to their position on the Y chromosome 
(not to scale). Each row represents one of the tumour samples, which are ordered from bottom to top in increasing order of 
the total intensity ratio across all 384 probes. Each ratio has been colour-coded according to four different thresholds (0.5, 
0.8, 1.0 and 1.2) as shown in the legend. 
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A similar pattern is observed for the COAD and HNSC datasets, with a slightly lower 
proportion (33%) of COAD samples and a slightly higher proportion (50%) of HNSC samples 
appearing to have suffered overall copy number loss of chromosome Y of at least 20%. 
It occurred to me that the above results could have been caused simply by lower amounts of 
tumour DNA having been used (compared with normal samples). To check this was not the 
case, I produced similar heatmaps for other chromosomes. Figure 54 shows, as an example, 
the heatmap for chromosome 1 for the KIRC matched tumour samples, which are included in 
the same order form top to bottom based on their Y chromosome total ratios: 
 
Figure 54 - heatmap of chromosome 1 intensity ratios for KIRC matched tumours 
For each KIRC matched tumour / normal pair, for each of the chromosome 1 probes, the ratio of the total intensity for the 
tumour sample over the normal sample was calculated. Each column of the heatmap represents one of the probes, which 
are ordered from left to right according to their position on chromosome 1 (not to scale). Each row represents one of the 
tumour samples, which are ordered from bottom to top in increasing order of the total intensity ratio across all Y 
chromosome probes. Each ratio has been colour-coded according to four different thresholds (0.5, 0.8, 1.0 and 1.2) as 
shown in the legend. 
Unlike the heatmap shown in figure 52, there is no clear pattern of increasing intensity ratios 
from bottom to top. For example, there was no significant overlap between samples with the 
lowest 39% chromosome 1 ratios and the 39% of samples which appeared to have suffered at 
least 20% loss of the Y chromosome (chi-squared p-value = 0.1524). 
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Similar results were obtained for the COAD and HNSC datasets and for other chromosomes. 
Hence the results shown in figures 52 and 53 are not caused by technical artefacts. 
4.1.1 Probes with apparently reduced copy number loss 
A common feature within the heatmaps for all three matched tumour datasets (and also the 
unmatched samples – see next section) is the small subset of probes for which there appears to 
be much reduced copy number loss.  
I inspected the intensity ratios for all samples / probes to find out more about the affected 
probes. There are two main groups of probes affected, one in the region between 6.11 and 
6.17 mega-bases, and the other between 9.17 and 9.38 mega-bases. Both of these subsets of 
probes lie within the so-called “ampliconic” region of the Y chromosome15.  
The ampliconic region contains highly repetitive DNA sequences. For a sample of the 
affected probes, I checked where they aligned to the human genome using NCBI’s nucleotide 
BLAST facility, and discovered that each probe aligned to multiple parts of the Y 
chromosome with high (>90%) homology. Hence, this would explain why the intensity 
measurements do not reduce for samples with copy number loss to the same extent as the 
measurements for probes in other parts of the chromosome. 
4.1.2 Summary 
A sizeable proportion (between one third and one half) of matched tumour samples in each 
dataset appeared to have suffered at least 20% loss of chromosome Y DNA. Around 10% of 
the probes are located in the ampliconic region of chromosome Y, and therefore gave 
misleading estimates of copy number loss. 
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4.2 Analysis of unmatched tumours using methylation data 
I then considered the unmatched tumour samples. As I could not make a direct comparison for 
each tumour sample with its corresponding normal sample, I instead calculated a benchmark 
“normal” total intensity for each of the 384 probes against which I would compare all of the 
tumour samples. For this purpose I used the median total intensity across all normal samples 
for each probe. I then performed similar analyses as I had for the matched tumour samples. 
Figure 55 contains a heatmap of the resultant total intensity ratios for all of the KIRC 
unmatched tumour samples: 
 
Figure 55 - heatmap of Y chromosome intensity ratios for KIRC unmatched tumours 
For each KIRC unmatched tumour sample, for each of the 384 Y chromosome probes, the ratio of the total intensity for the 
tumour sample over the median total intensity across all normal samples was calculated. Each column of the heatmap 
represents one of the 384 probes, which are ordered from left to right according to their position on the Y chromosome 
(not to scale). Each row represents one of the tumour samples, which are ordered from bottom to top in increasing order of 
the total intensity ratio across all 384 probes. Each ratio has been colour-coded according to four different thresholds (0.5, 
0.8, 1.0 and 1.2) as shown in the legend. 
Figure 56 shows similar heat-maps for the COAD and HNSC unmatched tumours: 
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Figure 56 - heatmaps of Y chromosome intensity ratios for COAD & HNSC unmatched tumours 
For each COAD (left) and HNSC (right) unmatched tumour sample, for each of the 384 Y chromosome probes, the ratio of 
the total intensity for the tumour sample over the median total intensity across all normal samples was calculated. Each 
column of the heatmap represents one of the 384 probes, which are ordered from left to right according to their position 
on the Y chromosome (not to scale). Each row represents one of the tumour samples, which are ordered from bottom to 
top in increasing order of the total intensity ratio across all 384 probes. Each ratio has been colour-coded according to four 
different thresholds (0.5, 0.8, 1.0 and 1.2) as shown in the legend. 
In all cases a similar pattern was observed as had been seen previously for the matched 
tumour samples. 46% of unmatched KIRC tumour samples, 38% of COAD samples and 34% 
of HNSC samples appear to have suffered overall copy number loss of chromosome Y of at 
least 20%. 
Summary 
Similar patterns of Y chromosome loss were observed for the unmatched tumour samples. 
 
4.3 Corroboration of results using TCGA copy number data 
The above analyses were all carried out using TCGA’s level 2 methylation intensity data. To 
check the accuracy of the results, I also downloaded TCGA’s level 3 copy number data, as 
described in Chapter 2. I then compared the two sets of results, separately for matched and 
unmatched tumour samples. 
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4.3.1 Comparison for matched tumour samples 
TCGA’s level 3 copy number data contains segmented results for each sample and 
chromosome – i.e. for each sample, each chromosome has been broken up into segments 
within which the copy number has been assessed to be invariant. So that I could compare 
these data against my methylation-based results, I produced an alternative segmentation based 
on the total intensity ratios derived from the methylation data using the DNAcopy package in 
R (default parameters). 
For each matched tumour sample, I then plotted the segmented results from both the copy 
number data and my methylation analyses. Generally, for all datasets, the two sets of 
segmentation results were very similar - some examples for the KIRC dataset are shown in 
figure 57: 
  
Figure 57 - example comparisons of segmented copy number results for KIRC matched tumours 
Examples of Y chromosome segmented copy number data for two KIRC tumour samples. Both plots show position on the Y 
chromosome on the x-axis and copy number on the y-axis. In each case, the orange line represents TCGA’s level 3 
segmented copy number data. The pink line represents the segmentation calculated using the DNAcopy package in R, based 
on the methylation total intensity ratios. 
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I also calculated, for each set of segmented results, a copy number “index”, being the average 
copy number across the whole length of the Y chromosome (for the methylation-based results 
I considered only the region spanned by the 384 probes). Figure 58 shows a plot of the 
resultant index figures for the KIRC matched tumour samples: 
 
Figure 58 - comparison of Y chromosome copy number indices for KIRC matched tumours 
Using the segmented copy number data, an average copy number “index” was calculated for the whole Y chromosome for 
all KIRC matched tumour samples. The plot shows the index value based on the methylation data (x-axis) against the index 
value based on TCGA’s copy number data (y-axis) for each sample. 
Figure 59 shows the comparable plots for the COAD and HNSC matched tumours: 
  
Figure 59 - comparison of Y chromosome copy number indices for COAD & HNSC matched tumours 
Using the segmented copy number data, an average copy number “index” was calculated for the whole Y chromosome for 
all COAD (left) and HNSC (right) matched tumour samples. Each plot shows the index value based on the methylation data 
(x-axis) against the index value based on TCGA’s copy number data (y-axis) for each sample. 
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In all cases there is a very good correlation between the index measurements (Pearson 
correlation = 0.94, 0.98 and 0.96 respectively, all p-values < 0.0001), although the 
methylation-based index values are generally slightly lower than those based on TCGA’s 
copy number data. 
4.3.2 Comparison for unmatched tumour samples 
I then performed similar comparisons for the unmatched tumour samples.  Once again, there 
was generally very good correspondence between TCGA’s segmented copy number data and 
my methylation-based segmented results. Figures 60 and 61 show comparisons of the copy 
number index figures for the KIRC, COAD and HNSC unmatched tumour samples: 
 
Figure 60 - comparison of Y chromosome copy number indices for KIRC unmatched tumours 
Using the segmented copy number data, an average copy number “index” was calculated for the whole Y chromosome for 
all KIRC unmatched tumour samples. The plot shows the index value based on the methylation data (x-axis) against the 
index value based on TCGA’s copy number data (y-axis) for each sample. 
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Figure 61 - comparison of Y chromosome copy number indices for COAD & HNSC unmatched tumours 
Using the segmented copy number data, an average copy number “index” was calculated for the whole Y chromosome for 
all COAD (left) and HNSC (right) unmatched tumour samples. Each plot shows the index value based on the methylation 
data (x-axis) against the index value based on TCGA’s copy number data (y-axis) for each sample. 
In all cases there was again a very good correlation between the index measurements (Pearson 
correlation = 0.93, 0.79 and 0.89 respectively, all p-values < 0.0001), although there is a bit 
more variability for small numbers of COAD and HNSC samples. 
4.3.3 Summary 
The copy number results based on the methylation data were generally corroborated by 
TCGA’s segmented copy number data. 
 
4.4 Comparison with other chromosomes 
I was then interested to know how the levels of Y chromosome loss compared with copy 
number changes for other chromosomes. For this purpose I used TCGA’s segmented copy 
number data, and grouped all tumour samples together, rather than differentiating between 
matched and unmatched samples.  
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For each sample, I calculated the copy number index (as above) for each chromosome. Figure 
62 shows a heatmap of the results for the KIRC tumour samples. The samples have been 
ordered according to their Y chromosome copy number indices, increasing from bottom to 
top. Each chromosome is represented by a separate column. The extent of Y chromosome loss 
is clearly much more substantial than for any other chromosome – in particular 8% of samples 
have a Y chromosome index value of less than 0.5. 
 
Figure 62 - heatmap of copy number indices by chromosome for KIRC male tumours 
Using TCGA’s segmented copy number data, an average copy number “index” was calculated across the whole length of 
each chromosome for all KIRC tumour samples. Each column of the heatmap represents one of the chromosomes in 
numerical order. Each row represents one of the tumour samples, which are ordered from bottom to top in increasing 
order of their Y chromosome index values. Each ratio has been colour-coded according to four different thresholds (0.5, 0.8, 
1.0 and 1.2) as shown in the legend. 
Figure 63 shows similar heatmaps for the COAD and HNSC male tumours: 
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Figure 63 - heatmaps of copy number indices by chromosome for COAD & HNSC male tumours 
Using TCGA’s segmented copy number data, an average copy number “index” was calculated across the whole length of 
each chromosome for all COAD (left) and HNSC (right) tumour samples. Each column of both heatmaps represents one of 
the chromosomes in numerical order from left to right. Each row represents one of the tumour samples, which are ordered 
from bottom to top in increasing order of their Y chromosome index values. Each ratio has been colour-coded according to 
four different thresholds (0.5, 0.8, 1.0 and 1.2) as shown in the legend. 
Again, the Y chromosome has suffered the greatest copy number losses.  
Summary 
Across all three datasets, the extent of loss of the Y chromosome was greater than the loss 
incurred by any other chromosome. 
 
4.5 Analysis of changes at chromosomal arm level 
Next I refined the analysis in the previous section by looking at copy number changes at the 
level of chromosome arms, rather than whole chromosomes. Research has shown that copy 
number changes often occur at arm-level
98
. I repeated the analysis of the previous section, but 
this time calculating copy number indices for each chromosomal arm. Figure 64 shows a 
heatmap of the results for the KIRC tumour samples: 
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Figure 64 - heatmap of copy number indices by chromosome arm for KIRC male tumours 
Using TCGA’s segmented copy number data, an average copy number “index” was calculated across the whole length of 
each chromosome arm for all KIRC tumour samples. Each column of the heatmap represents one of the chromosome arms 
in numerical order. Each row represents one of the tumour samples, which are ordered from bottom to top in increasing 
order of their Y chromosome short arm index values. Each ratio has been colour-coded according to four different 
thresholds (0.5, 0.8, 1.0 and 1.2) as shown in the legend. 
The samples have been ordered according to their Y chromosome short-arm copy number 
indices, increasing from bottom to top. The extent of loss is similar in both Y chromosome 
arms, and is again more substantial than for any other chromosomal arm. However, there are 
some other chromosomal arms, notably 3p, which have also suffered losses of at least 20% in 
a large proportion of tumour samples.  
Note that the solid blue columns for chromosome arms 13p, 14p, 15p and 22p are caused by a 
complete lack of data for these arms, rather than being indicative of significant copy number 
losses. These chromosomes are all acrocentric. 
Figure 65 shows similar heatmaps for the COAD and HNSC male tumours: 
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Figure 65 - heatmaps of copy number indices by chromosome arm for COAD & HNSC male tumours 
Using TCGA’s segmented copy number data, an average copy number “index” was calculated across the whole length of 
each chromosome arm for all COAD (left) and HNSC (right) tumour samples. Each column of the heatmap represents one of 
the chromosome arms in numerical order. Each row represents one of the tumour samples, which are ordered from bottom 
to top in increasing order of their Y chromosome short arm index values. Each ratio has been colour-coded according to 
four different thresholds (0.5, 0.8, 1.0 and 1.2) as shown in the legend. 
Both Y chromosome arms have again suffered greater losses than any other chromosomal 
arms, although there are other arms which have suffered significant losses in individual 
cancers (both arms of chromosome 18 for COAD, and 3p for HNSC). 
Summary 
In all three datasets, both arms of the Y chromosome have suffered similar amounts of loss, 
and these losses are much greater than those for any other chromosomal arm. However, there 
are some other chromosome arms which have also been subject to significant levels of loss 
within one of more of the datasets. 
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4.6 Conclusions 
The key conclusions from my analyses of Y chromosome copy number changes in male 
tumours are as follows:  
 the methylation intensity data indicated that sizeable proportions of male tumour 
samples (between one third and one half) had suffered at least 20% loss of 
chromosome Y DNA in all three datasets; 
 a small proportion of the 384 methylation probes appeared to cross-hybridise with 
multiple regions of the Y chromosome, and therefore gave misleading results for the 
copy number analyses; 
 the methylation-based results were corroborated by TCGA’s level 3 copy number 
data; 
 the Y chromosome was unique in the level of loss suffered across all chromosomes; 
 both arms of the Y chromosome had been subject to similar levels of copy number 
loss; 
 arm-level losses are also greater in the Y chromosome than for any other chromosome, 
although there are some other arms, particularly 3p in kidney and head and neck 
cancer, which have also suffered significant losses. 
In the next chapter, I will consider the impact of both aberrant methylation and copy number 
loss on expression of Y chromosome genes. 
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5. Expression of Y chromosome genes 
In the previous chapter I showed that significant subsets of tumours in all three datasets 
appear to have lost the Y chromosome in some cells. Furthermore, in chapter 3 I showed that 
there are several genes on the Y chromosome which are affected by aberrant methylation, in 
particular hyper-methylation, in some tumour samples. In this chapter I investigate the 
potential biological implications of these phenomena by analysing expression levels of Y 
chromosome genes.   
My analyses are based on TCGA’s level 3 RNA-sequencing data. I have concentrated on 
samples and genes which are represented in both the RNA-seq and 450k methylation data. 
An overview of the process I have followed is provided in figure 66: 
 
 
 
 
 
Figure 66 - overview of experimental process for gene expression analyses 
I set out details of each of the above stages in the following sections. 
 
 
 
 
Identification of Y chromosome genes which are expressed in any of the three datasets 
Analysis of impact of copy number variation on gene expression 
Analysis of impact of aberrant methylation on gene expression 
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5.1 Y chromosome gene expression data 
5.1.1 Data used 
As described in chapter 2, I used TCGA’s level 3 RNA-seq data produced using the Illumina 
HiSeq 2000 RNA Sequencing platform (Version 2) for the purposes of my gene expression 
analyses. These data provide genome-wide measures of gene expression (in the form of read 
counts) which have been normalised between samples. 
I chose this version of the RNA-seq data as it has the best overlap with the 450k methylation 
data (out of the options available) in terms of samples covered. However, there are still 
samples for which methylation data were available but RNA-seq data were unavailable (and 
vice-versa). To ensure consistency with my methylation results, I only considered samples for 
which both methylation and RNA-seq data were available. 
The numbers of samples which I have included in my gene expression analyses are set out in 
table 7 (numbers in brackets are those used for my previous methylation analyses): 
 COAD HNSC KIRC 
Tumour samples 134 (142) 372 (374) 188 (188) 
Normal samples 11 (21) 15 (38) 18 (105) 
Total 145 (163) 387 (412) 206 (293) 
Table 7 - summary of data numbers for gene expression analyses 
A small number of COAD and HNSC tumour samples were present in the methylation data 
but not in the RNA-seq data. However, much larger numbers of normal samples were not 
present in the RNA-seq data for all three datasets (especially KIRC). 
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5.1.2 Y chromosome genes which are expressed 
I previously identified 55 Y chromosome genes which are represented on the 450k 
methylation platform. Expression data were also available for most of these genes. However, 
on inspection of the expression values, I discovered that only 16 genes were expressed in any 
samples within the three datasets.  
15 of the 16 genes were expressed in all three datasets, albeit not always at the same level. 
The genes concerned are: RPS4Y1, ZFY, TBL1Y, PRKY, TTTY15, USP9Y, DDX3Y, UTY, 
TMSB4Y, NLGN4Y, NCRNA00185, TTTY14, CYorf15A, KDM5D, and EIF1AY.  This list 
includes the two putative tumour suppressor genes and further 10 genes suggested as being 
important for male viability, which I highlighted in section 3. 
One gene, SRY, was only expressed in the HNSC dataset. 
My subsequent analyses concentrate on these 16 genes.  
5.1.3 Summary 
15 genes on the Y chromosome were expressed in all three datasets. The SRY gene was also 
expressed in the HNSC dataset only. 
 
5.2 Analysis of impact of copy number variation on expression 
I showed in chapter 4 that loss of the Y chromosome appeared to have occurred in sizeable 
proportions of male patients in all three datasets. I, therefore, concentrated initially on the 
extent to which chromosomal loss appears to impact on gene expression. 
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5.2.1 General association between copy number and gene expression 
I first considered how expression levels of the 16 genes varied with general levels of Y 
chromosome copy number. To measure the latter, I used the copy number index calculated in 
chapter 4 based on TCGA’s segmented copy number data. 
Figure 67 contains a heatmap of the expression values for all the KIRC male tumour samples. 
For each of the 16 genes, samples have been categorised into expression value quartiles. Each 
row contains a different sample, and samples have been ordered (from bottom to top) in 
increasing order of their Y chromosome copy number index. Each column represents an 
individual gene, and genes have been ordered (from left to right) according to their position 
on the Y chromosome. 
 
Figure 67 - heatmap of Y chromosome gene expression values for KIRC tumours 
For each of the 16 genes being considered, all male KIRC tumour samples have been categorised into expression value 
quartiles (legend indicates colour-coding). Each row contains a different sample, and samples have been ordered (from 
bottom to top) in increasing order of their Y chromosome copy number index. Each column represents an individual gene, 
and genes have been ordered (from left to right) according to their position on the Y chromosome. 
The heatmap shows that for most of the 16 genes, expression values within the KIRC dataset 
generally increase with increasing copy number. The three main exceptions to this pattern are 
genes SRY (not expressed), TBL1Y and PRKY. 
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Figure 68 shows corresponding heatmaps for the COAD and HNSC datasets:  
  
Figure 68 - heatmaps of Y chromosome gene expression values for COAD & HNSC tumours 
For each of the 16 genes being considered, all male COAD (left) and HNSC (right) tumour samples have been categorised 
into expression value quartiles (legend indicates colour-coding). Each row contains a different sample, and samples have 
been ordered (from bottom to top) in increasing order of their Y chromosome copy number index. Each column represents 
an individual gene, and genes have been ordered (from left to right) according to their position on the Y chromosome. 
For the HNSC dataset, expression values for all 16 genes generally increase with increasing 
copy number, although the pattern is less clear for TBL1Y in particular. Within the COAD 
dataset, there are five genes (SRY, TBL1Y, NLGN4Y, NCRNA00185 and TTTY14) for 
which there is no clear pattern of expression increasing with copy number. 
5.2.2 Probe-level association between copy number and expression 
To refine the above results, I then used the methylation intensity data to analyse the 
associations between expression and copy number at the level of individual probes. 
Out of the 384 probes which I have previously used for my methylation analyses, 152 are 
targeted at CpG sites linked to the 16 genes under consideration. For each relevant probe, I 
plotted total intensity against gene expression, and calculated the (Pearson) correlation 
between the two values. Example plots for the ZFY gene are shown in figures 69 (KIRC) and 
70 (COAD and HNSC): 
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Figure 69 - example plot of total intensity vs ZFY gene expression (KIRC) 
Example plot for methylation probe cg24837623 of total methylation intensity (x-axis) versus gene expression (y-axis) for all 
KIRC male samples. Tumour samples are plotted in red, and normal samples are plotted in blue. 
 
  
Figure 70 - example plots of total intensity vs ZFY gene expression (COAD & HNSC) 
Example plots for methylation probe cg24837623 of total methylation intensity (x-axis) versus gene expression (y-axis) for 
all COAD (left) and HNSC (right) male samples. Tumour samples are plotted in red, and normal samples are plotted in blue. 
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For all three datasets there is a high correlation between the total intensity for probe 
cg24837623 and ZFY expression (r = 0.60, 0.74 and 0.66 respectively, all p-values < 0.0001). 
The same is true for other probes targeting the ZFY gene, although there is some variation in 
correlation values between probes. It is also true for many of the other 16 genes, but not for 
all. Table 8 shows details of the highest correlations observed for each gene across each of the 
three datasets: 
Gene 
Position 
(Mbp) 
Number of 
450k probes 
Highest correlation 
COAD HNSC KIRC 
SRY 2.65 6 N/A 0.72 N/A 
RPS4Y1 2.71 5 0.45 0.75 0.68 
ZFY 2.80 18 0.78 0.86 0.66 
TBL1Y 6.78 11 0.16 0.33 0.38 
PRKY 7.14 9 0.62 0.75 0.42 
TTTY15 14.77 7 0.58 0.72 0.74 
USP9Y 14.81 1 0.54 0.72 0.65 
DDX3Y 15.02 13 0.72 0.83 0.69 
UTY 15.45 7 0.76 0.81 0.80 
TMSB4Y 15.81 7 0.56 0.61 0.65 
NLGN4Y 16.63 18 0.12 0.67 0.59 
NCRNA00185 21.04 2 0.45 0.56 0.49 
TTTY14 21.10 10 0.32 0.53 0.59 
CYorf15A 21.73 11 0.66 0.76 0.78 
KDM5D 21.87 8 0.64 0.79 0.56 
EIF1AY 22.74 17 0.75 0.72 0.82 
Table 8 - summary of probe intensity / gene expression correlations 
The correlations in table 8 generally confirm the results from the earlier heatmap analyses, 
which show that copy number variation is an important factor in gene expression levels. All 
correlations were statistically significant (p < 0.05, and mostly < 0.0001) except for TBL1Y 
(COAD) and NLGN4Y (COAD). 
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5.2.3 Summary 
Copy number variation of the Y chromosome is highly correlated with gene expression for 
most of the 16 genes across all three datasets. Anomalous genes include, in particular, TBL1Y 
(all datasets) and NLGN4Y (COAD). 
 
5.3 Analysis of impact of aberrant methylation on expression 
Of course, although copy number variation appears to have a significant influence on gene 
expression, it is not the only factor that can contribute to such variation. Therefore, building 
on my work in chapter 3, I next considered whether aberrant methylation of the Y 
chromosome may also impact on gene expression levels.  
5.3.1 Genes whose expression may be affected by aberrant methylation 
In chapter 3 I identified a number of CpG sites which were either hypo- or hyper-methylated 
in some tumour samples (relative to normal samples) for at least one of the datasets. Some of 
these sites are within the 16 genes which are expressed. In particular: 
 Sites within SRY, RPS4Y1, ZFY, TBL1Y, PRKY, TTTY15,  DDX3Y, NLGN4Y, 
TTTY14, CYorf15A and EIF1AY were hyper-methylated in some tumour samples; 
and 
 Sites within TBL1Y and NLGN4Y were hypo-methylated in some tumour samples. 
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To determine whether aberrant methylation of any of these sites may be having an effect on 
gene expression, I produced, for each dataset, 2- dimensional and 3-dimensional plots of total 
probe intensity, beta value and gene expression for all of the sites within the genes mentioned 
above. I then scrutinised each of the graphs to identify any sites where hypo- or hyper-
methylation appeared to be linked to unusually low / high gene expression. Figure 71 shows 
examples of these plots for one of the CpG sites within the RPS4Y1 gene (for the HNSC 
dataset): 
 
 
Figure 71 - example 2D & 3D plots of probe intensity, beta value and gene expression 
Example 2D (left) and 3D (right) plots for methylation probe cg25443613. The 2D plot shows  total methylation intensity (x-
axis) versus gene expression (y-axis) for all HNSC male samples - non-hyper-methylated tumour samples are plotted in red, 
hyper-methylated tumour samples are plotted in black (40% threshold) or grey (20% threshold) and normal samples are 
plotted in blue. The 3D plot shows total methylation intensity plotted against gene expression and beta value – tumour 
samples are shown in red and normal samples are shown in blue. 
The 2D plot on the left shows probe intensity plotted against gene expression, and has been 
colour-coded to show any hyper-methylated samples. The black dots represent hyper-
methylated samples (using the 40% threshold), and the plot clearly shows a small number of 
samples which are hyper-methylated, and have very low gene expression values (< 2,000, 
below all the normal samples), although their total intensity levels are over 3,000, consistent 
with the normal samples.  
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The 3D plot on the right provides a different visualisation of the same pattern – the height of 
each “stick” indicates the level of gene expression, and the beta value measure is shown on 
the horizontal axis. Once again there is a small group of samples with higher than normal beta 
values and low expression. 
By looking at all of the charts, I determined whether aberrant methylation of any of the sites I 
had identified appeared to be associated with unusual gene expression in at least one of the 
datasets. I concluded that methylation of many of the sites did not appear to be associated 
with aberrant gene expression. However, for five of the genes there were some sites which 
merited further analysis – the genes concerned are SRY, RPS4Y1, TBL1Y, NLGN4Y and 
TTTY14. I consider each of these genes in turn in the following sections. 
5.3.2 Analysis of SRY gene methylation 
SRY is located on the short arm of chromosome Y at around 2.65Mbp. It is a potentially 
interesting gene, since it only appears to be expressed in the HNSC dataset. Even then, the 
expression levels (as measured by normalised read counts) are very low compared to other 
genes, but the magnitude of the differences between the HNSC dataset and the other two 
datasets suggest that there is some SRY activity in the former.  
The box-plots in figure 72 compare expression levels across the three datasets: 
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Figure 72 - comparison of SRY expression levels across datasets 
Boxplots of expression values of the SRY gene for all male samples, broken down by the three datasets. The left hand plot 
shows the distribution of expression values for normal samples – COAD, HNSC and KIRC datasets are colour-coded red, blue 
and green respectively. The right hand plot shows the distribution of expression values for all samples, split by sample type 
and dataset. The distributions for normal samples are shown in blue, and those for tumour samples are shown in red. 
HNSC tumour samples have generally lower SRY expression than normal samples (Kruskal-
Wallis p-value = 0.0115), although there are some tumours with higher expression.  
As I showed previously, SRY expression levels in the HNSC dataset appear to be influenced 
by copy number variation. To illustrate this further, figure 73 shows a plot of total probe 
intensity versus gene expression for one of the methylation probes targeted at SRY (the plot is 
colour-coded as shown in the legend – in particular, black dots represent tumour samples 
which are hyper-methylated at the 40% threshold level, and grey dots represent those hyper-
methylated according to the lower 20% threshold): 
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Figure 73 - example plot of total intensity and SRY expression (HNSC) 
Scatterplot for methylation probe cg13654344 located within the SRY gene. The plot shows  total methylation intensity (x-
axis) versus gene expression (y-axis) for all HNSC male samples - non-hyper-methylated tumour samples are plotted in red, 
hyper-methylated tumour samples are plotted in black (40% threshold) or grey (20% threshold) and normal samples are 
plotted in blue. 
In total, there are six methylation probes targeted at CpG sites within SRY. Methylation levels 
are generally slightly lower in the HNSC normal samples compared with the other two 
datasets. An example for probe cg13654344 (Kruskal-Wallis p-value < 0.0001) is shown in 
figure 74: 
 
Figure 74 - plot of beta values for cg13654344 vs SRY gene expression 
Scatterplot for all normal male samples of methylation beta value for probe cg13654344 (x-axis) versus expression value for 
the SRY gene (y-axis). COAD, HNSC and KIRC samples are shown in red, blue and green respectively. 
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This lower level of methylation could be a factor in the higher gene expression observed in 
the HNSC normal samples compared with the other datasets. There is a negative correlation 
between beta values and expression values (r = -0.61, p-value < 0.0001). 
All six CpG sites are hyper-methylated in a subset of HNSC tumour samples. In particular, 
the four middle probes (cg04169747, cg11898347, cg27636129 and cg09595415), which are 
located near the transcriptional start site, are hyper-methylated together (with the odd 
exception) in around one quarter of the tumour samples (hyper-methylation is also observed 
in the COAD and KIRC datasets).  
There is some evidence that this hyper-methylation may be associated with reduced gene 
expression. Taking probe cg27636129 as an example, figure 75 shows 2D and 3D plots of 
probe intensity, beta value and gene expression: 
 
 
Figure 75 - plots of probe intensity, beta value and gene expression for cg27636129 (HNSC) 
2D (left) and 3D (right) plots for methylation probe cg27636129 located within the SRY gene. The 2D plot shows  total 
methylation intensity (x-axis) versus gene expression (y-axis) for all HNSC male samples - non-hyper-methylated tumour 
samples are plotted in red, hyper-methylated tumour samples are plotted in black (40% threshold) or grey (20% threshold) 
and normal samples are plotted in blue. The 3D plot shows total methylation intensity plotted against gene expression and 
beta value – tumour samples are shown in red and normal samples are shown in blue. 
 
118 
 
There is a subset of hyper-methylated cases which have low expression values (< 5) but do 
not have low total intensity values (> 3,000), which suggests that hyper-methylation may be a 
factor in reduced SRY gene expression for some HNSC tumour samples, in addition to 
reduced expression caused by chromosomal loss. However, there are other hyper-methylated 
samples which do not have low gene expression, which suggests that there may also be other 
mechanisms by which gene expression is reduced in tumours. 
5.3.3 Analysis of RPS4Y1 gene methylation 
RPS4Y1 is located close to SRY at around 2.71Mbp. It is expressed at slightly higher levels 
in HNSC normal samples compared with COAD and KIRC (Kruskal-Wallis p-value = 
0.0002), and its expression is clearly impacted by copy number variation as shown earlier in 
this chapter. Figure 76 compares expression levels across the datasets: 
 
Figure 76 - comparison of RPS4Y1 expression levels across datasets 
Boxplots of expression values of the RPS4Y1 gene for all male samples, broken down by sample type and dataset. The 
distributions for normal samples are shown in blue, and those for tumour samples are shown in red. 
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Expression levels in tumour samples are more variable than in normal samples for each 
dataset (Levene p-value = 0.0021, 0.0088 and < 0.0001 for COAD, HNSC and KIRC 
respectively). Also, expression levels in HNSC tumour samples are lower than in HNSC 
normal samples (Kruskal-Wallis p-value = 0.0022). 
There are five methylation probes targeted at CpG sites within RPS4Y1, and three of these 
(cg01375382, cg25443613 and cg01311227), all of which are located near the transcriptional 
start site, are hyper-methylated in a small number of both COAD & HNSC tumour samples.  
In both datasets, the same samples are hyper-methylated at each site, and these samples all 
show low gene expression levels. In figure 71 I showed example plots for cg25443613 in the 
HNSC dataset, and in figure 77 I show corresponding plots for the COAD dataset: 
  
Figure 77 - plots of probe intensity, beta value and gene expression for cg25443613 (COAD) 
2D (left) and 3D (right) plots for methylation probe cg25443613 located within the RPS4Y1 gene. The 2D plot shows  total 
methylation intensity (x-axis) versus gene expression (y-axis) for all COAD male samples - non-hyper-methylated tumour 
samples are plotted in red, hyper-methylated tumour samples are plotted in black (40% threshold) or grey (20% threshold) 
and normal samples are plotted in blue. The 3D plot shows total methylation intensity plotted against gene expression and 
beta value – tumour samples are shown in red and normal samples are shown in blue. 
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For both COAD and HNSC datasets, there is a small subset of hyper-methylated tumour 
samples (shown in black) which have low expression values (< 2,000) but do not have low 
total intensity values (> 3,000). The plots for the other two probes (not included here) show a 
similar pattern, which indicates that for a small number of COAD and HNSC tumour samples, 
hyper-methylation may be another cause of reduced RPS4Y1 gene expression. 
5.3.4 Analysis of TBL1Y gene methylation 
TBL1Y is located further along the short arm of the Y chromosome at around 6.78Mbp. Like 
SRY, gene expression levels vary considerably between normal samples in the three datasets 
(Kruskal-Wallis p-value < 0.0001). In particular, there is no expression in COAD normal 
samples. The box-plots in figure 78 compare expression levels across the three datasets: 
  
Figure 78 - comparison of TBL1Y expression levels across datasets 
Boxplots of expression values of the TBL1Y gene for all male samples, broken down by the three datasets. The left hand plot 
shows the distribution of expression values for normal samples – COAD, HNSC and KIRC datasets are colour-coded red, blue 
and green respectively. The right hand plot shows the distribution of expression values for all samples, split by sample type 
and dataset. The distributions for normal samples are shown in blue, and those for tumour samples are shown in red. 
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As I showed previously, across all three datasets the correlation between gene expression and 
copy number variation is much lower for TBL1Y than for most of the other 16 genes. For the 
HNSC and KIRC datasets, expression is generally lower in tumour samples relative to normal 
samples (Kruskal-Wallis p-values < 0.0001 in both cases), although there are some tumour 
samples with higher expression, which appears to be related to higher copy number. 
Methylation levels also vary between the datasets. In particular, out of the 11 CpG sites 
within TBL1Y, two (cg09728865 and cg15700967) have methylation levels which appear to 
correlate negatively with gene expression in normal samples (r = -0.74 and -0.52 respectively, 
p-values < 0.0001 and 0.0034 respectively), as shown in figure 79: 
  
Figure 79 - plots of beta values for cg09728865 & cg15700957 vs TBL1Y expression 
Scatterplots for all normal male samples of methylation beta value (x-axis) for probe cg09728865 (left) and cg15700967 
(right) versus expression value for the TBL1Y gene (y-axis). COAD, HNSC and KIRC samples are shown in red, blue and green 
respectively. 
 
The differences in methylation between the datasets are particularly clear for cg09728865, 
which is located within the 5’ untranslated region of TBL1Y. 
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There is another CpG site (cg08921682) located within the 5’ untranslated region for which 
there appears to be a positive correlation between methylation and gene expression in normal 
samples (r = 0.63, p-value < 0.0001), as shown in figure 80: 
 
Figure 80 - plot of beta values for cg08921682 vs TBL1Y expression 
Scatterplot for all normal male samples of methylation beta value for probe cg08921682 (x-axis) versus expression value for 
the TBL1Y gene (y-axis). COAD, HNSC and KIRC samples are shown in red, blue and green respectively. 
The above figures suggest that methylation may be an important factor in regulating TBL1Y 
expression. 
As I mentioned in chapter 3, there is evidence of both hypo- and hyper-methylation in tumour 
samples across all three datasets. CpG site cg15700967 in particular is prone to hypo-
methylation, especially amongst COAD tumour samples, but this does not appear to impact 
on gene expression amongst COAD tumours. However, within the HNSC dataset, and to a 
lesser extent KIRC too, there is a subset of tumour samples for which this CpG site is hypo-
methylated and for which TBL1Y gene expression is low. Scatterplots for the two datasets are 
shown in figure 81 (tumours hypo-methylated based on the 40% threshold are shown in 
green, and those hypo-methylated based on the 20% threshold are shown in light blue): 
123 
 
  
Figure 81 - plots of probe intensity versus gene expression for cg15700967 (HNSC & KIRC) 
Scatterplots for methylation probe cg15700967 located within the TBL1Y gene. The plots show  total methylation intensity 
(x-axis) versus gene expression (y-axis) for all HNSC (left) and KIRC (right) male samples - non-hypo-methylated tumour 
samples are plotted in red, hypo-methylated tumour samples are plotted in green (40% threshold) or light blue (20% 
threshold) and normal samples are plotted in blue. 
For both the HNSC and KIRC datasets, there is a small subset of hypo-methylated tumour 
samples (shown in green) which have low expression values (< 5, lower than the normal 
samples) but do not have low total intensity values (> 2,000), which indicates that hypo-
methylation may be an important factor in variation in TBL1Y expression in some HNSC and 
KIRC tumour samples. The effect of hypo-methylation on expression might explain why the 
correlation between copy number variation and expression is lower than for other genes.  
I also observed hyper-methylation of three of the 11 CpG sites (cg02839557, cg01707559 and 
cg09728865) in subsets of samples in both the HNSC and KIRC datasets. However, this 
hyper-methylation does not appear to be associated with low gene expression. 
5.3.5 Analysis of NLGNY gene methylation 
NLGN4Y is located on the long arm of chromosome Y at around 16.63Mbp. Expression 
levels are similar for HNSC and KIRC, but lower in COAD samples (Kruskal-Wallis p-value 
= 0.0006 for normal samples), as shown in figure 82: 
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Figure 82 - comparison of NLGN4Y expression levels across datasets 
Boxplots of expression values of the NLGN4Y gene for all male samples, broken down by sample type and dataset. The 
distributions for normal samples are shown in blue, and those for tumour samples are shown in red. 
In both the COAD and HNSC datasets, expression levels are lower in tumour samples relative 
to normal samples (Kruskal-Wallis p-values = 0.0053 and 0.0405 respectively).  
I previously showed that there is reasonable correlation between copy number and gene 
expression for the HNSC and KIRC datasets, but that the correlation for COAD is low.  
There are 19 methylation probes targeted at CpG sites within NLGN4Y. Most of these CpG 
sites show consistent levels of methylation in normal samples across all three datasets. 
However, there is one site (cg09748856), located in the body of the gene, for which COAD 
normal samples are more highly methylated than normal samples in the other datasets. All of 
the HNSC and KIRC normal samples have very low methylation at this site, whereas the 
COAD normal samples are typically 50% methylated on average, as shown in figure 83: 
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Figure 83 - plot of beta values for cg09748856 vs NLGN4Y expression 
Scatterplot for all normal male samples of methylation beta value for probe cg09748856 (x-axis) versus expression value for 
the NLGN4Y gene (y-axis). COAD, HNSC and KIRC samples are shown in red, blue and green respectively. 
Once again this may indicate that methylation is an important regulator of gene expression for 
NLGN4Y. 
Hypo-methylation of tumour samples is a common feature for several of the CpG sites, 
especially in the COAD dataset. However, there is no obvious association between hypo-
methylation and variation in gene expression. 
Hyper-methylation of tumour samples is also a common feature across all three datasets. 
Again it is particularly prevalent in the COAD dataset, and this time there are three CpG sites 
(cg25518695, cg18113731 and cg19244032) for which hyper-methylation in COAD tumour 
samples does appear to be associated with lower gene expression. All three sites are located in 
the gene body, and there is high correlation between their beta values (i.e. all three sites tend 
to be hyper-methylated together within the same samples). An example of the association 
between beta value and gene expression is shown for cg25518695 in figure 84: 
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Figure 84 - plots of probe intensity, beta value and gene expression for cg25518695 (COAD) 
2D (left) and 3D (right) plots for methylation probe cg25518695 located within the NLGN4Y gene. The 2D plot shows  total 
methylation intensity (x-axis) versus gene expression (y-axis) for all COAD male samples - non-hyper-methylated tumour 
samples are plotted in red, hyper-methylated tumour samples are plotted in black (40% threshold) or grey (20% threshold) 
and normal samples are plotted in blue. The 3D plot shows total methylation intensity plotted against gene expression and 
beta value – tumour samples are shown in red and normal samples are shown in blue. 
There is a small subset of hyper-methylated tumour samples (shown in black) which have low 
expression values (< 25, lower than the normal samples) but do not have low total intensity 
values (> 2,000), which indicates that hyper-methylation may be an important factor in 
reduced expression of NLGN4Y in a subset of COAD tumour samples. 
5.3.6 Analysis of TTTY14 gene methylation 
TTTY14 is located further along the long arm of the Y chromosome at around 21.21Mbp. It is 
expressed at slightly different levels in normal samples across the three datasets (Kruskal-
Wallis p-value = 0.0002). In particular, HNSC normal samples have higher expression levels 
than their COAD and KIRC counterparts, as shown in figure 85: 
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Figure 85 - comparison of TTTY14 expression levels across datasets 
Boxplots of expression values of the TTTY14 gene for all male samples, broken down by sample type and dataset. The 
distributions for normal samples are shown in blue, and those for tumour samples are shown in red. 
Figure 85 also shows that TTTY14 expression is generally lower in tumour samples (Kruskal-
Wallis p-values < 0.0001 for COAD and HNSC and = 0.0013 for KIRC).  
I showed previously that the correlations between copy number and TTTY14 expression are 
lower for all datasets compared with other genes (particularly for COAD), which suggests that 
there could be other mechanisms affecting expression levels. 
There are 11 methylation probes targeted at CpG sites within TTTY14, and methylation levels 
are similar across all three datasets for each site. 
There is no evidence of hypo-methylation in tumour samples, but hyper-methylation is a 
common feature for eight of the 11 sites in all three datasets, especially COAD and HNSC. 
Once again there is high consistency in methylation levels between the eight sites, and hyper-
methylation is associated with low gene expression. A good example of this is site 
cg00212031, which is located near the transcriptional start site. Figure 86 shows the link 
between hyper-methylation and low gene expression for the COAD and HNSC datasets: 
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Figure 86 - plots of probe intensity, beta value and gene expression for cg00212031 (COAD & HNSC) 
Scatterplots for methylation probe cg00212031 located within the TTTY14 gene. The plots show total methylation intensity 
(x-axis) versus gene expression (y-axis) for all COAD (left) and HNSC (right) male samples - non-hyper-methylated tumour 
samples are plotted in red, hyper-methylated tumour samples are plotted in black (40% threshold) or grey (20% threshold) 
and normal samples are plotted in blue. 
There is a subset of hyper-methylated tumour samples which have low expression values (< 2, 
lower than the normal samples) but do not have low total intensity values (> 4,000 for COAD 
and > 6,000 for HNSC), which indicates that hyper-methylation may be an important factor in 
reduced expression of TTTY14 in subsets of both COAD and HNSC tumour samples. 
5.3.7 Summary 
For four of the 16 genes (SRY, RPS4Y1, NLGN4Y and TTTY14) there is evidence of hyper-
methylation being associated with low gene expression in some tumour samples for at least 
one of the datasets. Furthermore, hypo-methylation of TBL1Y is also associated with low 
gene expression. 
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5.4 Conclusions 
The key conclusions from my analyses of Y chromosome gene expression in male tumours 
are as follows:  
 15 Y chromosome genes (RPS4Y1, ZFY, TBL1Y, PRKY, TTTY15, USP9Y, 
DDX3Y, UTY, TMSB4Y, NLGN4Y, NCRNA00185, TTTY14, CYorf15A, KDM5D, 
and EIF1AY)  are expressed in all three datasets; 
 SRY gene is also expressed in the HNSC dataset, but not in COAD or KIRC; 
 across all three datasets there is generally high correlation between copy number and 
gene expression; 
 however the correlation is lower for some genes, in particular TBL1Y and NLGN4Y; 
 in addition to the effects of copy number variations, for four of the 16 genes (SRY, 
RPS4Y1, NLGN4Y and TTTY14) there is evidence that hyper-methylation of 
tumours is associated with low gene expression for some samples in at least one of the 
datasets; 
 hypo-methylation of TBL1Y is also associated with low gene expression for some 
samples in the HNSC and KIRC datasets 
In the next chapter, I will consider the impact of differences in Y chromosome copy number, 
methylation and gene expression on patient survival for the three datasets. 
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6. Analysis of Y chromosome aberrations and survival 
In this chapter I investigate whether there are any associations between the changes in the Y 
chromosome observed in the previous three chapters and patient survival. I concentrate, in the 
first instance, on copy number variations, as these are the most commonly observed 
alterations in all three datasets. Based on these results, I then look in more detail at the HNSC 
dataset only.   
An overview of the process I have followed is provided in figure 87: 
 
 
 
 
 
 
 
Figure 87 - overview of experimental process for survival analyses 
 
I set out details of each of the above stages in the following sections. 
 
 
 
Initial univariate analysis of association between copy number variation and survival 
Multivariate analysis for HNSC dataset 
Extension of HNSC analysis to gene expression 
Analysis of link between aberrant methylation and survival for HNSC dataset 
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6.1 Initial univariate analysis of survival 
In order to identify which, if any, of the datasets show an association between Y chromosome 
copy number variation and survival, I initially performed my analyses on a univariate basis, 
without allowing for the effect of any other factors which may influence survival. The TCGA 
clinical data include items “days to last follow up” and “days to death”, both measured from 
date of initial diagnosis, which allowed me to investigate overall survival (i.e. death from any 
cause). 
For the purposes of my analyses, I used the TCGA copy number index for the Y chromosome 
which I described in chapter 4. Figure 88 below shows a plot of the distribution of these index 
values for all KIRC male cases: 
 
Figure 88 - density plot of KIRC Y chromosome copy number index values 
Density plot of Y chromosome copy number index values for KIRC male tumour samples calculated using TCGA’s copy 
number data. The plot shows the frequency distribution of the index values. 
Figure 88 shows, in particular, that there is a clear bimodal distribution of Y chromosome 
copy number index values for the KIRC samples, with an initial peak at 0.56 and a second 
higher peak at 1.07, with an intervening trough at 0.79. 
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The bimodal distribution suggests that there are two separate subsets of samples, one which 
has lost the Y chromosome (the first peak) and one which has not (the second peak), and there 
is clearly some overlap between the two distributions. The reason why the first peak 
(representing samples which have lost the Y chromosome) is not at a lower value could be 
because not all tumour cells in any one sample have lost the Y chromosome. Also, the tumour 
samples may not be “pure” tumour and may contain some adjacent normal tissue which has 
not lost the Y chromosome. 
TCGA provide estimates of how “pure” each tumour sample is (based on cell nuclei), and so I 
adjusted the copy number index values I had calculated to allow for this impurity. For this 
purpose I assumed that if the tumour sample, for example, was estimated to be 70% tumour, 
then the other 30% would be normal tissue which had a copy number of one. Figure 89 shows 
the index values for the KIRC samples after I made this adjustment: 
 
Figure 89 - density plot of KIRC adjusted Y chromosome copy number index values 
Density plot of Y chromosome copy number index values for KIRC male tumour samples calculated using TCGA’s copy 
number data after adjustment for sample tumour percentages. The plot shows the frequency distribution of the adjusted 
index values. 
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The peaks have now moved slightly to 0.46 and 1.09 respectively (i.e. further away from one, 
as expected), and the trough has moved to 0.74. Figure 90 contains similar plots for the 
COAD and HNSC cases: 
 
 
Figure 90 - density plots of COAD & HNSC adjusted Y chromosome copy number index values 
Density plots of Y chromosome copy number index values for COAD (left) and HNSC (right) male tumour samples calculated 
using TCGA’s copy number data after adjustment for sample tumour percentages. The plots show the frequency 
distributions of the adjusted index values. 
Both plots again show bimodal distributions, though the first peak is lower for COAD cases. 
The COAD peaks occur at adjusted index values of 0.39 and 1.02, and the trough is at 0.62. 
The HNSC peaks are at 0.47 and 1.04, and the trough is at 0.71. 
I then used the adjusted index values to perform Kaplan-Meier analyses of overall survival. In 
each dataset, I initially subdivided cases according to whether their adjusted index values 
were less than or greater than the value at which the trough in the bimodal distribution 
occurred, as this seemed a natural point to split the two distributions.  The results for the 
COAD and KIRC datasets are shown in figure 91 (probability values calculated using log-
rank test): 
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Figure 91 – COAD & KIRC Kaplan-Meier plots using single Y chromosome copy number index thresholds 
Kaplan-Meier plots of overall survival for COAD (left) and KIRC (right) male tumour samples. In each case, samples have 
been subdivided into two groups based on threshold values of 0.62 and 0.74 respectively for the adjusted Y chromosome 
copy number index values. 
For both datasets there is no association between loss of the Y chromosome and overall 
survival. However, it is possible that the accuracy of the analyses was affected by the group of 
samples which fell within the overlap of the two distributions of index values (as I cannot be 
certain whether cases which fall within this range have lost the Y chromosome or not).  
To attempt to reduce the impact of this potential inaccuracy, I repeated the analysis by only 
considering those cases whose adjusted index values were lower than the value at which the 
first peak occurred or higher that the value at which the second peak occurred (i.e. ignoring 
cases which fell between the two peaks of the bimodal distribution).  Figure 92 shows the 
results of these analyses for the COAD and KIRC datasets: 
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Figure 92 – COAD & KIRC Kaplan-Meier plots using dual Y chromosome copy number index thresholds 
Kaplan-Meier plots of overall survival for COAD (left) and KIRC (right) male tumour samples. In each case, only samples with 
adjusted Y chromosome copy number index values above 1.02 and 1.09 respectively or below 0.39 and 0.46 respectively 
have been used. 
Again the plots indicate that there is no obvious association between Y chromosome copy 
number and overall survival in the COAD and KIRC datasets (log-rank p-values > 0.05). 
However, the Kaplan-Meier plots in figure 93 show a different picture for the HNSC dataset: 
  
Figure 93 – HNSC Kaplan-Meier plots using single and dual Y chromosome copy number index thresholds 
Kaplan-Meier plots of overall survival for HNSC male tumour samples. In the left hand plot, all samples have been 
subdivided into two groups based on a threshold value of 0.71 for the adjusted Y chromosome copy number index value. In 
the right hand plot, only samples with adjusted Y chromosome copy number index values above 1.04 or below 0.47 have 
been used. 
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This time there is a statistically significant link between reduced Y chromosome copy number 
and worse survival (log-rank p-value = 0.0398 based on splitting all samples using the value 
at which the trough occurred), and the association is stronger when the two extremes of the 
bimodal distribution are used (log-rank p-value = 0.0013). I, therefore, decided to concentrate 
my subsequent analyses on the HNSC dataset only, as set out in the following sections. 
Summary 
Univariate survival analysis indicated a possible link between loss of the Y chromosome and 
impaired overall survival for the HNSC dataset. No associations were observed for either the 
COAD or the KIRC dataset. 
 
6.2 Multivariate survival analyses for HNSC dataset 
Having discovered that there may be an association between loss of the Y chromosome and 
impaired overall survival in the HNSC dataset, I then refined my analyses of this dataset to 
allow for other factors which may influence the results. 
6.2.1 Effect of HPV infection 
Infection with human-papillomavirus (HPV) is an increasingly important factor in the 
development of a subset of head and neck cancers (in particular of the oropharynx)
13
. So HPV 
status is a natural item by which to sub-divide patients. The first question I asked, therefore, 
was whether there is any difference in overall survival between HPV positive and HPV 
negative patients within the HNSC male dataset.  
The TCGA clinical data include an item indicating whether each sample has been categorised 
as HPV positive or negative. Of the 370 male patients in total, 85 had been categorised as 
HPV positive and 284 as HPV negative (data item was unavailable for one patient).  
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Based on this information, figure 94 shows that there was no obvious difference in overall 
survival between the two groups: 
 
 
Figure 94 – Kaplan-Meier plot of overall survival for HNSC cases split by HPV status 
Kaplan-Meier plot of overall survival for HNSC male tumour samples, with samples split according to HPV status 
I then considered the adjusted chromosome Y copy number index values for each group. The 
distributions of these values are shown in figure 95: 
  
Figure 95 – density plots of adjusted Y chromosome copy number index values for HNSC HPV-ve and HPV+ve cases 
Density plots of Y chromosome copy number index values for HNSC HPV-ve (left) and HPV+ve (right) male tumour samples 
calculated using TCGA’s copy number data after adjustment for sample tumour percentages. The plots show the frequency 
distributions of the adjusted index values. 
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Again these is a clear bimodal distribution for both groups, although the first peak is a lot 
higher for HPV negative cases, which suggests that loss of the Y chromosome is more 
prevalent in these cases than in HPV positive cases. 
I next considered whether there was an association between Y chromosome copy number 
variation for either HPV category. Figure 96 shows the resultant Kaplan-Meier plots using 
samples split by the values at which the troughs in the bimodal distributions occurred: 
 
 
Figure 96 - Kaplan-Meier plots for HNSC HPV-ve & HPV+ve males using single Y chromosome copy number index 
threshold 
Kaplan-Meier plots of overall survival for HNSC HPV-ve (left) and HPV+ve (right) male tumour samples. In each case, 
samples have been subdivided into two groups based on threshold values of 0.74 and 0.64 respectively for the adjusted Y 
chromosome copy number index values. 
The above plots suggest that loss of the Y chromosome may be associated with impaired 
overall survival, especially for HPV negative cases, although neither result was statistically 
significant (log-rank p-values = 0.1598 and 0.1462 for HPV negative and HVP positive cases 
respectively).  
I also performed Cox Proportional Hazards analyses for both groups, and there was a 
statistically significant result for HPV negative cases (hazard ratio = 0.52 - i.e. a higher index 
value implies better survival - p-value = 0.0192), but not for HPV positive cases. 
139 
 
I then repeated the Kaplan-Meier analyses using only samples whose adjusted index values 
were lower than the values at which the first peaks occurred or higher that the values at which 
the second peaks occurred. Figure 97 shows the resultant Kaplan-Meier plots: 
  
Figure 97 - Kaplan-Meier plots for HNSC HPV-ve and HPV+ve males using dual Y chromosome copy number index 
thresholds 
Kaplan-Meier plots of overall survival for HNSC HPV-ve (left) and HPV+ve (right) male tumour samples. In each case, only 
samples with adjusted Y chromosome copy number index values above 1.01 and 1.08 respectively or below 0.48 and 0.45 
respectively have been used. 
 This time there is a clear association between Y chromosome copy number and survival for 
the HPV negative patients (log-rank p-value = 0.0032), but not for the HPV positive patients. 
I, therefore, focussed my subsequent analyses on the HPV negative cases only.  
I also discovered statistically significant associations for HPV negative cases using the 
adjusted copy number index for each individual arm of the Y chromosome (data not shown). 
Furthermore, these were the only chromosomal arms for which there were significant 
associations. 
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6.2.2 Other factors potentially affecting overall survival 
There are numerous other factors which may affect overall survival. For head and neck 
cancers, the most commonly used information in a clinical setting is nodal status – i.e. the 
extent to which the cancer has spread to the lymph nodes. TCGA’s clinical data includes an 
item “pathologic N” which indicates nodal status. 
Other factors which may potentially affect survival and which are available for most samples 
in the TCGA HNSC clinical data are: 
 Pathologic T – a standard indicator of tumour size and extent of invasion into nearby 
tissue; 
 Perineural invasion – an indicator  of whether the tumour has invaded areas 
surrounding nerves; 
 Pathologic stage 
 Histologic grade 
 Age 
 Smoking history – smoking is a known risk factor for head and neck cancer89. 
TCGA’s data include an item indicating whether each patient has ever smoked, and if 
they have, whether they are still smoking, stopped within the last 15 years or stopped 
more than 15 years ago. 
 Anatomic site – head and neck cancer covers several distinct regions, as shown in 
figure 98: 
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Figure 98 - diagram of head & neck cancer regions 
I also included an indicator of whether each sample harboured a mutation of the TP53 gene. 
TP53 is very commonly mutated in head and neck cancer, and such mutations may be 
regarded as a sign of more general chromosomal instability
13
. For this purpose I downloaded 
TCGA’s level 2 somatic mutation data, as described in chapter 2. 
6.2.3 Univariate Kaplan-Meier analyses using other factors 
All of the above items were available for most, but not all, of the 284 HPV negative male 
patients. For each item I performed a separate, univariate Kaplan-Meier analysis of overall 
survival. In table 9 I set out the resultant (log-rank) probability values for each analysis using 
all HPV negative samples – for the Y chromosome analysis I split samples at the trough value 
of 0.74, which results in a 50/50 split: 
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Item 
No. patients for which 
data available 
Categories used for 
Kaplan-Meier analysis P-value 
Adjusted chrY index 284 < 0.74 vs > 0.74 0.1598 
Pathologic N 247 N0/N1/N2/N3 < 0.0001 
Pathologic T 261 T1/T2/T3/T4/T4a/T4b 0.0035 
Perineural invasion 210 Yes / No 0.0115 
Pathologic stage 259 Stage I/II/III/IV 0.1329 
Histologic grade 276 G1/G2/G3/G4 0.2883 
TP53 mutation 270 Yes / No 0.3366 
Age (median split) 284 < median / > median 0.3515 
Smoking history 276 As described above 0.5247 
Anatomic site 284 
Oral cavity / Larynx / 
Oropharynx * 
0.6077 
*  one patient categorised as hypopharynx excluded 
Table 9 - summary of univariate survival analyses for HPV-ve males 
The table shows, for each of the data items in the first column, the number of HNSC HPV-ve samples for which that item 
was available, the categories used to split samples for the Kaplan-Meier analysis of overall survival, and the log-rank p-value 
from the analysis. 
The table shows that the association of pathologic N with survival is by far the most 
significant, followed by the associations with pathologic T and occurrence of perineural 
invasion. 
 Table 10 shows the corresponding results when the analysis was restricted to those cases 
whose adjusted Y chromosome copy number index values were lower than the value at which 
the first peak occurred or higher that the value at which the second peak occurred. This split 
samples into the lowest 29% and the highest 28% by index value. 
Pathologic N still has the most significant association with overall survival, but it is now 
closely followed by the adjusted Y chromosome copy number index. 
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Item 
No. patients for which 
data available 
Categories used for 
Kaplan-Meier analysis P-value 
Adjusted chrY index 159 < 0.48 vs > 1.01 0.0032 
Pathologic N 139 N0/N1/N2/N3 0.0028 
Pathologic T 146 T1/T2/T3/T4/T4a/T4b 0.0061 
Perineural invasion 119 Yes / No 0.0267 
Pathologic stage 145 Stage I/II/III/IV 0.1881 
Histologic grade 153 G1/G2/G3/G4 0.4975 
TP53 mutation 155 Yes / No 0.3172 
Age (median split) 159 < median / > median 0.2120 
Smoking history 153 As described above 0.9479 
Anatomic site 159 
Oral cavity / Larynx / 
Oropharynx * 
0.9248 
*  one patient categorised as hypopharynx excluded 
Table 10 - summary of univariate survival analyses for HPV-ve males split by dual Y chromosome copy number index 
thresholds 
The table shows, for each of the data items in the first column, the number of HNSC HPV-ve samples for whom that item 
was available, the categories used to split samples for the Kaplan-Meier analysis of overall survival, and the log-rank p-value 
from the analysis. For these analyses, only samples with an adjusted Y chromosome copy number index of greater than 1.01 
or less than 0.48 were used. 
6.2.4 Multivariate analyses using Cox-proportional hazards 
I then performed multivariate survival analyses using the Cox proportional hazards model, 
with adjusted Y chromosome copy number index and either pathologic N or pathologic T as 
my explanatory variables. In the former case, pathologic N retained a significant association 
with survival, but Y chromosome copy number did not. In the latter case, neither association 
was significant (at the 5% level), although the Y chromosome copy number association was 
border-line significant (Wald test p-value = 0.0548). 
I next considered how Y chromosome copy number varied over the different pathologic N 
and pathologic T categories. Figure 99 shows that there is little variation in Y chromosome 
copy number between the pathologic N groups (Kruskal-Wallis p-value = 0.5073): 
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Figure 99 - boxplots of Y chromosome copy number by pathologic N 
Boxplots of adjusted Y chromosome copy number index values for HNSC HPV-ve male tumours, subdivided by pathologic N 
data item. 
However, figure 100 shows a statistically significant (Kruskal-Wallis p-value = 0.0002), 
pattern of Y chromosome copy number reducing with increasing pathologic T levels: 
 
Figure 100 - boxplots of Y chromosome copy number by pathologic T 
Boxplots of adjusted Y chromosome copy number index values for HNSC HPV-ve male tumours, subdivided by pathologic T 
data item. 
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Finally I performed a Cox proportional hazards analysis including only Y chromosome copy 
number index, TP53 mutation, age, smoking history and anatomic site as the explanatory 
variables, and using only samples whose adjusted Y chromosome copy number index values 
were lower than the value at which the first peak occurred or higher that the value at which 
the second peak occurred (samples were grouped on this basis). My reasoning for doing this is 
that the other variables (pathologic N etc) are essentially observed tumour outcomes whereas 
these five variables are potential, biological causes of those outcomes. Using this multivariate 
model, the grouping by Y chromosome index values was the only variable to show a border-
line statistically significant association with overall survival (Wald test p-value = 0.0499). 
6.2.5 Limitation of analyses 
At this stage I should point out that there are a number of limitations to the survival analyses I 
have undertaken.  First, TCGA did not create their datasets with the primary intention of 
performing detailed survival analyses on the data, and hence there was no proper control of 
patients as there would be in a full clinical trial. In particular, there is inconsistency in the 
treatment regimes which have been applied to the patients in question (details available within 
TCGA’s clinical data). I have ignored this complication in my analyses as the treatment data 
were too varied (and sometimes missing) for them to be sensibly included. Furthermore, 
contact was lost with many patients at quite early time points, and so these people were 
censored and their contributions to the analyses are small. 
Second, there are several factors which may influence survival rates, and I have been limited 
to those which are available within TCGA’s clinical data (for example, useful data on alcohol 
consumption, another potential risk factor, was not available). Furthermore, even when a data 
item was available for most patients, it may have been missing for some, thereby reducing its 
reliability. 
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The number of potential factors is in itself a problem, as there are a limited number of 
samples, and so there is insufficient statistical power when several factors are tested 
simultaneously in a multivariate analysis. 
Finally, for ease of presentation, I have in some cases created categorical variables from 
otherwise continuous, numerical variables, by using suitable cut-off values (e.g. for the copy 
number and median age). This is not ideal practice, but does enable graphical representation 
of trends in survival rates. 
Despite the above issues, my analyses should provide, at the very least, reasonable indications 
of trends in survival. 
6.2.6 Summary 
For the HNSC dataset, loss of the Y chromosome is significantly associated with impaired 
overall survival in HPV negative cases (but not in HPV positive cases). Similar associations 
were observed for each arm of the Y chromosome, but not for any other chromosomal arm. 
 
6.3 Analysis of association between gene expression and survival 
I next considered whether there was also an association between reduced gene expression and 
impaired survival for the HPV negative cases. I expected that there probably would be, as I 
had previously shown in chapter 5 that for most of the 16 genes which were expressed, there 
was a strong correlation between Y chromosome copy number and expression level. 
 
 
147 
 
I performed univariate survival analyses using expression values for each of the 16 genes in 
turn as the explanatory variable. I initially produced Kaplan-Meier plots, splitting samples by 
whether their expression levels were below or above the median value (consistent with the 
fact that the trough of the bimodal distribution of adjusted Y chromosome copy number index 
values split cases into two equal groups.). 
In a similar vein to my analyses using the copy number index values, I also performed 
alternative analyses whereby I excluded those samples for which expression values were close 
to the median. For this purpose I compared, for each gene separately, those samples with 
expression either below the 29
th
 percentile or above the 72% percentile (consistent with the 
numbers of cases whose adjusted Y chromosome copy number index values were either lower 
than the value at which the first peak occurred or higher that the value at which the second 
peak occurred). In addition, I carried out Cox proportional hazards analyses based on 
expression levels for all samples.  
I set out the results of all these analyses (log-rank probability values for the Kaplan-Meier 
analyses and hazard ratios and Wald probability values for the Cox proportional hazards 
analyses) in table 11.  
In all cases, low expression was associated with worse overall survival, and for five genes 
(ZFY, PRKY, USP9Y, UTY and NLGN4Y) the results were statistically significant at the 5% 
level for both the Kaplan-Meier and Cox proportional hazards analyses. However, there is 
clearly a lot of variability in the statistical significance of the results depending on the method 
used to split the samples, which I attribute, in part, to noise in the expression data. 
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Gene 
Log-rank p-value Cox proportional hazards 
Median split <P29 / >P72 Hazard ratio P-value 
 
  
  
SRY 0.0993 0.1087 0.9683 0.1095 
RPS4Y1 0.0502 0.4216 1.0000 0.2033 
ZFY 0.1198 0.0108 0.9989 0.0339 
TBL1Y 0.8633 0.5461 0.9800 0.1986 
PRKY 0.0470 0.0320 0.9990 0.0492 
TTTY15 0.0620 0.0180 0.9981 0.0825 
USP9Y 0.0049 0.0014 0.9991 0.0216 
DDX3Y 0.0141 0.0213 0.9997 0.0610 
UTY 0.0033 0.0113 0.9987 0.0155 
TMSB4Y 0.0360 0.0377 0.9910 0.1131 
NLGN4Y 0.0004 0.0012 0.9979 0.0156 
NCRNA00185 0.4065 0.1502 0.9891 0.2772 
TTTY14 0.4751 0.8682 0.9805 0.3892 
CYorf15A 0.0723 0.2325 0.9990 0.2159 
KDM5D 0.0024 0.0297 0.9996 0.1875 
EIF1AY 0.5004 0.4061 1.0000 0.8728 
Table 11 - results of survival analyses based on gene expression 
The second and third columns show, for each of the 16 Y chromosome genes, the results of Kaplan-Meier analyses of 
overall survival for HNSC HPV-ve male samples split by median expression and also with samples split into those whose 
expression was lower than the 29th percentile or greater than the 72nd percentile. The final two columns show the results 
of Cox proportional hazards analyses for all HNSC HPV-ve male samples using gene expression as the explanatory variable. 
The Kaplan-Meier analyses based on comparing samples whose expression levels were below 
the 29
th
 percentile against those whose expression levels were above the 72
nd
 percentile were 
intended to reduce the effect of noise in the data by ignoring samples whose categorisation 
could be influenced by a small variation in expression level. Based on these analyses, 
expression levels for nine of the 16 genes had a statistically significant association with 
survival. However, there are four genes (RPS4Y1, TBL1Y,  TTTY14 and EIF1AY) for which 
there was little association. 
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It may be the case that the analyses for these four genes were affected by samples whose 
expression had been reduced by another mechanism. In particular, I observed in chapter 5 that 
expression levels of RPS4Y1 and TTTY14 (hyper-methylated) and TBL1Y (hypo-
methylated) may have been affected by abnormal methylation. There was also some evidence 
of hyper-methylation affecting EIF1AY expression levels for a very small subset of samples. 
Summary 
For each of the 16 genes, low levels of expression were generally associated with worse 
overall survival for HPV negative cases, although the results were not always statistically 
significant. There were four genes in particular, for which the association with survival was 
much weaker than for the other genes. 
 
6.4 Aberrant methylation and survival 
Finally, for RPS4Y1, TBL1Y and TTTY14, I investigated whether there was any difference 
in survival between patients who may have had reduced gene expression as a result of 
aberrant methylation, and those whose expression appeared to be reduced as a result of 
chromosomal loss. For each gene I performed univariate Kaplan-Meier analyses, with HPV 
negative patients whose expression levels were below the median split into two groups: 
1. Hypo-methylated (TBL1Y) or hyper-methylated (RPS4Y1 and TTTY14) based on the 
40% threshold (probes cg15700967, cg25443613 and cg00212031 respectively); and 
2. Not hypo- / hyper- methylated 
The resultant plots for TBL1Y and TTTY14 are shown in figure 101: 
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Figure 101 - Kaplan-Meier plots based on methylation for TBL1Y and TTTY14 
Kaplan-Meier plots of overall survival for HNSC HPV-ve male tumour samples with below median expression values for 
TBL1Y gene (left) and TTTY14 gene (right). In the left hand plot, samples have been split into those which were hypo-
methylated (40% threshold) and those which were not. In the right hand plot, samples have been split into those which 
were hyper-methylated (40% threshold) and those which were not. 
For TBL1Y, those patients which had experienced hypo-methylation enjoyed statistically 
significant better survival (log-rank p-value = 0.0254) than those which were not subject to 
aberrant methylation. The result for hyper-methylation of TTTY14 was similar, but not quite 
statistically significant (log-rank p-value = 0.0549). A similar association was also observed 
for RPS4Y1, but there were too few hyper-methylated samples for the results to be 
statistically significant. 
Summary 
Patients whose expression of RPS4Y1, TBL1Y and TTTY14 may have been reduced by 
aberrant methylation appear to enjoy better survival rates relative to those patients who have 
suffered loss of the Y chromosome. 
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6.5 Conclusions 
The key conclusions from my survival analyses are as follows:  
 there appears to be no association between loss of the Y chromosome and overall 
survival in the COAD and KIRC datasets; 
 however, there does appear to be an association in the HNSC dataset; 
 in particular, for HPV negative head and neck cancer patients there is a link between 
loss of the Y chromosome and impaired overall survival; 
 the association for HPV negative patients also applied separately to each arm of the Y 
chromosome, and these results were unique amongst all chromosomal arms; 
 for HNSC HPV negative patients nodal status is by far the most significant factor 
influencing survival; 
 but amongst potential causes of HNSC tumours, loss of the Y chromosome is the most 
significant factor; 
 associations between gene expression and survival are generally consistent with those 
for loss of the Y chromosome; 
 however, for RPS4Y1, TTTY14 and TBL1Y in particular, reduced expression through 
aberrant methylation may be associated with improved survival compared to patients 
whose expression is reduced by chromosomal loss. 
In my final results chapter I look in more detail at the analyses for the HNSC dataset. 
 
 
 
 
 
152 
 
7. Further analyses of head and neck tumours 
In this chapter I investigate in greater detail the associations between loss of the Y 
chromosome and key risk factors for male head and neck tumours. 
I decided to concentrate on chromosomal loss as this is by far the most common Y 
chromosome abnormality I have observed in tumours. I chose the HNSC dataset as it is the 
only one of the three datasets I have analysed for which TCGA provide useable data on 
patients’ smoking histories, and for which there appears to be a link between Y chromosome 
loss and impaired survival. 
An overview of the process I have followed is provided in figure 102: 
 
 
 
 
 
 
 
Figure 102 - overview of experimental process for further analyses of HNSC tumours 
I set out details of each of the above stages in the following sections. 
 
 
 
Analyse association between Y chromosome loss and HPV status 
Analyse association between Y chromosome loss and age 
Consider effect of smoking on Y chromosome loss 
Analyse association between Y chromosome loss and TP53 mutations 
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7.1 Analysis of Y chromosome loss by HPV status 
As I mentioned in the previous chapter, out of the 370 male tumour samples for which both 
methylation and copy number data were available, 369 also had information on HPV infection 
status . 85 (23.0%) of these had been classified as HPV positive, and the other 284 as HPV 
negative. This compares with 12 (8.9%) out of 135 female samples which had been 
categorised as HPV positive. Hence the prevalence of HPV infection was more than twice as 
high in the male patients. 
7.1.1 Loss of Y chromosome and HPV status 
I also mentioned previously that loss of the Y chromosome appeared to be more prevalent in 
HPV negative cases than in HPV positive cases, and this is shown in figure 103: 
 
Figure 103 - comparison of Y chromosome loss in HPV-ve & HPV+ve tumours 
Boxplots of adjusted Y-chromosome copy number index values for all HNSC males split by HPV status. The boxplot for HPV-
ve cases is shown in red and the boxplot for HPV+ve cases is shown in blue. 
Whilst there is evidence of some loss of Y chromosome in HPV positive tumours, it is much 
more common in HPV negative tumours (Kruskal-Wallis p-value < 0.0001). 
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7.1.2 Breakdown of HPV status by anatomical site 
There are five main sub-categories of head and neck cancer by anatomical site:- hypophayrnx, 
nasopharynx, oropharynx, larynx and oral cavity
88. TCGA’s data contain samples from all of 
these sites except nasopharynx. Table 12 shows the breakdown of the 369 male tumour 
samples by HPV status and anatomical site: 
Site HPV-ve HPV+ve Total 
Hypopharynx 1 5 6 
Oropharynx 20 49 69 
Larynx 88 6 94 
Oral cavity 175 25 200 
Total 284 85 369 
Table 12 - breakdown of HNSC tumour samples by HPV status and anatomical site 
HPV negative tumours are primarily found in the oral cavity and the larynx, whereas 
oropharyngeal and hypopharyngeal tumours are more commonly HPV positive. In figure 104 
I compare, for each HPV subgroup, the extent of Y chromosome loss across the different sites 
(hypopharynx excluded due to small numbers): 
  
Figure 104 - comparison of Y chromosome loss in different HNSC anatomical sites 
Boxplots of adjusted Y chromosome copy number index values for HNSC males split by anatomical site. The left hand plot 
shows HPV-ve cases and the right hand plot shows HPV+ve cases. The anatomical site categories are colour-coded red 
(oropharynx), blue (oral cavity), and green (larynx). 
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Amongst HPV negative tumours, the extent of Y chromosome loss is similar across the three 
sites shown, albeit slightly greater in laryngeal tumours (Kruskal-Wallis p-value = 0.1979). In 
the HPV positive tumours, oropharyngeal tumours generally show the lowest levels of Y 
chromosome loss, whilst laryngeal tumours again show the greatest level of loss (although 
this is only a small subset of samples, and is not statistically significant – Kruskal-Wallis p-
value = 0.1446).  
The higher level of Y chromosome loss in HPV negative tumours is evident in all three sites, 
although this is only statistically significant for oropharygeal cases (Kruskal-Wallis p-value = 
0.0019). 
7.1.3 Summary 
Loss of Y chromosome is more prevalent in HPV negative male patients, and this pattern is 
observed across different anatomical sites. 
 
7.2 Analysis of Y chromosome loss by age 
I next considered whether loss of the Y chromosome was associated with age. 
7.2.1 Analysis of age profile by HPV status 
Figure 105 compares the age profiles of the HPV negative and HPV positive patients: 
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Figure 105 - comparison of age profiles of HPV-ve & HPV+ve tumours 
Boxplots of ages for all HNSC males split by HPV status. The boxplot for HPV-ve cases is shown in red and the boxplot for 
HPV+ve cases is shown in blue. 
Figure 105 shows that the HPV positive male patients are slightly younger on average (57.3 
years) than the HPV negative patients (61.0 years), and this difference was statistically 
significant (Kruskal-Wallis p-value = 0.0084). Age was measured at date of initial cancer 
diagnosis. 
In figure 106 I compare, for each HPV group, the age profiles across the different sites 
(hypopharynx again excluded): 
  
Figure 106 - comparison of age profiles in different HNSC anatomical sites 
Boxplots of ages for HNSC males split by anatomical site. The left hand plot shows HPV-ve cases and the right hand plot 
shows HPV+ve cases. The anatomical site categories are colour-coded red (oropharynx), blue (oral cavity), and green 
(larynx). 
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For both HPV negative and HPV positive patients, those with laryngeal tumours tended to be 
slightly older on average and those with oropharyngeal tumours tended to be the youngest, 
although these differences were only statistically significant for the HPV positive cases 
(Kruskal-Wallis p-value = 0.0177). 
7.2.2 Variation of Y chromosome loss with age 
I then plotted age against adjusted Y chromosome copy number index for all the male 
patients. This is shown in figure 107, with colour-coding according to HPV status: 
 
Figure 107 - plot of age vs Y chromosome copy number for HNSC tumours 
Scatterplot of age (x-axis) versus adjusted Y chromosome copy number index value (y-axis) for all HNSC male tumours. HPV-
ve cases are shown in red and HPV+ve cases are shown in blue. 
There was a weak correlation (-0.118, p-value = 0.0230) between age and adjusted Y 
chromosome copy number index (i.e. loss of Y chromosome tended to increase slightly with 
age). Separate graphs for HPV negative and HPV positive tumours are set out in figure 108 
(colour-coded by anatomical site):  
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Figure 108 - plots of age vs Y chromosome copy number for HPV-ve and HPV+ve tumours 
Scatterplots of age (x-axis) versus adjusted Y chromosome copy number index value (y-axis) for HNSC male tumours. The 
left hand plot shows HPV-ve cases and the right hand plot shows HPV+ve cases. Cases are colour-coded by anatomical site: 
red (oropharynx), blue (oral cavity), green (larynx), and yellow (hypopharynx). 
A similar, small level of negative correlation (-0.115, p-value = 0.0515) was observed in the 
HPV negative tumours, whereas there was no correlation in the HPV positive tumours. 
7.2.3 Summary 
There was a weak correlation between loss of the Y chromosome and age, in particular for 
HPV negative patients. 
 
7.3 Analysis of Y chromosome loss by smoking history 
Smoking is a key risk factor for head and neck cancer
89
, and TCGA provide useful data on 
smoking history for most HNSC patients. I, therefore, decided to extend my analysis to 
consider the association of smoking with loss of the Y chromosome. 
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7.3.1 Summary of TCGA smoking data 
There is evidence that the influence of smoking on cancer occurrence diminishes over time 
once someone has stopped smoking
4,99
. TCGA categorise patients into four subgroups on this 
basis, as I mentioned in the previous chapter. Data on smoking history was available for 276 
of the 284 HPV negative patients and for 84 of the 85 HPV positive patients, as summarised 
in table 13:  
Smoking history HPV-ve HPV+ve Total 
Never smoked 41 (14.9%) 24 (28.6%) 65 (18.1%) 
Stopped >15 years ago 39 (14.1%) 12 (14.3%) 51 (14.2%) 
Stopped <15 years ago 82 (29.7%) 25 (29.8%) 107 (29.7%) 
Current smoker 114 (41.3%) 23 (27.4%) 137 (38.1%) 
Total 276 84 360 
Table 13 - breakdown of HNSC male tumour samples by HPV status and smoking history 
Table 13 shows that smoking was more prevalent amongst HPV negative patients (41.3% vs 
27.4% are current smokers, chi-squared p-value = 0.0186). 
Frequency of smoking is another, potential risk factor for head and neck cancer
4
. TCGA also 
provide some information on amount of cigarettes smoked, but this information was not 
available for 75 patients. Based on the data that were available, I observed no association 
between frequency of smoking and Y chromosome loss (data not shown). 
7.3.2 Association of smoking history and loss of Y chromosome 
I then considered the extent to which loss of the Y chromosome was associated with smoking 
history. In figure 109 I compare, for each HPV subgroup, the extent of Y chromosome loss 
across the four smoking categories: 
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Figure 109 - comparison of Y chromosome loss by smoking history 
Boxplots of adjusted Y chromosome copy number index values for HNSC males split by smoking history category. The left 
hand plot shows HPV-ve cases and the right hand plot shows HPV+ve cases. The smoking history categories are colour-
coded green (non-smoker), blue (former smoker who stopped more than 15 years ago), pink (former smoker who stopped 
within the last 15 years) and red (current smoker). 
For the HPV negative patients, there is a trend (Kruskal-Wallis p-value of 0.0682) for loss of 
the Y chromosome to increase across the subgroups (from non-smokers to current smokers). 
There is, however, no obvious trend amongst the HPV positive cases. 
7.3.3 Summary 
Smoking was more prevalent amongst HPV negative patients, and there was a trend for Y 
chromosome loss to be associated with smoking for these patients. 
 
7.4 Analysis of Y chromosome loss by TP53 mutations 
The final risk factor that I considered was whether each patient harboured a mutation of the 
TP53 gene. For this purpose I used TCGA’s somatic mutation data, which was available for 
270 of the 276 HPV negative and 78 of the 84 HPV positive male patients for whom smoking 
data were also available.  
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7.4.1 Summary of TP53 mutation data 
The breakdown of the male patients by HPV status, smoking history and TP53 mutation 
status is set out in table 14:  
Smoking history HPV-ve HPV+ve Total 
 
TP53-ve TP53+ve TP53-ve TP53+ve TP53-ve TP53+ve 
Never smoked 5 35 20 3 25 38 
Stopped >15 years ago 14 25 7 3 21 28 
Stopped <15 years ago 12 67 17 6 29 73 
Current smoker 21 91 13 9 34 100 
Total 52 218 57 21 109 239 
Table 14 - breakdown of HNSC tumours by HPV status, smoking history & TP53 status 
Table 14 shows that 239 (68.7%) out of the 348 male patients for which data were available 
had a mutation of TP53. However the frequency of mutation was much greater (chi-squared 
p-value < 0.0001) in HPV negative cases (80.7%) than in HPV positive cases (26.9%). For 
the former group, there was no clear evidence of mutational frequency being linked to 
smoking, whereas for HPV positive cases there was a trend (not statistically significant) for 
mutational frequency to be greater in smokers. 
7.4.2 Association of Y chromosome loss with TP53 mutations 
I then considered whether loss of the Y chromosome was associated with TP53 mutations. 
Initially I compared, for each HPV subgroup, the extent of Y chromosome loss between 
patients with and without a TP53 mutation, as shown in figure 110: 
162 
 
  
Figure 110 - comparison of Y chromosome loss by TP53 mutations 
Boxplots of adjusted Y chromosome copy number index values for HNSC HPV-ve (left) and HPV+ve (right) males split by 
TP53 mutation status. The boxplots for cases with a TP53 mutation are shown in red, and the boxplots for non-mutated 
cases are shown in blue. 
For HPV negative patients, the extent of Y chromosome loss did not appear to be associated 
with TP53 mutational status (Kruskal-Wallis p-value = 0.7688). However, HPV positive 
patients who harboured a TP53 mutation appeared to suffer greater loss of the Y chromosome 
than those who did not have a mutation (Kruskal-Wallis p-value = 0.0116). 
For each HPV subgroup, I then further sub-divided the data by smoking history. The 
comparisons for HPV negative patients are shown in figure 111: 
  
Figure 111 - comparison of Y chromosome loss by TP53 status & smoking history for HPV-ve patients 
Boxplots of adjusted Y chromosome copy number index values for HNSC HPV-ve males split by smoking history category. 
The left hand plot shows cases with no TP53 mutation and the right hand plot shows cases with a TP53 mutation. The 
smoking history categories are colour-coded green (non-smoker), blue (former smoker who stopped more than 15 years 
ago), pink (former smoker who stopped within the last 15 years) and red (current smoker). 
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For the 52 HPV negative patients who did not harbour a TP53 mutation, there was a clear 
association between loss of the Y chromosome and smoking (Kruskal-Wallis p-value = 
0.0047). However, there was no association for the 218 patients who did have a TP53 
mutation (Kruskal-Wallis p-value = 0.4561).  
Figure 112 shows the corresponding comparisons for the HPV positive patients: 
  
Figure 112 - comparison of Y chromosome loss by TP53 status & smoking history for HPV+ve patients 
Boxplots of adjusted Y chromosome copy number index values for HNSC HPV+ve males split by smoking history category. 
The left hand plot shows cases with no TP53 mutation and the right hand plot shows cases with a TP53 mutation. The 
smoking history categories are colour-coded green (non-smoker), blue (former smoker who stopped more than 15 years 
ago), pink (former smoker who stopped within the last 15 years) and red (current smoker). 
In both cases there was no obvious association between loss of the Y chromosome and 
smoking (Kruskal-Wallis p-values = 0.3568 and 0.3196 respectively). 
For the HPV negative cases with no TP53 mutation, I also carried out the same comparison 
for each arm of the Y chromosome, as shown in figure 113:  
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Figure 113 - comparison of Y chromosome arm-level loss by smoking history for HPV-ve/TP53-ve patients 
Boxplots of adjusted Y chromosome arm-level copy number index values for HNSC HPV-ve males with no TP53 mutation 
split by smoking history category. The left hand plot shows results for the short arm (Yp) and the right hand plot shows 
results for the long arm (Yq). The smoking history categories are colour-coded green (non-smoker), blue (former smoker 
who stopped more than 15 years ago), pink (former smoker who stopped within the last 15 years) and red (current 
smoker). 
Similar, statistically significant associations with smoking were observed for both the short 
and long arms of the Y chromosome (Kruskal-Wallis p-values = 0.0055 and 0.0086 
respectively). Furthermore, I performed the same analyses for every chromosome arm, and 
discovered that statistically significant associations were unique to the Y chromosome. 
7.4.3 Summary 
HPV positive patients with a TP53 mutation had generally higher levels of Y chromosome 
loss than their counterparts with no mutation. However, the levels of Y chromosome loss for 
HPV negative patients were similar regardless of TP53 mutation status. For HPV negative 
patients with no TP53 mutation there was a clear association between smoking and loss of 
chromosome Y. This association was observed in both arms of the Y chromosome, and was 
not observed in any other chromosome. 
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7.5 Conclusions 
The main conclusions from my analyses of the associations of Y chromosome copy number 
changes and key risk factors in male head and neck tumours are as follows:  
 HPV infection was more than twice as prevalent in male than female HNSC patients; 
 loss of the Y chromosome was more prevalent in HPV negative male tumours than in 
HPV positive tumours; 
 and this difference was observed across different anatomical sites; 
 there was a minor correlation between loss of the Y chromosome and age, in particular 
for HPV negative tumours; 
 a history of smoking was more prevalent amongst HPV negative patients than 
amongst HPV positive patients; 
 for HPV negative patients there was a trend for loss of the Y chromosome to be 
associated with smoking; 
 mutations of TP53 were much more frequently observed in HPV negative patients 
than in HPV positive patients; 
 for HPV positive patients, there was some evidence that TP53 mutations are more 
frequently observed in smokers than non-smokers; 
 for HPV positive patients, loss of the Y chromosome was greater on average when 
there was a TP53 mutation; 
 however, the same association was not observed in HPV negative patients; 
 for HPV negative patients with no TP53 mutation, there was a clear association 
between loss of the Y chromosome and smoking; 
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 furthermore, the same association with smoking was observed independently in both 
arms of the Y chromosome; 
 and this association was unique to the Y chromosome. 
I will discuss all of my results in the next chapter. 
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8. Discussion 
To my knowledge this is the first time that a detailed, multi-‘omic analysis of the male-
specific region of the Y chromosome has been performed using TCGA, or indeed any, 
dataset. By limiting my research solely to the Y chromosome, thereby excluding all female 
samples, I have been able to discover features which are potentially overlooked in studies 
which follow unisex, genome-wide approaches. These are discussed in the following sections. 
8.1 Methylation analyses 
There has been very little research into aberrant methylation of the Y chromosome in human 
cancer. My analyses have yielded results which are largely consistent between the three 
datasets, and which are in line with previous, more general findings of methylation in cancer.  
First, methylation levels are generally similar in normal samples across the three datasets. 
However, there were some differences for a small proportion of individual CpG sites, which 
suggests that methylation could be an important regulator of gene transcription for some Y 
chromosome genes. 
Second, methylation levels are more variable amongst tumour samples than amongst normal 
samples, indicating that, consistent with the rest of the genome, the Y chromosome 
methylome is disrupted during the tumorigenic process. Furthermore, this disruption appears 
not to occur in an entirely random manner, as hyper-methylated CpG sites tend to be 
concentrated in relatively small, discrete regions of the Y chromosome, and are interspersed 
between much larger regions of general hypo-methylation
34
. 
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Hyper-methylation of the Y chromosome in tumour samples occurs predominantly in or near 
CpG islands and close to the transcriptional start sites of genes, which implies that it could be 
an important causative agent in aberrant gene expression (see below). Several genes are 
affected by hyper-methylation, including the putative tumour suppressor gene ZFY
6
 and other 
genes which have been suggested as important for male viability, namely RPS4Y1, TBL1Y, 
NLGN4Y, CYorf15A and EIF1AY
5
.  
The SRY gene is also hyper-methylated in a large number of tumour samples, in particular 
within the HNSC dataset. This is of particular interest for the following reasons: 
 SRY is expressed in normal HNSC samples but not in COAD or KIRC samples (see 
later); 
 Methylation levels are lower in normal HNSC samples compared with COAD and 
KIRC;  and 
 Previous research has suggested that SRY expression is regulated by methylation in 
prostate cancer, and can be restored using de-methylating agents
22
. 
Hypo-methylation is more common than hyper-methylation in all three datasets, but generally 
occurs at a lower level. Once again, CpG sites within a small number of genes are affected, 
including the afore-mentioned TBL1Y and NLGN4Y. 
My analyses also revealed some interesting, technical issues with TCGA’s methylation data. 
First, around 10% of the Y chromosome probes appear to cross-hybridise with other parts of 
the genome and are, therefore, unreliable. Problems with cross-hybridisation are a known 
feature of the Illumina platform
100
. 
169 
 
Second, methylation levels appear to be distorted by copy number changes, consistent with 
previous research
14
. This was clearly evident in cases which had lost the Y chromosome, but 
there was also some evidence (data not shown) that high copy number may also have a 
distorting effect for some probes. 
8.2 Copy number analyses 
Loss of the Y chromosome has previously been reported for all three cancer types 
studied
25,26,27
. My analyses, using both TCGA’s methylation and copy number data, confirm 
that the Y chromosome is frequently lost in each dataset, and that loss generally occurs at the 
whole chromosome level, with both arms being lost in similar proportions. 35%, 42% and 
39% of COAD, HNSC and KIRC male patients respectively appear to have suffered some 
loss of the Y chromosome, making this the most common copy number aberration in male 
tumours. 
For each dataset there was a clear bimodal distribution of copy number index values, which 
suggests that in each case there are two distinct sub-populations of patients – one who have 
lost the Y chromosome and another who have not. The first peaks of the distributions 
occurred at 0.39, 0.47, and 0.46 for COAD, HNSC and KIRC samples respectively, and the 
second peaks occurred at 1.02, 1.04 and 1.09 respectively. In each case there was an 
intervening trough at 0.62, 0.74 and 0.74 respectively. The two sub-populations merge 
together between the two peaks, and so for patients whose index values fall in this range, it is 
not clear which sub-population they actually belong to. The fact that the peaks are not sharper 
and that there is considerable overlap between the two distributions will in part be due to 
some inaccuracy within the data 
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Although the Y chromosome was frequently lost in each dataset, I rarely found that it was 
completely lost in any individual sample – for example, the peak of the distribution for 
samples which had lost the Y chromosome occurred at an index value of between 0.39 and 
0.47 rather than zero, even after making allowance for the proportion of cells in each sample 
which TCGA actually believed to be non-cancerous. Aside from any inaccuracy in the data 
measurements, there are a couple of possible explanations for this observation. First, the 
assessment of tumour purity on which I based my calculations may not be precise. Second, 
and probably more importantly, Y chromosome loss may not occur in every tumour cell, but 
may instead be restricted to a subset of cells.  
Whether Y chromosome loss is an important factor in tumorigenesis, or simply a by-stander 
effect of little consequence, has been a matter of debate. For example, research in acute 
myelogenous leukaemia has suggested that it is primarily a consequence of ageing, with no 
causal effect
101
. However, other research using a prostate cancer cell-line in a mouse model 
has shown that reintroducing a lost Y chromosome can suppress tumour formation
102
. These 
conflicting results raise the possibility that the importance of Y chromosome loss to cancer 
development may depend on the anatomical location in which it occurs. 
On a technical level, my work also confirms that total intensity measurements generated by 
the Illumina 450k methylation platform can be used to give very good estimates of copy 
number levels
14
. Furthermore, I discovered that a small number of Y chromosome probes on 
the 450k platform appear to cross-hybridise with other regions within the Y chromosome, and 
therefore give potentially unreliable measurements. 
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8.3 Gene expression analyses 
My analyses revealed that 15 Y chromosome genes are expressed in all three datasets. These 
include all 12 of the genes identified in the literature as potentially being important for male 
viability
5
, along with three others, namely TTTY14, TTTY15 and NCRNA00185. One further 
gene, SRY, was only expressed in the HNSC dataset. 
As might be expected, expression levels of each gene were associated with copy number 
variations. For most of the genes, these associations were strong. However, for a small 
number of genes, the associations were weaker, and in these cases, there was evidence that 
aberrant methylation, both hyper- and hypo-, may also be a contributory factor in reduced 
expression. 
The fact that all 12 of the genes put forward by Bellott
5
 as being essential for male viability 
were expressed in all of the three datasets suggests that their functionality is important across 
different tissue types. Furthermore, each has an X-chromosome homolog which escapes X-
inactivation in females, suggesting that maintenance of total expression levels across the X/Y 
homologs is important. 
Using gene ontologies based on their X-chromosome homologs, Bellott
5
 showed that at least 
eight of these genes are likely to play roles in several fundamental biological processes, as set 
out in the Venn diagram in figure 114 taken from his paper: 
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Figure 114 - Y chromosome gene ontologies 
This diagram is taken from Bellott
5
 and shows categorisations of genes on the Y chromosome using the ontologies of their 
X-chromosome counterparts 
Several of these genes have also been implicated in other pathologies
16
. For example: 
1.  DDX3Y, KDM5D, RPS4Y1, TMSB4Y, USP9Y and UTY have been shown to code 
for minor-histocompatability antigens which are believed to play a role in graft-
versus-host disease or graft rejection after sex-mismatched bone marrow transplants. 
2. TBL1Y and NLGN4Y have been implicated in the four-fold higher incidence of 
autism in males relative to females. 
3. Over-expression of DDX3Y, EIF1AY, RPS4Y1 and USP9Y has been implicated in 
gender differences in the incidence of cardiovascular disease.  
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Turning to the other three genes which were expressed in all three datasets, the fact that two 
genes of the TTTY family (TTTY14 and TTTY15) were expressed is potentially interesting in 
that these are, by definition, genes whose functionality is supposedly limited to the testes. 
Little is known about them, though they are believed to code for non-coding RNAs – indeed 
TTTY14 is also known as NCRNA000185 (http://www.ncbi.nlm.nih.gov/gene/83869). 
Finally, SRY is potentially the most interesting of all the 16 genes as it was only expressed in 
the HNSC dataset. SRY is also known as the testis-determining-factor, and is the key gene 
responsible for specification of the male gender
16
. As such, it is mainly expressed in male-
specific tissues such as the testes. However, it has also been shown to be expressed in other 
tissues, such as the brain
103
. Hence, it is possible that SRY has other male-specific roles 
beyond its main sex-determination function. 
8.4 Head and neck cancer analyses 
My analyses of overall survival provided some potentially interesting results for the HNSC 
dataset.  
First, I discovered that there was an association between loss of the Y chromosome and 
impaired overall survival in the HNSC dataset. No such association was evident in the COAD 
and KIRC datasets, which raises the possibility that Y chromosome loss may contribute to the 
pathogenesis of head and neck cancer. 
Previous research has reported that there may be an association between loss of the Y 
chromosome and impaired survival in head and neck cancer
27
. However, that research was 
based on a much smaller dataset than the one I have used.  
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Also, consistent with previous research
28
, my results suggest that Y chromosome loss in head 
and neck cancer is not simply a by-product of the ageing process, as there was only a very 
weak correlation between the extent of loss and age. 
To investigate the survival association in more detail, I decided to refine my analyses by first 
splitting samples between those which had been assessed by TCGA as HPV positive and 
those which had been assessed as HPV negative. I believe this is a reasonable subdivision of 
the data to make for the following reasons. HPV infection was first discovered in some 
tumours of the oropharynx in 1983
104
, and since then research has indicated that it is a 
primary cause of a subset of head and neck cancers
105
. In particular, HPV positive tumours 
differ from HPV negative tumours in several respects such as epidemiology, molecular 
biology and outcome
106
 – for example: 
 They tend to occur at younger ages, especially in males, and patients with HPV 
positive tumours tend to have lower consumption of tobacco and alcohol; 
 HPV positive tumours are much more prevalent in certain anatomical sites – in 
particular the oropharynx; 
 The ways in which key signalling pathways are disrupted are different – for example, 
the TP53 gene is the most commonly mutated gene in HPV negative tumours, 
potentially leading to disruption of downstream pathways involved with important 
biological processes such as cell-cycle control, apoptosis, DNA repair and 
metabolism. However, the frequency of TP53 mutation in HPV positive tumours is 
much lower. Instead, the p53 protein product of TP53 is often degraded by the viral 
oncoprotein E6; 
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 Patients with HPV positive tumours, especially of the oropharynx, have been found to 
have better survival compared to patients with HPV negative tumours. 
The first three of the above characteristics were all observed in my analyses, although the 
difference in outcome was not seen.  
Detection of HPV infection is a potential issue, as the techniques used for this purpose are not 
necessarily 100% reliable
107
. These techniques include p16 immunohistochemistry (the p16 
protein is used as a surrogate marker for HPV infection, since the viral oncoprotein E7 
degrades the RB1 gene which in turn leads to overexpression of p16), in-situ hybridisation for 
high risk HPV, quantitative polymerase chain reaction for either viral mRNA or DNA, and 
detection of viral mRNA using RNA-seq analysis
107
. In their determination of HPV statuses, 
TCGA used the last of these techniques
12
, which is regarded as being an accurate method for 
identifying HPV positive samples
107
. They aligned mRNA from each sample to the HPV 
transcriptome, and then, based on the distribution of results, they categorised any sample that 
had at least 1,000 aligned reads as being HPV positive. Whilst this threshold was an arbitrary 
choice, it appears to be reasonable based on the data. They also performed other techniques 
for determining HPV status, and observed good concordance of results
12
. 
For both HPV positive and HPV negative tumours I again observed bimodal distributions of 
Y chromosome copy number index values, indicating that both groups had sub-populations 
which had lost the Y chromosome. However the first peak (of tumours which had lost the Y 
chromosome) was much higher in HPV negative cases, suggesting that loss of the Y 
chromosome is much more prevalent in HPV negative cases. 
Whilst there was some evidence that loss of the Y chromosome may be associated with worse 
overall survival in HPV positive patients, the result was not statistically significant. However, 
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I did discover a statistically significant association in HPV negative patients. This applied to 
the whole chromosome and also to each arm separately. Furthermore, I observed that the 
association was unique to the Y chromosome, not being found in any other chromosomal arm. 
I also discovered a significant association between extent of Y chromosome loss and 
pathologic T categorisation. 
I then further subdivided samples depending on whether or not they harboured a mutation of 
the TP53 gene. TP53 is the gene most frequently mutated in head and neck cancer (in 
particular HPV negative tumours)
106
. TP53 mutation is believed to be an early event in 
carcinogenesis and potentially has multiple downstream impacts on important signalling 
pathways
108
. Consistent with previous research I observed that TP53 mutation was much 
more frequent in HPV negative tumours than in HPV positive tumours
106
. 
My analyses using TP53 mutation data provided two other pieces of evidence supporting the 
possibility that Y chromosome loss could be important in tumour formation for HPV negative 
head and neck cancer patients. First, I showed that the extent of Y chromosome loss is 
independent of TP53 mutation. Conversely, for HPV positive cases, Y chromosome loss was 
significantly greater in patients who harboured a TP53 mutation. This implies that for HPV 
negative cases, the Y chromosome can be lost in the absence of TP53 mutation. 
Second, for those HPV negative patients who did not harbour a TP53 mutation, I observed a 
statistically significant link between Y chromosome loss and a history of smoking. This result 
applied separately to both arms of the Y chromosome, and was again unique amongst all 
chromosomal arms. The corollary from this is that smoking could be a causative factor in Y 
chromosome loss, consistent with research published in 2015
4
. 
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I chose to subdivide samples by TP53 mutational status as TP53 is the most commonly 
mutated gene in head and neck cancer
106
, it is involved in numerous important signalling 
pathways, and it is also mutated in other types of cancer (e.g. lung cancer)
109
. Analysis of 
TCGA mutation data for 3,281 tumours from 12 different cancer types (including head and 
neck) found that TP53 was the most frequently mutated gene, occurring in 42% of all 
samples
109
. Other research has found it to be mutated in different cancer types, such as 
epithelial, mesenchymal and haematological malignancies
110
. 
Given the high prevalence of mutation across multiple cancer types, and the large number of 
critical signalling pathways which it affects, TP53 has earned the reputation as the “guardian 
of the genome”, as it is important for the maintenance of genomic stability108. Analysis using 
the COSMIC database of somatic mutations in cancer has shown that 22.38% of the 67 
autosomal genes in the TP53 pathway contain mutations which have been causally implicated 
in cancer, including ATM. MDM2 and CDKN2A
110
. This represented a 11.15-fold 
enrichment compared with the corresponding figure when all genes were considered. Figure 
115 overleaf shows a diagram of the TP53 pathways (taken from Stracquadanio
110
), including 
the genes included in the COSMIC list. 
Although TP53 is clearly a very important gene in head and neck cancer, there are, however, a 
variety of different mutations which occur, and they can have different downstream effects. 
TP53 is generally regarded as a tumour suppressor gene, and most loss-of-function mutations 
occur in its DNA-binding domain, which inhibits its function as a transcription factor
108
.  
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Figure 115 - schematic diagram of TP53 pathways and genes causally implicated in cancer 
This diagram is taken from Stracquadanio
110
 and shows the p53 pathway as annotated by Kyoto Encyclopedia of Genes and 
Genomes. Genes for which mutations have been causally implicated in cancer (COSMIC) are coloured according to the 
relevant cancer type(s) - blue (epithelial cancers), red (leukaemia or lymphoma), purple (mesenchymal) or orange (other). 
However, the precise mechanisms by which TP53 performs its tumour suppression role are 
unclear – for example, research in mice has suggested that suppression of TP53’s cell-cycle 
arrest, apoptosis and senescence functionality does not promote tumour formation
108
. To add 
to the complexity, other research has shown that certain TP53 mutations may actually cause 
gain-of-function which in turn promotes tumour progression
108
. Hence, whilst my 
observations of the associations between the existence of TP53 mutation and Y chromosome 
loss are potentially interesting, further detailed analysis of the different types of mutation, and 
its downstream consequences, would be necessary to refine the findings. 
Some research, including that of TCGA
12
, has indicated that HPV negative patients with a 
TP53 mutation suffer worse survival than those patients with no mutation
111
. However, I did 
not observe such an association for the HPV negative male patients. This could be because 
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TCGA’s (and other) analyses included both males and females, and hence the impact of Y 
chromosome loss on survival was reduced.  
Gross et al
112
 used TCGA’s data to investigate pairs of genomic events and their associations 
with survival. They discovered that for HPV negative cases TP53 mutation was often 
accompanied by loss of the short arm of chromosome 3 (3p), and that patients who had 
suffered both of these events had worse prognosis. However, once again males and females 
were combined. Furthermore, the Y chromosome was excluded from the analysis. For HPV 
negative males I observed frequent loss of 3p, but although there was some evidence that 
patients who had lost 3p had worse survival, the result was not statistically significant (data 
not shown).  
TCGA
12
 also identified a subset of HPV negative tumours which appeared to be driven by 
mutations and which had low level copy number changes (the so-called “M” class113). These 
patients were observed to have favourable outcomes. However, once again, male and female 
patients were not segregated, and the Y chromosome was not included in the analysis. 
It is interesting to speculate why Y chromosome loss should impact on survival for head and 
neck cancer patients but not for colon or kidney cancer patients.  
It could simply be the case that the result I have observed is purely a quirk of the data and will 
never be validated in another dataset (see below). Alternatively, it might be that there are 
other factors at play in the colon and kidney datasets, and that there were insufficient numbers 
of samples to observe a similar result. 
More intriguingly, it is also possible that a gene (or genes) on the Y chromosome are 
particularly important in the context of head and neck cancer. A prime candidate would be 
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SRY, which was only expressed in HNSC samples. However, my survival analyses based on 
gene expression levels suggest that low SRY expression on its own is not linked to worse 
overall survival. Also, the fact that low expression caused by aberrant methylation in 
RPS4Y1, SRY, TBL1Y and TTTY14 was associated with better survival compared with 
patients who had lost the Y chromosome, suggests that loss of expression in these genes on 
their own is not important.  An alternative theory could, therefore, be that loss of expression 
in a combination of genes, possibly including SRY, may be the important factor. 
Loss of some Y chromosome genes has been implicated in tumour formation / progression for 
other cancer types. For example, loss of the KDM5D gene on the long arm has been 
associated with resistance to chemotherapy in prostate cancer cell-lines
114
.  
Loss of UTY has been linked to increased cell proliferation in urothelial bladder cell-lines
115
. 
UTY is one of the two putative tumour suppressor genes mentioned in Davoli
6
. It is a 
homolog of UTX (also known as KDM6A) on the X chromosome, a gene which escapes X-
inactivation in females. UTX is known to act as a demethylase of lysine 27 on histone 3 
(H3K27), and research has shown that UTY may also share this enzymatic activity, albeit at a 
reduced level
116
. Furthermore, research using head and neck cancer cell-lines has shown that 
aberrant methylation of H3K27 is linked to dysregulated squamous cell differentiation
117
.  
TCGA discovered that 19% of head and neck tumours harboured an inactivating mutation in 
the NOTCH1 gene
12
, which is also involved in squamous cell differentiation. So it is possible 
that loss of UTY may play a role in dysregulation of squamous cell differentiation, which is 
known to be important in the pathogenesis of squamous cell carcinomas
117
. 
Another characteristic of head and neck tumours is their ability to evade immune 
surveillance
106
. The mechanisms by which this evasion is achieved include the down-
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regulation of antigen presenting molecules (such as TAP1/2), the expression of receptors 
which inhibit immune response (such as PD-L1), and the over-production of immune-
suppressive cytokines in the tumour micorenvironment
106
.  
Therapeutic targeting of tumour immune suppression is an active area of cancer research. 
Recently Ferris et al
118
 reported that treatment with the drug nivolumab resulted in increased 
overall survival of patients with chemotherapy-resistant, recurrent head and neck squamous 
cell carcinoma. Nivolumab is an inhibitor of a molecule called programmed death 1 (PD-1), 
which when bound by its ligand programmed death ligand 1 (PD-L1), suppresses the action of 
immune system T-cells. PD-L1 is often expressed by head and neck tumours
106
. 
It is possible that loss of the Y chromosome may contribute to the ability of tumours to evade 
immune detection. Research using mouse models
119
, showed that the Y chromosome is able 
to regulate, on a genome-wide basis, the expression of genes in immune cells via epigenetic 
mechanisms. Whilst that research was focussed on autoimmune diseases, there is the 
possibility that the same principle could be extended to tumour cells – for example, loss of the 
Y chromosome may result in dysregulated expression of proteins such as PD-L1. Obviously 
this is highly speculative at the present time, but it could be another mechanism through 
which loss of the Y chromosome impacts on the progression of male head and neck cancer. 
Further research will be required to attempt to identify which Y chromosome gene / genes are 
the most important, or whether it is the loss of them all collectively that is important in male, 
HPV negative head and neck cancer formation. However, my results open up the possibility 
that the Y chromosome may, in some way, be a useful biomarker of survival for such patients. 
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8.5 Further work 
Whilst my results have raised the possibility that loss of the Y chromosome may be a 
contributory factor in the pathogenesis of head and neck cancer, further work will be required 
to try and validate my findings.  
I have searched online for other datasets which I could use to check my findings in relation to 
head and neck cancer. Unfortunately, so far I have not been able to find a suitable dataset. 
Therefore, our group, in conjunction with our collaborators, are proposing to create our own 
data using tissue samples which have already been collected. We will use these, in particular, 
to investigate using FISH analysis the extent to which the Y chromosome is lost, and to 
perform survival analyses. In our analyses we will also include some oral dysplasia samples, 
which will enable us to investigate whether Y chromosome loss is an early event in 
tumorigenesis. 
We are also intending to carry out FISH analyses on selected, male head and neck cancer cell-
lines to investigate Y chromosome loss. For cell-lines which have lost the Y chromosome, we 
then intend to check that expression of a panel of selected genes is missing. If the Y 
chromosome is still intact, we will check whether expression of selected genes is depressed as 
a result of promoter hyper-methylation. Furthermore, we will investigate the phenotypic 
consequences of re-introducing these genes into the cell-lines. Expression of those genes with 
the most striking results will then be analysed in the tissue samples, with a view to assessing 
their potential utility as biomarkers of survival. 
8.6 Conclusions 
In conclusion, aberrant methylation and copy number loss of the Y chromosome were 
frequently observed in each dataset, and were often associated with reduced gene expression. 
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For HPV negative head and neck cancer cases, Y chromosome loss was associated with 
impaired survival, which raises the possibility that it could be used as a biomarker for such 
patients. However, further work is required to validate my findings. 
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Appendices 
Appendix 1 – 32 CpG sites removed from methylation analyses 
CpG site 
ID 
Infinium 
type 
Position 
(Mbp) 
Gene 
name 
Gene 
location 
Island 
region 
CpG 
count 
cg01053349 II 3.45 TGIF2LY TSS1500 Ocean 8 
cg03515901 II 3.45 TGIF2LY 5'UTR Ocean 17 
cg04477336 II 3.45 TGIF2LY Body Ocean 19 
cg27539833 I 3.45 TGIF2LY 3'UTR Ocean 12 
cg09703571 II 4.87 PCDH11Y TSS1500 N_Shore 21 
cg10465579 II 4.87 PCDH11Y TSS1500 Island 22 
cg08455548 II 4.87 PCDH11Y TSS1500 Island 23 
cg15295597 I 4.87 PCDH11Y 5'UTR Island 30 
cg02494853 I 4.87 PCDH11Y 5'UTR Island 29 
cg00223952 II 4.87 PCDH11Y 5'UTR N_Shore 25 
cg02432075 II 4.87 PCDH11Y 5'UTR Island 38 
cg13884608 II 5.61 PCDH11Y 3'UTR Ocean 5 
cg08045599 II 7.14 PRKY TSS1500 N_Shore 24 
cg04964672 I 7.43 nil nil Island 27 
cg01086462 II 7.43 nil nil S_Shore 3 
cg25059696 II 7.43 nil nil S_Shelf 4 
cg02624968 II 10.04 nil nil N_Shore 18 
cg04462340 I 13.91 nil nil S_Shore 13 
cg09093035 II 14.07 nil nil Island 43 
cg03258315 II 14.08 nil nil Island 23 
cg26520468 I 14.1 nil nil N_Shore 15 
cg05213048 I 14.1 nil nil Island 53 
cg04023335 I 14.1 nil nil Island 47 
cg09197443 II 14.11 nil nil Island 27 
cg15183843 II 14.53 nil nil N_Shelf 7 
cg02288797 II 14.53 nil nil N_Shore 22 
cg09730640 II 14.53 nil nil S_Shore 31 
cg02233183 II 16.63 NLGN4Y TSS1500 N_Shore 9 
cg27265812 II 16.63 NLGN4Y Body N_Shore 15 
cg03706273 I 16.64 NLGN4Y 1stExon Island 19 
cg09300505 II 16.94 NLGN4Y Body Island 34 
cg05939513 II 16.94 NLGN4Y Body S_Shore 29 
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Appendix 2 – hyper-methylated CpG sites 
CpG site 
ID 
Infinium 
type 
Position 
(Mbp) 
Gene 
name 
Gene 
location 
Island 
region 
CpG 
count 
cg04169747 II 2.66 SRY 5'UTR N_Shelf 14 
cg11898347 II 2.66 SRY TSS200 N_Shore 9 
cg27636129 II 2.66 SRY TSS200 N_Shore 9 
cg09595415 II 2.66 SRY TSS200 N_Shore 8 
cg01375382 II 2.71 RPS4Y1 TSS200 Ocean 21 
cg25443613 II 2.71 RPS4Y1 TSS200 Ocean 21 
cg01311227 II 2.71 RPS4Y1 1stExon Ocean 23 
cg14170959 II 2.80 ZFY TSS1500 N_Shore 13 
cg11131351 I 2.80 ZFY TSS1500 N_Shore 11 
cg14972466 II 2.80 ZFY TSS1500 N_Shore 11 
cg02002345 II 6.78 TBL1Y TSS1500 N_Shore 21 
cg27355713 II 6.78 TBL1Y TSS200 N_Shore 40 
cg04042030 I 6.78 TBL1Y TSS200 Island 44 
cg02839557 I 6.78 TBL1Y TSS200 Island 44 
cg01707559 I 6.78 TBL1Y TSS200 Island 52 
cg25032547 I 14.77 TTTY15 TSS1500 Ocean 13 
cg27443332 II 16.63 NLGN4Y Body N_Shore 14 
cg27214488 II 16.64 NLGN4Y TSS200 N_Shore 9 
cg25518695 I 16.64 NLGN4Y Body N_Shore 28 
cg18113731 II 16.64 NLGN4Y Body Island 34 
cg19244032 II 16.64 NLGN4Y Body Island 35 
cg10990737 II 16.64 NLGN4Y Body S_Shore 30 
cg03244189 I 21.24 TTTY14 Body Island 36 
cg13845521 II 21.24 TTTY14 Body Island 52 
cg10811597 II 21.24 TTTY14 Body Island 43 
cg11816202 II 21.24 TTTY14 TSS200 Island 34 
cg00212031 I 21.24 TTTY14 TSS200 Island 32 
cg15345074 I 21.24 TTTY14 TSS200 Island 38 
cg11684211 II 21.24 TTTY14 TSS1500 Island 40 
cg06628792 II 21.24 TTTY14 TSS1500 Island 27 
cg00121626 II 21.66 BCORL2 Body N_Shore 16 
cg00876332 II 21.66 BCORL2 Body Island 29 
cg15794778 II 21.67 BCORL2 Body Island 24 
cg25756647 I 21.73 CYorf15A TSS1500 N_Shore 14 
cg01988452 II 22.74 EIF1AY TSS1500 N_Shore 5 
cg13308744 II 22.74 EIF1AY TSS1500 N_Shore 5 
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Appendix 3 – hypo-methylated CpG sites 
CpG site 
ID 
Infinium 
type 
Position Gene 
name 
Gene 
location 
Island 
region 
CpG 
count 
cg15431336 II 4.87 PCDH11Y 5'UTR S_Shore 2 
cg13805219 II 6.14 nil nil S_Shelf 7 
cg15849038 II 6.17 nil nil N_Shore 12 
cg17972491 II 6.74 AMELY TSS1500 Ocean 5 
cg15700967 II 6.95 TBL1Y Body Ocean 16 
cg14778208 II 7.57 TTTY16 Body Ocean 1 
cg05098815 II 9.45 RBMY3AP Body Ocean 1 
cg08053115 II 9.61 TTTY1 Body Ocean 3 
cg18163559 II 9.74 nil nil N_Shelf 8 
cg02107461 II 14.10 nil nil N_Shelf 2 
cg07795413 II 16.73 NLGN4Y 5'UTR Ocean 5 
cg14151065 II 19.68 nil nil N_Shore 24 
cg06065495 II 21.67 BCORL2 TSS1500 S_Shore 10 
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